[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 194
1. Głab E, Barg E, Wikiera B, Grabowski M, Noczyńska A: Influence of GnRH analog therapy on body mass in central precocious puberty. Pediatr Endocrinol Diabetes Metab; 2009;15(1):7-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of GnRH analog therapy on body mass in central precocious puberty.
  • THE AIM OF THE STUDY: Was to evaluate the body mass index (BMI) changes in girls with central precocious puberty (CPP) treated with a GnRH analog (GnRHa) and to analyse the factors affecting BMI.
  • The treatment was initiated at the age of 7.5+/-2.1 year and continued for 3.3+/-2.2 year until the age of 11.4+/-0.9 year.
  • RESULTS: There was no statistical difference between BMI SD score before initiation of therapy and at the end of therapy (p=0.49).
  • 9.8% of the cohort were overweight and 22.0% were obese before treatment.
  • At the end of the therapy 18.6% children were overweight and 14.0% obese.
  • There was no significant correlation between overweight and obesity at the end of treatment and the duration of the therapy (r=-0.17) and with the duration of CPP before introduction of GnRH therapy (r= -0.11).
  • CONCLUSIONS: 1.Overweight and obesity are not related to long term pituitary-gonadal suppression due to GnRH analogue treatment.
  • 2. The rate of overweight and obesity among children with CPP is higher than in the general population.
  • Thus detailed evaluation of metabolic status of overweight children with CPP should be performed in order to prevent complications of the metabolic syndrome.
  • [MeSH-major] Body Mass Index. Overweight / epidemiology. Puberty, Precocious / drug therapy. Puberty, Precocious / epidemiology. Triptorelin Pamoate / therapeutic use
  • [MeSH-minor] Body Height / drug effects. Child. Cohort Studies. Comorbidity. Female. Humans. Obesity / epidemiology. Prevalence

  • Genetic Alliance. consumer health - Precocious puberty.
  • Genetic Alliance. consumer health - Central precocious puberty.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19454183.001).
  • [ISSN] 2081-237X
  • [Journal-full-title] Pediatric endocrinology, diabetes, and metabolism
  • [ISO-abbreviation] Pediatr Endocrinol Diabetes Metab
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 57773-63-4 / Triptorelin Pamoate
  •  go-up   go-down


2. Infante C, Díaz M, Hernández A, Constandil L, Pelissier T: Expression of nitric oxide synthase isoforms in the dorsal horn of monoarthritic rats: effects of competitive and uncompetitive N-methyl-D-aspartate antagonists. Arthritis Res Ther; 2007;9(3):R53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chronic pain is associated with N-methyl-D-aspartate (NMDA) receptor activation and downstream production of nitric oxide, which has a pivotal role in multisynaptic local circuit nociceptive processing in the spinal cord.
  • The formation of nitric oxide is catalyzed by three major nitric oxide synthase (NOS) isoforms (neuronal, nNOS; inducible, iNOS; endothelial, eNOS), which are increased in the spinal cord of rodents subjected to some tonic and chronic forms of experimental pain.
  • Despite the important role of NOS in spinal cord nociceptive transmission, there have been no studies exploring the effect of NMDA receptor blockade on NOS expression in the dorsal horn during chronic pain.
  • Furthermore, NOS isoforms have not been fully characterized in the dorsal horn of animals subjected to arthritic pain.
  • The aim of this work was therefore to study the expression of nNOS, iNOS and eNOS in the dorsal horns of monoarthritic rats, and the modifications in NOS expression induced by pharmacological blockade of spinal cord NMDA receptors.
  • At week 4, monoarthritic rats were given either the competitive NMDA antagonist (+/-)-3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid (CPP) or the uncompetitive NMDA antagonist ketamine.
  • Sample tissues were homogenized and subjected to immunoblotting with anti-nNOS, anti-iNOS or anti-eNOS monoclonal antibodies.
  • Intrathecal administration of CPP and ketamine reduced nNOS expression in monoarthritic rats but increased the expression of iNOS and eNOS.
  • Results suggest that blockade of spinal cord NMDA receptors produces complex regulatory changes in the expression of NOS isoforms in monoarthritic rats that may be relevant for nitridergic neuronal/glial mechanisms involved in the pathophysiology of monoarthritis and in the pharmacological response to drugs interacting with NMDA receptors.
  • [MeSH-minor] Adjuvants, Immunologic / toxicity. Animals. Blotting, Western. Excitatory Amino Acid Antagonists / administration & dosage. Freund's Adjuvant / toxicity. Functional Laterality. Injections, Spinal. Isoenzymes / biosynthesis. Isoenzymes / drug effects. Male. Rats. Rats, Sprague-Dawley. Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Pain.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Pharmacol. 1999 Apr;126(8):1840-6 [10372828.001]
  • [Cites] Pain. 2007 May;129(1-2):64-75 [17123734.001]
  • [Cites] Pharmacol Biochem Behav. 2005 Mar;80(3):493-503 [15740792.001]
  • [Cites] Somatosens Mot Res. 2004 Sep-Dec;21(3-4):211-5 [15763906.001]
  • [Cites] Pain. 2005 Dec 15;119(1-3):113-23 [16297560.001]
  • [Cites] Anesthesiology. 2006 Feb;104(2):328-37 [16436853.001]
  • [Cites] Glia. 2000 Jan 1;29(1):1-13 [10594918.001]
  • [Cites] Pharmacol Biochem Behav. 2000 Apr;65(4):621-5 [10764914.001]
  • [Cites] Anesthesiology. 2000 Aug;93(2):520-8 [10910503.001]
  • [Cites] Curr Rev Pain. 2000;4(6):459-66 [11060592.001]
  • [Cites] Neuroreport. 2001 Jun 13;12(8):1551-4 [11409714.001]
  • [Cites] Pain. 2001 Oct;94(1):47-58 [11576744.001]
  • [Cites] Eur J Pharmacol. 2001 Oct 19;429(1-3):23-37 [11698024.001]
  • [Cites] Brain Res Bull. 2002 Jun;58(2):161-71 [12127013.001]
  • [Cites] Neuroscience. 2003;120(3):847-54 [12895524.001]
  • [Cites] Int J Neurosci. 2003 Sep;113(9):1305-13 [12959746.001]
  • [Cites] Anesthesiology. 2003 Oct;99(4):969-75 [14508333.001]
  • [Cites] Neurosci Lett. 2003 Nov 27;352(1):64-6 [14615051.001]
  • [Cites] Exp Neurol. 2003 Nov;184(1):373-80 [14637107.001]
  • [Cites] Glia. 2004 Apr 1;46(1):53-62 [14999813.001]
  • [Cites] Neuroscience. 2004;128(2):421-30 [15350652.001]
  • [Cites] Life Sci. 2004 Oct 8;75(21):2527-38 [15363658.001]
  • [Cites] Pain. 1983 Jun;16(2):109-10 [6877845.001]
  • [Cites] J Neurosci. 1986 Dec;6(12):3423-9 [3794780.001]
  • [Cites] Pain. 1992 Jan;48(1):73-81 [1738577.001]
  • [Cites] Pain. 1992 Sep;50(3):331-44 [1454389.001]
  • [Cites] Brain Res. 1992 Dec 11;598(1-2):271-8 [1362520.001]
  • [Cites] Pain. 1993 Feb;52(2):127-36 [8455960.001]
  • [Cites] Brain Res. 1993 Mar 5;605(1):164-8 [8385540.001]
  • [Cites] Neurosci Lett. 1992 Dec 14;148(1-2):1-5 [1284437.001]
  • [Cites] J Exp Med. 1993 Jun 1;177(6):1779-84 [7684434.001]
  • [Cites] Pain. 1994 Jan;56(1):59-67 [8159442.001]
  • [Cites] J Pharmacol Toxicol Methods. 1994 Dec;32(4):197-200 [7881133.001]
  • [Cites] Pain. 1995 Feb;60(2):217-22 [7784107.001]
  • [Cites] Neurosci Lett. 1996 Jun 7;210(3):201-4 [8805130.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2676-80 [9122255.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Sep 18;238(2):617-21 [9299562.001]
  • [Cites] Exp Brain Res. 1998 Feb;118(4):457-65 [9504841.001]
  • [Cites] J Pharmacol Exp Ther. 1999 May;289(2):1060-6 [10215688.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1999 Jul;67(1):1-3 [10369810.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 2006 Sep 30;30(7):1209-18 [16626845.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • (PMID = 17521446.001).
  • [ISSN] 1478-6362
  • [Journal-full-title] Arthritis research & therapy
  • [ISO-abbreviation] Arthritis Res. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Excitatory Amino Acid Antagonists; 0 / Isoenzymes; 0 / Receptors, N-Methyl-D-Aspartate; 9007-81-2 / Freund's Adjuvant; EC 1.14.13.39 / Nitric Oxide Synthase
  • [Other-IDs] NLM/ PMC2206346
  •  go-up   go-down


3. Stoilova TB, Kovalchuk SI, Egorova NS, Surovoy AY, Ivanov VT: Gramicidin A-based peptide vector for intracellular protein delivery. Biochim Biophys Acta; 2008 Oct;1778(10):2026-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The development of the peptide-based vectors for the intracellular delivery of biologically active macromolecules has opened new prospects of their application in research and therapy.
  • Earlier the amphipathic cell-penetrating peptide (CPP) Pep-1 was reported to mediate cellular uptake of proteins without covalent binding to them.
  • In this work we studied the ability of a series of membrane-active amphipathic peptides, based on the gramicidin A sequence, to transport a model protein across the eukaryotic cell membrane.
  • In addition, a series of new gramicidin analogues were prepared and the effect of N-terminus modification of gramicidin on the protein transduction efficiency was studied.
  • [MeSH-major] Anti-Bacterial Agents / metabolism. Cell Membrane Permeability. Drug Delivery Systems. Genetic Vectors / metabolism. Gramicidin / metabolism. Peptides / metabolism

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18339303.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Peptides; 1405-97-6 / Gramicidin; EC 3.2.1.23 / beta-Galactosidase
  •  go-up   go-down


Advertisement
4. Wrede B, Hasselblatt M, Peters O, Thall PF, Kutluk T, Moghrabi A, Mahajan A, Rutkowski S, Diez B, Wang X, Pietsch T, Kortmann RD, Paulus W, Jeibmann A, Wolff JEA: Atypical choroid plexus papilloma: clinical experience in the CPT-SIOP-2000 study. J Neurooncol; 2009 Dec;95(3):383-392
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical choroid plexus papilloma: clinical experience in the CPT-SIOP-2000 study.
  • Atypical choroid plexus papilloma (APP) represents a novel intermediate-grade subtype of choroid plexus tumor (CPT), the clinical outcome of which has not been described yet.
  • We present the first analysis of a group of APP patients enrolled in the ongoing CPT-SIOP-2000 study of CPTs.
  • A worldwide registration and a randomized trial for those patients who require chemotherapy started in 2000.
  • After surgery, patients who had undergone complete resection were observed, whereas patients with incompletely resected or metastasized APP were treated with six chemotherapy courses (etoposide and vincristine, combined with either carboplatin or cyclophosphamide).
  • Of the 106 patients with a centrally confirmed CPT histology, 30 had APP, 42 CPP and 34 CPC.
  • APP patients were significantly younger (median = 0.7 years) than patients with CPP or CPC (both medians = 2.3 years).
  • Complete resection was achieved in 68 (64%) patients (79% in CPP, 63% in APP, and 47% in CPC).
  • Metastases were present at diagnosis in 17% of APP patients, 5% of CPP patients, and 21% of CPC patients.
  • All nine APP patients who received postoperative chemotherapy showed an early response after two cycles: two had complete remission, four had partial response, and three had stable disease.
  • In the treatment group, one patient with a metastasized tumor and incompletely resected APP died.
  • While APP was defined histologically, median percentages of both the Ki-67/MIB-1 proliferation marker and the p53 tumor suppressor protein increased across the three histological subtypes (from CPP to APP and then CPC), suggesting that the subtypes comprise an ordinal categorization of increasingly severe CPT tumors.
  • This ordering was reiterated by clinical outcome in the 92 patients treated per the study protocol, with 5-year EFS rates of 92% in 39 CPP patients, 83% in 24 APP patients, and 28% in 29 CPC patients.
  • APP responded favorably to chemotherapy.
  • The intermediate position of APP between CPP and CPC was supported by the clinical data.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Choroid Plexus Neoplasms / drug therapy. Choroid Plexus Neoplasms / mortality. Papilloma, Choroid Plexus / drug therapy. Papilloma, Choroid Plexus / mortality
  • [MeSH-minor] Adolescent. Adult. Carboplatin / administration & dosage. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Etoposide / administration & dosage. Female. Gadolinium. Humans. Infant. Kaplan-Meier Estimate. Magnetic Resonance Imaging. Male. Middle Aged. Registries. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Choroid Plexus Papilloma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Neurosurg. 1999 Sep;31(3):127-30 [10708353.001]
  • [Cites] J Neurooncol. 2000 Sep;49(3):263-8 [11212906.001]
  • [Cites] J Neurooncol. 2007 Dec;85(3):345-51 [17576522.001]
  • [Cites] Med Pediatr Oncol. 1993;21(7):480-7 [8341215.001]
  • [Cites] J Neurosurg. 2007 Sep;107(3 Suppl):199-202 [17918524.001]
  • [Cites] Lancet. 1999 Jun 19;353(9170):2126 [10382700.001]
  • [Cites] J Neurooncol. 2002 Feb;56(3):241-6 [12061730.001]
  • [Cites] Cancer. 1992 Jan 15;69(2):580-5 [1728390.001]
  • [Cites] J Neurosurg. 1998 Apr;88(4):757-60 [9525724.001]
  • [Cites] J Neurooncol. 1985;3(3):259-62 [2414413.001]
  • [Cites] J Neurooncol. 2004 May;68(1):49-55 [15174521.001]
  • [Cites] Surg Neurol. 1991 Jul;36(1):54-8 [2053075.001]
  • [Cites] Pediatr Neurosci. 1989;15(4):195-206 [2485914.001]
  • [Cites] Pediatr Neurosurg. 1991-1992;17(5):225-33 [1822687.001]
  • [Cites] J Neurooncol. 2007 Mar;82(1):69-74 [16955222.001]
  • [Cites] Anticancer Res. 2005 Nov-Dec;25(6C):4429-33 [16334121.001]
  • [Cites] Indian Pediatr. 1993 Oct;30(10):1217-8 [8077013.001]
  • [Cites] Acta Neurochir (Wien). 1979;50(1-2):79-90 [316268.001]
  • [Cites] Neuropathology. 2008 Apr;28(2):160-4 [18366349.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(7):802-10 [8869707.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Microsc Res Tech. 2001 Jan 1;52(1):104-11 [11135453.001]
  • [Cites] Neuropathology. 2009 Jun;29(3):293-8 [18627486.001]
  • [Cites] Neurol Med Chir (Tokyo). 1995 Oct;35(10):742-4 [8532130.001]
  • [Cites] Acta Neuropathol. 2002 Jan;103(1):1-10 [11837741.001]
  • [Cites] J Neurosurg Spine. 2006 Jun;4(6):494-6 [16776361.001]
  • [Cites] Pediatr Neurosurg. 1995;22(4):189-96 [7619719.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Nov;65(11):1069-73 [17086103.001]
  • [Cites] Neurosurgery. 1998 Mar;42(3):470-5 [9526979.001]
  • [Cites] J Neurosurg. 2004 Jun;100(6):1076-8 [15200124.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Pediatr Neurosurg. 2000 Apr;32(4):192-9 [10940770.001]
  • [Cites] J Neurosurg. 1980 Feb;52(2):251-5 [7351566.001]
  • [Cites] J Neurosurg. 1988 Dec;69(6):843-9 [3193190.001]
  • [Cites] Br J Cancer. 2002 Nov 4;87(10):1086-91 [12402146.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 May;56(5):551-6 [9143268.001]
  • [Cites] Neuropathol Appl Neurobiol. 2004 Jun;30(3):304-7 [15175083.001]
  • [Cites] Med Pediatr Oncol. 1995 Feb;24(2):104-8 [7990757.001]
  • [Cites] Neurosurgery. 1989 Sep;25(3):327-35 [2771002.001]
  • [Cites] Acta Neurochir (Wien). 2007 Dec;149(12):1229-36; discussion 1236-7 [17924056.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):66-74 [16330944.001]
  • [Cites] Histopathology. 1996 Aug;29(2):147-51 [8872148.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 May;64(5):391-7 [15892296.001]
  • [Cites] J Neurosurg. 1998 Mar;88(3):521-8 [9488307.001]
  • [Cites] Childs Nerv Syst. 1989 Oct;5(5):288-98 [2804999.001]
  • (PMID = 19543851.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00500890
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / R01 CA083932
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; AU0V1LM3JT / Gadolinium; BG3F62OND5 / Carboplatin
  •  go-up   go-down


5. Català-Temprano A, Claret Teruel G, Cambra Lasaosa FJ, Pons Odena M, Noguera Julián A, Palomeque Rico A: Intracranial pressure and cerebral perfusion pressure as risk factors in children with traumatic brain injuries. J Neurosurg; 2007 Jun;106(6 Suppl):463-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial pressure and cerebral perfusion pressure as risk factors in children with traumatic brain injuries.
  • OBJECT: The authors evaluated the initial intracranial pressure (ICP) and cerebral perfusion pressure (CPP) as prognostic factors in severe head injury in children and tried to determine the optimal CPP range.
  • METHODS: The authors performed a 9-year retrospective review of all patients with severe traumatic brain injuries (TBIs) who required invasive ICP monitoring and were admitted to the pediatric intensive care unit at their institution between January 1995 and December 2003.
  • An unfavorable outcome was observed in more than 60% of patients with an initial CPP lower than 40 mm Hg.
  • CONCLUSIONS: Initial ICP and CPP measurements were useful as prognostic factors in pediatric patients with severe TBIs: patients with initial CPPs between 40 and 70 mm Hg were found to have a better neurological prognosis than those with CPPs either higher or lower than that range.
  • [MeSH-major] Blood Pressure. Brain Injuries / physiopathology. Cerebrovascular Circulation. Intracranial Pressure
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Glasgow Coma Scale. Glasgow Outcome Scale. Humans. Infant. Intracranial Hypertension / drug therapy. Intracranial Hypertension / etiology. Prognosis. Retrospective Studies. Risk Factors. Trauma Severity Indices. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17566403.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Follis F, Blisard K, Varvitsiotis PS, Pett SB Jr, Temes T, Wernly JA: Competitive NMDA receptor antagonists and spinal-cord ischemia. J Invest Surg; 2000 Mar-Apr;13(2):117-21; discussion 123-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Accordingly, we investigated the protective effect during spinal cord ischemia of two competitive antagonists, 4-(3-phosphonopropyl)-2-piperazine-carboxylic acid (CPP) and cis-4-(phosphonomethyl)-2-piperidine-carboxylic acid (CGS).
  • Male Sprague-Dawley rats underwent intrathecal administration of 10 microL saline, CGS, and CPP 10 mM solutions, in a randomized blinded fashion, and were subjected to balloon occlusion of the thoracic aorta.
  • In the acute protocol, 21 rats divided in 3 groups of 7 (saline, CPP, and CGS) were used to calculate the aortic occlusion time (AOT) resulting in paraplegia in 50% of animals (P50).
  • In the chronic study, 24 rats divided in 4 groups of 6 (saline, CPP, CGS, sham) underwent 12-min occlusion.
  • In the acute study, the P50 of CGS (10 min 48 s) and CPP (11 min 11 s) was longer than saline (10 min 27 s).
  • In the chronic groups, analysis of variance of neurologic (p = .66) and histologic (p = .66) scores did not disclose differences between CGS, CPP, and saline.
  • In conclusion, blockade of NMDA receptors with CPP or CGS may afford some protection for durations of occlusion around the P50, but it is not beneficial when ischemic injury is more protracted.
  • [MeSH-major] Excitatory Amino Acid Antagonists / pharmacology. Pipecolic Acids / pharmacology. Piperazines / pharmacology. Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors. Spinal Cord Ischemia / drug therapy
  • [MeSH-minor] Acute Disease. Animals. Arterial Occlusive Diseases / drug therapy. Chronic Disease. Disease Models, Animal. Male. Paraplegia / drug therapy. Rats. Rats, Sprague-Dawley. Spinal Cord / blood supply. Spinal Cord / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10801049.001).
  • [ISSN] 0894-1939
  • [Journal-full-title] Journal of investigative surgery : the official journal of the Academy of Surgical Research
  • [ISO-abbreviation] J Invest Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Excitatory Amino Acid Antagonists; 0 / Pipecolic Acids; 0 / Piperazines; 0 / Receptors, N-Methyl-D-Aspartate; 100828-16-8 / 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid; 4VGJ4A41L2 / selfotel
  •  go-up   go-down


7. Levy ML, Goldfarb A, Hyder DJ, Gonzales-Gomez I, Nelson M, Gilles FH, McComb JG: Choroid plexus tumors in children: significance of stromal invasion. Neurosurgery; 2001 Feb;48(2):303-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Choroid plexus tumors in children: significance of stromal invasion.
  • OBJECTIVE: A group of choroid plexus tumors fit the cellular criteria for choroid plexus papilloma (CPP) except for invasion into the adjacent parenchyma, with associated loss of the normal villus architecture at the site of invasion.
  • These tumors retain a benign cellular appearance.
  • In the existing literature, it is unclear whether these tumors are classified as choroid plexus carcinomas or as CPPs.
  • In our experience, although evidence of invasion is present, these tumors tend to exhibit benign behavior.
  • We suggest that stromal invasion of this type remains consistent with a benign clinical course, although surgical results may demonstrate higher morbidity rates, given the invasive nature of the tumors.
  • After gross total tumor removal, none of the eight children with CPPs received adjuvant therapy at our institution; all are alive without evidence of tumor recurrence after surgical excision (mean, 108 mo).
  • The one patient who underwent subtotal resection received chemotherapy at another facility.
  • CONCLUSION: It is recommended that CPPs with a benign cellular appearance but with evidence of local parenchymal invasion and loss of the normal villus architecture at the site of invasion be classified as CPPs.
  • Patients with these tumors respond to surgical therapy alone, without the need for adjuvant treatment.
  • [MeSH-major] Choroid Plexus Neoplasms / pathology. Choroid Plexus Neoplasms / surgery. Papilloma / pathology. Papilloma / surgery
  • [MeSH-minor] Child. Child, Preschool. Humans. Infant. Neoplasm Invasiveness. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11220372.001).
  • [ISSN] 0148-396X
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Mascia L, Andrews PJ, McKeating EG, Souter MJ, Merrick MV, Piper IR: Cerebral blood flow and metabolism in severe brain injury: the role of pressure autoregulation during cerebral perfusion pressure management. Intensive Care Med; 2000 Feb;26(2):202-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebral blood flow and metabolism in severe brain injury: the role of pressure autoregulation during cerebral perfusion pressure management.
  • OBJECTIVE: To ascertain if norepinephrine can be used as part of the cerebral perfusion pressure (CPP) management to increase arterial blood pressure (MAP) without causing cerebral hyperemia after severe head injury (HI).
  • INTERVENTIONS: CPP management ( = 70 mmHg).
  • Pressure autoregulation (assessed by norepinephrine infusion) was defined intact if % CPP/%CVR < or = 2.
  • Norepinephrine increased CPP by 33 % (+/- 4).
  • CONCLUSIONS: During CPP management norepinephrine can be used to increase MAP without potentiating hyperemia if pressure autoregulation is preserved.
  • The assessment of pressure autoregulation should be considered as a guide for arterial pressure-oriented therapy after HI.
  • [MeSH-major] Brain Injuries / drug therapy. Brain Injuries / physiopathology. Cerebrovascular Circulation. Intracranial Pressure / drug effects. Norepinephrine / therapeutic use. Vasoconstrictor Agents / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Analysis of Variance. Blood Flow Velocity / drug effects. Blood Flow Velocity / physiology. Blood Pressure / drug effects. Blood Pressure / physiology. Female. Glasgow Coma Scale. Humans. Infusions, Intravenous. Intensive Care Units. Male. Middle Aged. Oxygen / metabolism. Prospective Studies. Ultrasonography, Doppler, Transcranial

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Norepinephrine .
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10784309.001).
  • [ISSN] 0342-4642
  • [Journal-full-title] Intensive care medicine
  • [ISO-abbreviation] Intensive Care Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Vasoconstrictor Agents; S88TT14065 / Oxygen; X4W3ENH1CV / Norepinephrine
  •  go-up   go-down


9. Szendei G, Hernádi Z, Dévényi N, Csapó Z: Is there any correlation between stages of endometriosis and severity of chronic pelvic pain? Possibilities of treatment. Gynecol Endocrinol; 2005 Aug;21(2):93-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there any correlation between stages of endometriosis and severity of chronic pelvic pain? Possibilities of treatment.
  • We report herein findings on 181 patients, suffering from pelvic endometriosis confirmed by histology, whose main symptom was chronic pelvic pain (CPP).
  • The short form of the McGill pain questionnaire was used for the evaluation of CPP.
  • After the first operative intervention, therapy with a gonadotropin-releasing hormone (GnRH) analog was given for 6 months.
  • Second-look laparoscopy was performed 8-10 weeks after the end of GnRH-analog treatment, which was followed by a non-conventionally administered, monophasic oral contraceptive (OC) treatment.
  • In the long term, 118 patients received the non-conventionally administered, monophasic OC treatment, which contained a third-generation progestogen, to be taken continuously for at least 6 months.
  • The other 63 patients who did not receive OC treatment for one reason or another were evaluated as a control group.
  • We analyzed data on CPP before the first surgical intervention, then following therapy with the GnRH analog at the second-look operation, and then after 6, 12, 18 and 24 months.
  • We also reviewed potential causes of CPP, especially focused on endometriosis.
  • No correlation was found between the stage of endometriosis according to R-AFS score and the severity of CPP.
  • At the 24-month follow-up after second-look laparoscopy, the non-conventionally administered monophasic OC treatment was found not only to significantly reduce pain scores, but also the required radical operative solution (hysterectomy plus bilateral adnexectomy) for CPP by OC users.
  • [MeSH-major] Contraceptives, Oral, Combined / therapeutic use. Endometriosis / drug therapy. Gonadotropin-Releasing Hormone / therapeutic use. Pelvic Pain / prevention & control
  • [MeSH-minor] Combined Modality Therapy. Drug Administration Schedule. Dysmenorrhea / drug therapy. Dyspareunia / drug therapy. Female. Humans. Laparoscopy. Pain Measurement. Secondary Prevention

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Pelvic Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16109595.001).
  • [ISSN] 0951-3590
  • [Journal-full-title] Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • [ISO-abbreviation] Gynecol. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contraceptives, Oral, Combined; 33515-09-2 / Gonadotropin-Releasing Hormone
  •  go-up   go-down


10. Han Y, Li CS: [Effects of hypertension state induced by norepinephrine on liver in a swine model of cardiopulmonary resuscitation]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2010 Feb;22(2):89-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At the same time, the animals of two groups received normal saline at the speed of 10 ml * kg(-1) * h(-1).
  • RESULTS: The heart rate (HR), MAP, cardiac output (CO) and coronary perfusion pressure (CPP) were obviously higher, while the oxygen extraction ratio was lower in the HT group than in the NP group.
  • [MeSH-major] Heart Arrest / therapy. Hypertension / chemically induced. Liver / drug effects. Norepinephrine / pharmacology
  • [MeSH-minor] Animals. Cardiopulmonary Resuscitation. Disease Models, Animal. Female. Hemodynamics / drug effects. Male. Swine. Ventricular Fibrillation / pathology. Ventricular Fibrillation / physiopathology. Ventricular Fibrillation / therapy

  • MedlinePlus Health Information. consumer health - Cardiac Arrest.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • Hazardous Substances Data Bank. Norepinephrine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20170612.001).
  • [ISSN] 1003-0603
  • [Journal-full-title] Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue
  • [ISO-abbreviation] Zhongguo Wei Zhong Bing Ji Jiu Yi Xue
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] X4W3ENH1CV / Norepinephrine
  •  go-up   go-down


11. Takamatsu Y, Yamanishi Y, Hagino Y, Yamamoto H, Ikeda K: Differential effects of donepezil on methamphetamine and cocaine dependencies. Ann N Y Acad Sci; 2006 Aug;1074:418-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Donepezil, a choline esterase inhibitor, has been widely used as a medicine for Alzheimer's disease.
  • Recently, a study showed that donepezil inhibited addictive behaviors induced by cocaine, including cocaine-conditioned place preference (CPP) and locomotor sensitization to cocaine.
  • In counterbalanced CPP tests, the intraperitoneal (i.p.) administration of 3 mg/kg donepezil prior to 2 mg/kg METH i.p. failed to inhibit METH CPP, whereas pretreatment with 3 mg/kg donepezil abolished the CPP for cocaine (10 mg/kg, i.p.).
  • [MeSH-minor] Amphetamine-Related Disorders / drug therapy. Animals. Behavior, Animal / drug effects. Cocaine-Related Disorders / drug therapy. Conditioning (Psychology). Male. Mice. Mice, Inbred C57BL. Motor Activity / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17105940.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indans; 0 / Piperidines; 8SSC91326P / donepezil
  •  go-up   go-down


12. Tonini G, Lazzerini M: Side effects of GnRH analogue treatment in childhood. J Pediatr Endocrinol Metab; 2000 Jul;13 Suppl 1:795-803
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Side effects of GnRH analogue treatment in childhood.
  • There are a few reports of side-effects of LHRHa treatment in childhood, the mechanisms of which remain little understood.
  • Such effects can be local reactions: erythema, induration, wheal and sterile abscess formation, which can be possible causes of therapy failure.
  • There are negative effects on growth velocity and final height requiring rhGH therapy or a suppressive treatment when bone age >13 years.
  • The latter appears related to CPP onset with pre-existing hyperandrogenism, although lengthier follow-up is necessary to confirm this.
  • Bone density decreases during therapy, but final peak bone mass is in the normal range.
  • [MeSH-major] Brain Diseases / complications. Puberty, Precocious / drug therapy. Puberty, Precocious / etiology
  • [MeSH-minor] Body Height / drug effects. Body Weight / drug effects. Female. Fertility / drug effects. Gonadotropin-Releasing Hormone / adverse effects. Growth. Humans. Menstrual Cycle / drug effects. Mental Disorders / chemically induced. Ovary / drug effects

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10969924.001).
  • [ISSN] 0334-018X
  • [Journal-full-title] Journal of pediatric endocrinology & metabolism : JPEM
  • [ISO-abbreviation] J. Pediatr. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 33515-09-2 / Gonadotropin-Releasing Hormone
  • [Number-of-references] 31
  •  go-up   go-down


13. El-Andaloussi S, Johansson HJ, Holm T, Langel U: A novel cell-penetrating peptide, M918, for efficient delivery of proteins and peptide nucleic acids. Mol Ther; 2007 Oct;15(10):1820-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present a novel CPP, M918, that efficiently translocates various cells in a non-toxic fashion.
  • Our data demonstrate that M918 is a novel CPP that can be used to translocate different cargoes inside various cells efficiently.
  • [MeSH-minor] Amino Acid Sequence. Endocytosis. Glycosaminoglycans / metabolism. HeLa Cells. Humans. Molecular Sequence Data. RNA Splicing / drug effects

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17622242.001).
  • [ISSN] 1525-0016
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glycosaminoglycans; 0 / Peptide Nucleic Acids; 0 / Proteins
  •  go-up   go-down


14. Zhang H, Zhao Q, Bhattacharya S, Waheed AA, Tong X, Hong A, Heck S, Curreli F, Goger M, Cowburn D, Freed EO, Debnath AK: A cell-penetrating helical peptide as a potential HIV-1 inhibitor. J Mol Biol; 2008 May 2;378(3):565-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The capsid domain of the human immunodeficiency virus type 1 (HIV-1) Gag polyprotein is a critical determinant of virus assembly, and is therefore a potential target for developing drugs for AIDS therapy.
  • Using this structural information, we have utilized a structure-based rational design approach to stabilize the alpha-helical structure of CAI and convert it to a cell-penetrating peptide (CPP).
  • This proof-of-concept cell-penetrating peptide may aid validation of capsid as an anti-HIV-1 drug target and may help in designing peptidomimetics and small molecule drugs targeted to this protein.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Sep 21;407(6802):409-13 [11014200.001]
  • [Cites] Biophys J. 2001 Jul;81(1):586-94 [11423440.001]
  • [Cites] AIDS. 2001;15 Suppl 5:S13-20 [11816161.001]
  • [Cites] J Virol. 2002 Mar;76(6):2641-7 [11861830.001]
  • [Cites] J Virol. 2002 Jul;76(14):6900-8 [12072491.001]
  • [Cites] Virology. 2006 Apr 25;348(1):84-95 [16442581.001]
  • [Cites] J Virol. 2006 Jun;80(12):5716-22 [16731910.001]
  • [Cites] J Virol. 2006 Aug;80(16):7939-51 [16873251.001]
  • [Cites] PLoS Biol. 2006 Dec;4(12):e435 [17147474.001]
  • [Cites] J Virol. 2007 Jul;81(14):7476-90 [17507489.001]
  • [Cites] Antimicrob Agents Chemother. 2002 Nov;46(11):3597-605 [12384371.001]
  • [Cites] J Biol Chem. 2003 Jan 3;278(1):585-90 [12411431.001]
  • [Cites] J Mol Biol. 2003 Jan 24;325(4):759-72 [12507478.001]
  • [Cites] J Mol Biol. 2003 Apr 11;327(5):1013-20 [12662926.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11273-8 [13679575.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13555-60 [14573704.001]
  • [Cites] Angew Chem Int Ed Engl. 2005 Oct 14;44(40):6525-9 [16172999.001]
  • [Cites] J Virol. 2004 Jan;78(2):922-9 [14694123.001]
  • [Cites] J Virol. 2004 Feb;78(3):1375-83 [14722292.001]
  • [Cites] J Virol. 2004 Mar;78(5):2545-52 [14963157.001]
  • [Cites] Bioorg Med Chem Lett. 2004 Mar 22;14(6):1403-6 [15006371.001]
  • [Cites] J Virol. 2004 Jun;78(11):5670-8 [15140964.001]
  • [Cites] Protein Sci. 2004 Jun;13(6):1512-23 [15152086.001]
  • [Cites] Biochemistry. 2004 Aug 17;43(32):10435-41 [15301542.001]
  • [Cites] Science. 2004 Sep 3;305(5689):1466-70 [15353804.001]
  • [Cites] J Gen Virol. 2004 Oct;85(Pt 10):2903-13 [15448352.001]
  • [Cites] Antimicrob Agents Chemother. 2004 Nov;48(11):4349-59 [15504864.001]
  • [Cites] J Virol. 1986 Aug;59(2):284-91 [3016298.001]
  • [Cites] J Exp Med. 1991 Dec 1;174(6):1557-63 [1836013.001]
  • [Cites] J Gen Virol. 1994 Jun;75 ( Pt 6):1469-74 [8207412.001]
  • [Cites] J Virol. 1996 Aug;70(8):5106-14 [8764018.001]
  • [Cites] Science. 1997 Oct 31;278(5339):849-53 [9346481.001]
  • [Cites] Eur J Biochem. 1997 Oct 15;249(2):592-600 [9370371.001]
  • [Cites] Virology. 1998 Nov 10;251(1):1-15 [9813197.001]
  • [Cites] Biochemistry. 2004 Nov 9;43(44):13926-31 [15518540.001]
  • [Cites] J Biol Chem. 2005 May 6;280(18):17664-70 [15734744.001]
  • [Cites] Nat Struct Mol Biol. 2005 Aug;12(8):678-82 [16041386.001]
  • [Cites] Nat Struct Mol Biol. 2005 Aug;12(8):671-7 [16041387.001]
  • [Cites] Biochemistry. 2000 Sep 26;39(38):11657-66 [10995233.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3503-8 [10725407.001]
  • [Cites] J Virol. 2000 Apr;74(8):3859-70 [10729160.001]
  • [Cites] J Virol. 2004 Jan;78(2):724-32 [14694104.001]
  • (PMID = 18374356.001).
  • [ISSN] 1089-8638
  • [Journal-full-title] Journal of molecular biology
  • [ISO-abbreviation] J. Mol. Biol.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / Z01 BC010778-01; United States / NIGMS NIH HHS / GM / P41 GM066354-05; United States / NIGMS NIH HHS / GM / GM-66354; United States / NIGMS NIH HHS / GM / P41 GM066354; United States / NIGMS NIH HHS / GM / P41 GM066354-01; United States / NIGMS NIH HHS / GM / GM066354-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Gene Products, gag; 0 / NYAD-1 peptide; 0 / Peptides; 0 / Peptides, Cyclic
  • [Other-IDs] NLM/ NIHMS76587; NLM/ PMC2695608
  •  go-up   go-down


15. Leung JC, Ragland N, Marphis T, Silverstein DM: NMDA agonists and antagonists induce renal culture cell toxicity. Med Chem; 2008 Nov;4(6):565-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The NMDA receptor (NMDAR) is expressed in the renal proximal tubule.
  • We studied the effect of NMDAR agonists and antagonists on renal cell survival in renal culture cells: proximal tubule-like opossum kidney (OK) and distal-tubule-like madine darby canine kidney cells (MDCK) cells.
  • Exposure of cells to the non-competitive NMDAR blocker MK-801 or the competitive NMDAR antagonist CPP induced a time and dose-dependent increase in cell death and apoptosis.
  • The presence of fetal bovine serum in the pre-incubation media attenuated the toxicity caused by MK-801 and CPP.
  • Finally, pre-treatment of OK cells with the renal cytoprotective glycine completely blunted the affect of MK-801 on renal cell survival.
  • [MeSH-major] Excitatory Amino Acid Agonists / pharmacology. Excitatory Amino Acid Antagonists / pharmacology. Kidney / cytology. Kidney / drug effects. Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Line. Cell Survival / drug effects. Cells, Cultured. Dizocilpine Maleate / pharmacology. Dogs. Glycine / pharmacology. L-Lactate Dehydrogenase / metabolism. Opossums. Piperazines / toxicity

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GLYCINE .
  • Hazardous Substances Data Bank. DIZOCILPINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18991741.001).
  • [ISSN] 1573-4064
  • [Journal-full-title] Medicinal chemistry (Shāriqah (United Arab Emirates))
  • [ISO-abbreviation] Med Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Excitatory Amino Acid Agonists; 0 / Excitatory Amino Acid Antagonists; 0 / Piperazines; 0 / Receptors, N-Methyl-D-Aspartate; 100828-16-8 / 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid; 6LR8C1B66Q / Dizocilpine Maleate; EC 1.1.1.27 / L-Lactate Dehydrogenase; TE7660XO1C / Glycine
  •  go-up   go-down


16. Herrold AA, Shen F, Graham MP, Harper LK, Specio SE, Tedford CE, Napier TC: Mirtazapine treatment after conditioning with methamphetamine alters subsequent expression of place preference. Drug Alcohol Depend; 2009 Jan 1;99(1-3):231-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mirtazapine treatment after conditioning with methamphetamine alters subsequent expression of place preference.
  • There are currently no FDA approved pharmacotherapies for the MP addict.
  • This study evaluated the potential of Mirt as a therapeutic agent for MP addiction and described associated changes in neuronal signaling.
  • A single pairing conditioned place preference (CPP) paradigm was utilized as a behavioral measure of MP-induced effects.
  • Mirt (5.0 mg/kg i.p.) was given in the home cage on day 3 and CPP was assessed on day 4.
  • To evaluate signaling events that correlate with this behavior, brain tissue of these rats were dissected for immunoblot assays of extracellular signal-regulated kinase (ERK) and a transcriptional regulator, cAMP response element-binding protein (CREB) after the CPP test.
  • During the CPP test, rats conditioned with MP spent more time in the environment associated with MP.
  • Importantly, rats given Mirt did not express CPP.
  • MP-induced CPP was associated with a decrease in phosphorylated CREB (pCREB) in the ventral tegmental area, and decreased phosphorylated ERK and pCREB in the nucleus accumbens and treatment with Mirt did not reverse these changes.
  • Overall, a post-conditioning treatment with Mirt can nullify MP-induced associative learning.
  • [MeSH-major] Adrenergic alpha-Antagonists / pharmacology. Central Nervous System Stimulants / pharmacology. Conditioning, Operant / drug effects. Methamphetamine / pharmacology. Mianserin / analogs & derivatives
  • [MeSH-minor] Animals. Blotting, Western. Cues. Cyclic AMP Response Element-Binding Protein / metabolism. Extracellular Signal-Regulated MAP Kinases / metabolism. Male. Memory / drug effects. Phosphorylation. Rats. Rats, Sprague-Dawley. Receptors, Serotonin / drug effects. Signal Transduction / drug effects. Taste / drug effects

  • MedlinePlus Health Information. consumer health - Methamphetamine.
  • Hazardous Substances Data Bank. MIANSERIN .
  • Hazardous Substances Data Bank. d-METHAMPHETAMINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18945553.001).
  • [ISSN] 1879-0046
  • [Journal-full-title] Drug and alcohol dependence
  • [ISO-abbreviation] Drug Alcohol Depend
  • [Language] eng
  • [Grant] United States / NIDA NIH HHS / DA / DA015760; United States / NIDA NIH HHS / DA / DA016496; United States / NIDA NIH HHS / DA / DA019763; United States / NIDA NIH HHS / DA / DA023306
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Central Nervous System Stimulants; 0 / Cyclic AMP Response Element-Binding Protein; 0 / Receptors, Serotonin; 250PJI13LM / Mianserin; 44RAL3456C / Methamphetamine; A051Q2099Q / mirtazapine; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  •  go-up   go-down


17. Yang H, Liu S, Cai H, Wan L, Li S, Li Y, Cheng J, Lu X: Chondroitin sulfate as a molecular portal that preferentially mediates the apoptotic killing of tumor cells by penetratin-directed mitochondria-disrupting peptides. J Biol Chem; 2010 Aug 13;285(33):25666-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chondroitin sulfate as a molecular portal that preferentially mediates the apoptotic killing of tumor cells by penetratin-directed mitochondria-disrupting peptides.
  • The use of cell-penetrating peptides (CPPs) as drug carriers for targeted therapy is limited by the unrestricted cellular translocation of CPPs.
  • The preferential induction of tumor cell death by penetratin (Antp)-directed peptides (PNC27 and PNC28), however, suggests that the CPP Antp may contribute to the preferential cytotoxicity of these peptides.
  • The IC(50) values of PNC27 in tumor cells were 2-3 times lower than in normal cells.
  • However, all three engineered peptides demonstrated similar cytotoxic effects in tumor and normal cells.
  • Another three chimeric peptides containing the leader peptide Antp with different mitochondria-disrupting peptides (KLA-Antp (KGA), B27-Antp (BA27), and B28-Antp (BA28)), preferentially induced apoptosis in tumor cells.
  • The IC(50) values of these peptides (3-10 microM) were 3-6 times lower in tumor cells than in normal cells.
  • In contrast, TAT-directed peptides (TAT-KLA (TK), TAT-B27 (TB27), and TAT-B28 (TB28)), were cytotoxic to both tumor and normal cells.
  • Furthermore, Antp-directed peptides bind chondroitin sulfate (CS), and the removal of endogenous CS reduces the cytotoxic effects of Antp-directed peptides in tumor cells.
  • The overexpression of CS in tumor cells is positively correlated to the cell entry and cytotoxicity of Antp- directed peptides.
  • These results suggest that CS overexpression in tumor cells is an important molecular portal that mediates the preferential cytotoxicity of Antp-directed peptides.
  • [MeSH-major] Apoptosis / drug effects. Carrier Proteins / pharmacology. Chondroitin Sulfates / pharmacology. Mitochondria / drug effects. Mitochondria / metabolism. Peptides / pharmacology
  • [MeSH-minor] Animals. Biological Transport / drug effects. Cell Line. Cell Line, Tumor. Cell Survival / drug effects. Female. Glycosaminoglycans / metabolism. Glycosaminoglycans / pharmacology. HeLa Cells. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. Tumor Suppressor Protein p53 / pharmacology. Tumor Suppressor Protein p53 / therapeutic use. Xenograft Model Antitumor Assays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10233-7 [17079438.001]
  • [Cites] AAPS J. 2006;8(3):E532-51 [17025272.001]
  • [Cites] Eur J Cancer. 2007 Jun;43(9):1460-6 [17446061.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6368-75 [17616696.001]
  • [Cites] Biochem Soc Trans. 2007 Aug;35(Pt 4):788-93 [17635149.001]
  • [Cites] J Pharm Sci. 2008 Jan;97(1):144-62 [17763452.001]
  • [Cites] Acc Chem Res. 2008 Jan;41(1):98-107 [17705444.001]
  • [Cites] Bioconjug Chem. 2008 Jan;19(1):70-5 [18001077.001]
  • [Cites] Adv Drug Deliv Rev. 2008 Mar 1;60(4-5):580-97 [18045730.001]
  • [Cites] Org Biomol Chem. 2008 Jul 7;6(13):2242-55 [18563254.001]
  • [Cites] In Vivo. 2008 May-Jun;22(3):385-9 [18610752.001]
  • [Cites] J Biol Chem. 2008 Aug 29;283(35):24274-84 [18603532.001]
  • [Cites] Biochim Biophys Acta. 2008 Dec;1786(2):126-38 [18440319.001]
  • [Cites] Ann Surg Oncol. 2008 Dec;15(12):3588-600 [18931881.001]
  • [Cites] Curr Drug Discov Technol. 2008 Dec;5(4):289-301 [19075609.001]
  • [Cites] Bioconjug Chem. 2008 Dec;19(12):2363-74 [19053306.001]
  • [Cites] Cancer Metastasis Rev. 2009 Jun;28(1-2):233-45 [19160015.001]
  • [Cites] J Biol Chem. 1999 Dec 3;274(49):34924-31 [10574967.001]
  • [Cites] Curr Opin Cell Biol. 2000 Aug;12(4):400-6 [10873818.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12438-43 [11606716.001]
  • [Cites] Mol Cell Biol. 2002 Mar;22(6):1926-35 [11865069.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4282-8 [12154030.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Nov 1;298(3):439-49 [12413961.001]
  • [Cites] Oncogene. 2003 Mar 13;22(10):1431-44 [12629507.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1307-15 [12738679.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35109-14 [12837762.001]
  • [Cites] Cell Mol Life Sci. 2004 Jul;61(14):1785-94 [15241554.001]
  • [Cites] J Biol Chem. 1996 Nov 8;271(45):28375-81 [8910461.001]
  • [Cites] Cell. 1997 Feb 7;88(3):323-31 [9039259.001]
  • [Cites] Biochemistry. 1997 Feb 25;36(8):2104-11 [9047309.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 May 26;95(11):6079-84 [9600920.001]
  • [Cites] Nat Med. 1999 Sep;5(9):1032-8 [10470080.001]
  • [Cites] Int J Cancer. 2005 May 20;115(1):55-64 [15645452.001]
  • [Cites] Biochem J. 2005 Sep 1;390(Pt 2):407-18 [15859953.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7840-6 [16140953.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10646-50 [16322205.001]
  • [Cites] Mol Cancer Ther. 2006 Jan;5(1):20-8 [16432159.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3764-72 [16585203.001]
  • [Cites] Int J Cancer. 2006 Oct 1;119(7):1577-85 [16688716.001]
  • [Cites] Mol Cancer Ther. 2006 Aug;5(8):1944-9 [16928814.001]
  • [Cites] J Am Chem Soc. 2007 Apr 25;129(16):4961-72 [17397150.001]
  • (PMID = 20484051.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Glycosaminoglycans; 0 / PNC-27; 0 / Peptides; 0 / Tumor Suppressor Protein p53; 0 / penetratin; 9007-28-7 / Chondroitin Sulfates
  • [Other-IDs] NLM/ PMC2919130
  •  go-up   go-down


18. Toumba M, Bacopoulou I, Savva SC, Skordis N: Efficacy of combined treatment with growth hormone and gonadotropin releasing hormone analogue in children with poor prognosis of adult height. Indian Pediatr; 2007 Jul;44(7):497-502
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of combined treatment with growth hormone and gonadotropin releasing hormone analogue in children with poor prognosis of adult height.
  • OBJECTIVE: This study was conducted to study the role of combination therapy of growth hormone and Gonadotropin-releasing hormone (GnRH) analogues in girls with idiopathic central precocious puberty (CPP) or idiopathic short stature (ISS).
  • METHODS: Five girls with CPP (median age 9.1 y, pubertal stage 2-3) (3 of them previously treated with GnRH analogue (GnRHa) for 16.2 +/- 0.3 months) and 8 girls with ISS (median age 11.4 y, pubertal stage 2-3) (previously treated with GH for 10.95 +/- 1.42 months), were treated with recombinant human GH (0.33 mg/kg/week) and GnRHa (3.75 mg/28 days) for 22 months.
  • RESULTS: Height of girls with CPP improved from - 1.3 to - 0.2 SDS and height for BA from - 2.1 to - 0.6 SDS (P = 0.042).
  • CONCLUSION: Combined treatment improves height and PAH in CPP.
  • [MeSH-major] Body Height / drug effects. Gonadotropin-Releasing Hormone / analogs & derivatives. Growth Disorders / drug therapy. Growth Hormone / therapeutic use. Puberty, Precocious / drug therapy
  • [MeSH-minor] Algorithms. Bone Development / drug effects. Child. Drug Therapy, Combination. Female. Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Growth Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17684302.001).
  • [ISSN] 0019-6061
  • [Journal-full-title] Indian pediatrics
  • [ISO-abbreviation] Indian Pediatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 33515-09-2 / Gonadotropin-Releasing Hormone; 9002-72-6 / Growth Hormone
  •  go-up   go-down


19. Miller BS, Shukla AR: Sterile abscess formation in response to two separate branded long-acting gonadotropin-releasing hormone agonists. Clin Ther; 2010 Sep;32(10):1749-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Long-acting forms of gonadotropin-releasing hormone (GnRH) receptor agonists are commonly used for the treatment of central precocious puberty (CPP).
  • OBJECTIVE: The aim of this study was to report an adverse drug reaction in a child with sterile abscess formation following treatment with 2 different branded long-acting forms of GnRH agonists.
  • CASE SUMMARY: An otherwise healthy 8-year-old white female (weight, 40.7 kg; height, 140.1 cm) with documented CPP and no known drug allergies developed a sterile abscess at the site of the monthly intramuscular injection of 15 mg of leuprolide acetate.
  • At the time of the removal of the second insert, Gram stain and swab culture of the purulent wound discharge were negative.
  • The Naranjo Adverse Drug Reaction Causality Score was 10 (definite, ≥9).
  • CONCLUSION: This report describes a case of sterile abscess formation definitely associated with 2 different forms of long-acting GnRH agonist treatment in a child.
  • [MeSH-minor] Child. Delayed-Action Preparations. Drug Implants. Female. Humans. Injections, Intramuscular. Nafarelin / administration & dosage. Nafarelin / therapeutic use. Puberty, Precocious / drug therapy

  • MedlinePlus Health Information. consumer health - Abscess.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LEUPROLIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Excerpta Medica Inc. All rights reserved.
  • (PMID = 21194598.001).
  • [ISSN] 1879-114X
  • [Journal-full-title] Clinical therapeutics
  • [ISO-abbreviation] Clin Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Delayed-Action Preparations; 0 / Drug Implants; 0 / Receptors, LHRH; 1X0094V6JV / Nafarelin; 33515-09-2 / Gonadotropin-Releasing Hormone; EFY6W0M8TG / Leuprolide
  •  go-up   go-down


20. Gupte SA, Tateyama M, Okada T, Oka M, Ochi R: Epiandrosterone, a metabolite of testosterone precursor, blocks L-type calcium channels of ventricular myocytes and inhibits myocardial contractility. J Mol Cell Cardiol; 2002 Jun;34(6):679-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epiandrosterone, a metabolite of testosterone precursor, blocks L-type calcium channels of ventricular myocytes and inhibits myocardial contractility.
  • We found that EPI (10-100 microM) also dose-dependently decreases left-ventricular developed pressure (LVDP), the rate of myocardial contraction (+d p /d t), and the pressure rate product (PRP); at 100 microM EPI, LVDP (131+/-9 vs 34+/-7 mmHg), +d p /dt (1515+/-94 vs 542+/-185 mmHg/s), and PRP (37870+/-2471 vs 9498+/-2375 HR x mmHg/min) were all significantly (P<0.05) reduced.
  • EPI also elevated CPP in isolated hearts, decreased levels of myocardial NADPH and nitrite, and dose-dependently relaxed rat aortic rings pre-contracted with KCl.
  • Electrophysiological analysis of single ventricular myocytes using whole cell clamp showed EPI to dose-dependently (100 n M-100 microM) and reversibly inhibit L-type channel currents carried by Ba2+ (IBa) (IC50=42+/-6 microM) by as much as 50%.
  • These results suggest that EPI may act as a L-type Ca2+ channel antagonist with properties similar to those of 1,4-dihydropyridine (DHP) Ca2+ channel blockers.
  • [MeSH-major] Androsterone / physiology. Calcium / metabolism. Calcium Channel Blockers. Calcium Channels, L-Type / metabolism. Myocytes, Cardiac / metabolism

  • Hazardous Substances Data Bank. TESTOSTERONE .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Elsevier Science Ltd. All rights reserved.
  • (PMID = 12054855.001).
  • [ISSN] 0022-2828
  • [Journal-full-title] Journal of molecular and cellular cardiology
  • [ISO-abbreviation] J. Mol. Cell. Cardiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Calcium Channel Blockers; 0 / Calcium Channels, L-Type; 0 / Nitrites; 3XMK78S47O / Testosterone; 459AG36T1B / Dehydroepiandrosterone; 53-59-8 / NADP; C24W7J5D5R / Androsterone; SY7Q814VUP / Calcium
  •  go-up   go-down


21. Said Hassane F, Saleh AF, Abes R, Gait MJ, Lebleu B: Cell penetrating peptides: overview and applications to the delivery of oligonucleotides. Cell Mol Life Sci; 2010 Mar;67(5):715-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cell penetrating peptides (CPP), also named protein transduction domains, comprise short and usually basic amino acids-rich peptides originating from proteins able to cross biological barriers, such as the viral Tat protein, or are rationally designed.
  • They have emerged as a new class of non-viral vectors allowing the delivery of various biomolecules across biological barriers from low molecular weight drugs to nanosized particles.
  • Encouraging data with CPP-conjugated oligonucleotides have been obtained both in vitro and in vivo in animal models of diseases such as Duchenne muscular dystrophy.
  • Whether CPP-cargo conjugates enter cells by direct translocation across the plasma membrane or by endocytosis remains controversial.
  • [MeSH-major] Cells / metabolism. Drug Delivery Systems. Oligonucleotides / administration & dosage. Peptides / pharmacokinetics
  • [MeSH-minor] Animals. Cell Membrane Permeability / drug effects. Gene Transfer Techniques. Humans. Muscular Dystrophy, Duchenne / therapy

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Protein Pept Sci. 2003 Apr;4(2):133-40 [12678852.001]
  • [Cites] FEBS Lett. 2007 Feb 20;581(4):702-6 [17274989.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17867-72 [15601762.001]
  • [Cites] J Biol Chem. 2003 Sep 5;278(36):34141-9 [12773529.001]
  • [Cites] Cardiovasc Res. 2007 Mar 1;73(4):699-709 [17234167.001]
  • [Cites] Org Lett. 2003 Sep 18;5(19):3459-62 [12967299.001]
  • [Cites] Adv Drug Deliv Rev. 2008 Mar 1;60(4-5):452-72 [18164781.001]
  • [Cites] Adv Drug Deliv Rev. 2008 Mar 1;60(4-5):499-516 [18093693.001]
  • [Cites] Biochemistry. 1998 May 5;37(18):6235-9 [9572837.001]
  • [Cites] Biochim Biophys Acta. 2004 Oct 11;1665(1-2):48-56 [15471570.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14814-9 [18806224.001]
  • [Cites] J Biol Chem. 1994 Apr 8;269(14):10444-50 [8144628.001]
  • [Cites] Eur J Biochem. 2001 Mar;268(5):1304-14 [11231282.001]
  • [Cites] J Control Release. 2005 Jan 20;102(1):247-53 [15653149.001]
  • [Cites] J Biol Chem. 2005 Apr 15;280(15):15300-6 [15687490.001]
  • [Cites] Bioconjug Chem. 2000 May-Jun;11(3):301-5 [10821645.001]
  • [Cites] Bioconjug Chem. 1999 Mar-Apr;10(2):186-91 [10077466.001]
  • [Cites] Biochem Soc Trans. 2007 Aug;35(Pt 4):821-5 [17635156.001]
  • [Cites] FASEB J. 1998 Jan;12(1):67-77 [9438412.001]
  • [Cites] J Biol Chem. 2001 Jul 13;276(28):26204-10 [11346640.001]
  • [Cites] Biochim Biophys Acta. 2001 Dec 1;1515(2):101-9 [11718666.001]
  • [Cites] Hum Mol Genet. 2009 Nov 15;18(22):4405-14 [19692354.001]
  • [Cites] Nucleic Acids Res. 2001 Oct 1;29(19):3965-74 [11574678.001]
  • [Cites] J Pharm Sci. 2008 Jan;97(1):144-62 [17763452.001]
  • [Cites] J Control Release. 2008 Nov 24;132(1):21-5 [18727945.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):42-7 [11120883.001]
  • [Cites] Biochem J. 2002 Nov 1;367(Pt 3):761-9 [12137567.001]
  • [Cites] J Biol Chem. 2003 Dec 12;278(50):50188-94 [14517218.001]
  • [Cites] Nucleic Acids Res. 1997 Jul 15;25(14):2730-6 [9207018.001]
  • [Cites] J Virol. 2007 Jun;81(11):5637-48 [17344287.001]
  • [Cites] Nat Med. 2004 Mar;10(3):310-5 [14770178.001]
  • [Cites] Lancet Neurol. 2009 Oct;8(10):918-28 [19713152.001]
  • [Cites] Curr Opin Mol Ther. 2001 Apr;3(2):147-52 [11338927.001]
  • [Cites] Nucleic Acids Res. 2008 Nov;36(20):6343-54 [18796528.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35109-14 [12837762.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):664-8 [8290579.001]
  • [Cites] Oligonucleotides. 2006 Summer;16(2):145-57 [16764538.001]
  • [Cites] Adv Drug Deliv Rev. 2008 Mar 1;60(4-5):608-13 [18037528.001]
  • [Cites] J Biol Chem. 1997 Jun 20;272(25):16010-7 [9188504.001]
  • [Cites] Trends Neurosci. 2007 Jun;30(6):260-7 [17418905.001]
  • [Cites] Science. 1999 Sep 3;285(5433):1569-72 [10477521.001]
  • [Cites] Adv Drug Deliv Rev. 2008 Aug 17;60(11):1241-51 [18508157.001]
  • [Cites] Nat Med. 2006 Feb;12(2):175-7 [16444267.001]
  • [Cites] Nat Biotechnol. 2009 Jun;27(6):567-71 [19448630.001]
  • [Cites] Bioconjug Chem. 2000 Nov-Dec;11(6):762-71 [11087323.001]
  • [Cites] J Control Release. 2009 Mar 19;134(3):221-7 [19105971.001]
  • [Cites] Adv Drug Deliv Rev. 2005 Feb 28;57(4):579-96 [15722165.001]
  • [Cites] Nucleic Acids Res. 2007;35(13):4495-502 [17584792.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Feb 22;291(2):367-71 [11846414.001]
  • [Cites] J Pept Res. 2000 Nov;56(5):318-25 [11095185.001]
  • [Cites] Mol Biol Cell. 2004 May;15(5):2347-60 [15020715.001]
  • [Cites] Traffic. 2007 Jul;8(7):848-66 [17587406.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12128-33 [18713866.001]
  • [Cites] Nat Biotechnol. 1998 Sep;16(9):857-61 [9743120.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8786-91 [11438707.001]
  • [Cites] J Biol Chem. 2009 Feb 6;284(6):3370-8 [19047062.001]
  • [Cites] Biol Cell. 2008 Apr;100(4):201-17 [18341479.001]
  • [Cites] Mol Pharmacol. 2002 Oct;62(4):864-72 [12237333.001]
  • [Cites] Mol Pharm. 2009 May-Jun;6(3):686-95 [19397332.001]
  • [Cites] N Engl J Med. 2007 Dec 27;357(26):2677-86 [18160687.001]
  • [Cites] J Control Release. 2006 Feb 21;110(3):595-604 [16377019.001]
  • [Cites] Hum Mol Genet. 2008 Dec 15;17(24):3909-18 [18784278.001]
  • [Cites] Mol Ther. 2007 Sep;15(9):1587-92 [17579573.001]
  • [Cites] Nucleic Acids Res. 2005 Nov 30;33(21):6837-49 [16321967.001]
  • [Cites] Int J Mol Sci. 2008 Jun;9(7):1276-320 [19325804.001]
  • [Cites] Eur J Cardiothorac Surg. 2005 Jan;27(1):117-21 [15621482.001]
  • [Cites] Chembiochem. 2006 Oct;7(10):1497-515 [16972294.001]
  • [Cites] RNA. 2007 Oct;13(10):1609-24 [17684229.001]
  • [Cites] Nucleic Acids Res. 2008 Nov;36(20):6418-28 [18842625.001]
  • [Cites] FEBS Lett. 2006 Feb 20;580(5):1451-6 [16460737.001]
  • [Cites] J Biol Chem. 2003 Jan 3;278(1):585-90 [12411431.001]
  • [Cites] New Biol. 1991 Nov;3(11):1121-34 [1777485.001]
  • [Cites] Adv Drug Deliv Rev. 2008 Mar 1;60(4-5):517-29 [18037527.001]
  • [Cites] J Neurosci. 2004 Aug 4;24(31):6880-8 [15295022.001]
  • [Cites] J Control Release. 2006 Dec 1;116(3):304-13 [17097177.001]
  • [Cites] Nucleic Acids Res. 2009 Aug;37(14):4559-69 [19483097.001]
  • [Cites] Biochemistry. 2001 Feb 13;40(6):1824-34 [11327845.001]
  • [Cites] Adv Drug Deliv Rev. 2008 Mar 1;60(4-5):548-58 [18053612.001]
  • [Cites] Curr Pharm Des. 2008;14(24):2415-47 [18781991.001]
  • [Cites] J Med Chem. 2002 Aug 15;45(17):3612-8 [12166934.001]
  • [Cites] J Pept Sci. 2008 Apr;14(4):455-60 [18236382.001]
  • [Cites] Bioconjug Chem. 2005 Sep-Oct;16(5):1176-80 [16173795.001]
  • [Cites] Hum Mol Genet. 1998 Jul;7(7):1083-90 [9618164.001]
  • [Cites] Curr Pharm Des. 2008;14(34):3628-36 [19075739.001]
  • [Cites] J Gene Med. 2006 Feb;8(2):207-16 [16285002.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1768-75 [11280720.001]
  • [Cites] Cell. 1988 Dec 23;55(6):1189-93 [2849510.001]
  • [Cites] Mol Ther. 2008 Sep;16(9):1624-9 [18545222.001]
  • [Cites] Biochim Biophys Acta. 1998 Nov 11;1414(1-2):127-39 [9804921.001]
  • [Cites] Expert Opin Drug Deliv. 2006 Nov;3(6):739-46 [17076596.001]
  • [Cites] Nat Med. 2000 Nov;6(11):1253-7 [11062537.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):198-203 [15608067.001]
  • [Cites] J Control Release. 2007 Apr 2;118(2):216-24 [17239466.001]
  • [Cites] Chem Biol. 2005 Aug;12(8):923-9 [16125104.001]
  • [Cites] Biopolymers. 2008;90(5):604-10 [18381624.001]
  • [Cites] J Biol Chem. 2001 Feb 23;276(8):5836-40 [11084031.001]
  • [Cites] Pharm Res. 2004 Sep;21(9):1662-9 [15497694.001]
  • (PMID = 19898741.001).
  • [ISSN] 1420-9071
  • [Journal-full-title] Cellular and molecular life sciences : CMLS
  • [ISO-abbreviation] Cell. Mol. Life Sci.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U105178803
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Oligonucleotides; 0 / Peptides
  • [Number-of-references] 99
  •  go-up   go-down


22. Esmaeili B, Basseda Z, Dehpour AR: Antagonism of muscarinic M1 receptors by dicyclomine inhibits the consolidation of morphine-associated contextual memory. Brain Res Bull; 2008 Jul 1;76(4):380-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • M1 muscarinic receptor has been shown to be involved in cognitive functions of the brain.
  • Conditioned place preference (CPP) paradigm involves memory for the association between environmental stimuli and the rewarding properties produced by a treatment.
  • Using a balanced CPP design, we studied the possible involvement of M1 muscarinic receptors on the acquisition, expression and consolidation of morphine place conditioning in male mice.
  • Subcutaneous administration of morphine sulphate-induced CPP in a dose-dependent manner.
  • Using a 6-day schedule of conditioning, it was found that dicyclomine, an M1 muscarinic antagonist, significantly reduced the time spent by mice in the morphine compartment when given immediately, but not 6h, after each conditioning session (consolidation).
  • It had no effect when administered 30 min before each conditioning session during CPP training period (acquisition) or 30 min before testing for place preference in the absence of morphine (expression).
  • It is concluded that M1 muscarinic receptors may play a time-dependent role in the consolidation of reward-related memory of morphine.
  • [MeSH-major] Dicyclomine / pharmacology. Learning / drug effects. Memory / drug effects. Morphine / pharmacology. Receptor, Muscarinic M1 / antagonists & inhibitors
  • [MeSH-minor] Animals. Brain / drug effects. Brain / metabolism. Conditioning (Psychology) / drug effects. Conditioning (Psychology) / physiology. Dose-Response Relationship, Drug. Drug Interactions / physiology. Male. Mice. Morphine Dependence / drug therapy. Morphine Dependence / metabolism. Muscarinic Antagonists / pharmacology. Narcotics / pharmacology. Reward. Time Factors

  • MedlinePlus Health Information. consumer health - Memory.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MORPHINE .
  • Hazardous Substances Data Bank. DICYCLOMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18502314.001).
  • [ISSN] 1873-2747
  • [Journal-full-title] Brain research bulletin
  • [ISO-abbreviation] Brain Res. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Muscarinic Antagonists; 0 / Narcotics; 0 / Receptor, Muscarinic M1; 4KV4X8IF6V / Dicyclomine; 76I7G6D29C / Morphine
  •  go-up   go-down


23. Wrede B, Liu P, Wolff JE: Chemotherapy improves the survival of patients with choroid plexus carcinoma: a meta-analysis of individual cases with choroid plexus tumors. J Neurooncol; 2007 Dec;85(3):345-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy improves the survival of patients with choroid plexus carcinoma: a meta-analysis of individual cases with choroid plexus tumors.
  • BACKGROUND: Choroid plexus carcinomas (CPC) are rare brain tumors with a dismal prognosis.
  • Although the role of surgery has been well established, the question of whether chemotherapy improves the prognosis is still under discussion.
  • METHODS: We created a database of all cases of choroid plexus tumors (CPT) reported in the literature up to the year 2004 to determine prognostic factors and different therapeutic modalities.
  • RESULTS: Of 857 documented cases of CPT (median patient age at diagnosis, 3 years), 347 were CPC, 15 atypical choroid plexus papilloma (APP), and 495 choroid plexus papilloma (CPP).
  • The 104 CPC patients who received chemotherapy had a statistically better survival than those without chemotherapy (P = .0004).
  • When subgroups were defined by radiation treatment, chemotherapy remained beneficial in the subgroup of nonirradiated tumors (P = .0001).
  • The benefit of chemotherapy was also significant when the analysis was restricted to the subgroup of patients with less than completely resected CPC (2-year overall survival (OS) 54.8 +/- 7% (standard deviation (SD) vs. 24.4 +/- 7%, P < .0001) and when this subgroup was further divided into smaller subgroups.
  • Likewise, in a multivariate analysis, chemotherapy was highly significantly linked to better prognosis (P = .0001).
  • CONCLUSION: Patients with less than completely resected CPC should receive chemotherapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma / drug therapy. Choroid Plexus Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Child. Child, Preschool. Combined Modality Therapy. Databases, Bibliographic. Databases, Factual. Female. Humans. Infant. Infant, Newborn. Male. Middle Aged. Prognosis. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Choroid Plexus Carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2002 Apr;57(2):123-6 [12125972.001]
  • [Cites] Pediatr Neurosurg. 1999 Sep;31(3):127-30 [10708353.001]
  • [Cites] Med Pediatr Oncol. 1993;21(7):480-7 [8341215.001]
  • [Cites] Lancet. 1999 Jun 19;353(9170):2126 [10382700.001]
  • [Cites] Eur J Pediatr. 1983 Mar;140(1):51-6 [6873113.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 May 1;44(2):249-54 [10760416.001]
  • [Cites] Cancer. 1992 Jan 15;69(2):580-5 [1728390.001]
  • [Cites] Brain Pathol. 2003 Jul;13(3):409-14 [12946029.001]
  • [Cites] Am J Hum Genet. 1999 Nov;65(5):1342-8 [10521299.001]
  • [Cites] Med Pediatr Oncol. 1994;22(4):274-8 [8107660.001]
  • [Cites] Pediatr Neurosci. 1989;15(4):195-206 [2485914.001]
  • [Cites] Pediatr Neurosurg. 1991-1992;17(5):225-33 [1822687.001]
  • [Cites] J Neurosurg. 1987 Jun;66(6):800-5 [3572508.001]
  • [Cites] Anticancer Res. 2005 Nov-Dec;25(6C):4429-33 [16334121.001]
  • [Cites] Histopathology. 1995 Feb;26(2):137-43 [7737660.001]
  • [Cites] Indian Pediatr. 1993 Oct;30(10):1217-8 [8077013.001]
  • [Cites] J Neurosurg. 1983 Sep;59(3):369-83 [6886750.001]
  • [Cites] Acta Neurochir (Wien). 1979;50(1-2):79-90 [316268.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(6):557-63 [9755322.001]
  • [Cites] Noshuyo Byori. 1996 Nov;13(2):99-105 [8958514.001]
  • [Cites] Neuropediatrics. 1996 Jun;27(3):143-8 [8837074.001]
  • [Cites] Neurol Med Chir (Tokyo). 1995 Oct;35(10):742-4 [8532130.001]
  • [Cites] Pediatr Neurosurg. 1995;22(4):189-96 [7619719.001]
  • [Cites] Acta Oncol. 1990;29(2):241-3 [2185805.001]
  • [Cites] Neurosurgery. 1998 Mar;42(3):470-5 [9526979.001]
  • [Cites] J Neurosurg. 1980 Feb;52(2):251-5 [7351566.001]
  • [Cites] J Neurosurg. 1988 Dec;69(6):843-9 [3193190.001]
  • [Cites] Br J Cancer. 2002 Nov 4;87(10):1086-91 [12402146.001]
  • [Cites] Neoplasma. 2004;51(4):306-12 [15254663.001]
  • [Cites] Childs Brain. 1975;1(2-3):81-115 [1081032.001]
  • [Cites] Childs Nerv Syst. 1999 Oct;15(10):571-7 [10550588.001]
  • [Cites] Neurosurgery. 1980 Apr;6(4):380-4 [7393420.001]
  • [Cites] Neurosurgery. 1989 Sep;25(3):327-35 [2771002.001]
  • [Cites] Neurol Med Chir (Tokyo). 1996 Mar;36(3):179-84 [8869156.001]
  • [Cites] J Neurooncol. 1992 Jan;12 (1):69-74 [1541980.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):66-74 [16330944.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 May;64(5):391-7 [15892296.001]
  • [Cites] J Neurosurg. 1998 Mar;88(3):521-8 [9488307.001]
  • [Cites] Pediatr Neurosci. 1988;14(3):134-9 [3075286.001]
  • (PMID = 17576522.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


24. Peng PW, Castano ED: Survey of chronic pain practice by anesthesiologists in Canada. Can J Anaesth; 2005 Apr;52(4):383-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To describe the pattern of chronic pain practice (CPP) among anesthesiologists in Canada.
  • While 38% of responding anesthesiologists were involved in CPP, in the majority of cases, this accounted for less than 20% of their clinical time.
  • Thirty percent of those involved in CPP had previous training in pain management.
  • The types of CPP included nerve blocks (84%) and pharmacological treatment (60%) in non-cancer pain (85%) and cancer pain (50%) patients.
  • Ten percent and 28% of anesthesiologists were involved in research and teaching respectively while 26% were affiliated with a multidisciplinary clinic.
  • Seventy percent of anesthesiologists prescribed opioids as part of their CPP.
  • [MeSH-minor] Analgesia, Epidural. Analgesics, Opioid / therapeutic use. Autonomic Nerve Block. Chronic Disease. Humans. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Pain.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15814753.001).
  • [ISSN] 0832-610X
  • [Journal-full-title] Canadian journal of anaesthesia = Journal canadien d'anesthésie
  • [ISO-abbreviation] Can J Anaesth
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Analgesics, Opioid
  •  go-up   go-down


25. Herzig V, Schmidt WJ: Anti-craving drugs acamprosate and naloxone do not reduce expression of morphine conditioned place preference in isolated and group-housed rats. Neurosci Lett; 2005 Feb 10;374(2):119-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-craving drugs acamprosate and naloxone do not reduce expression of morphine conditioned place preference in isolated and group-housed rats.
  • Relapse prevention in clean addicts is a great challenge for addiction-therapy.
  • As strong cravings often precede relapse, anti-craving drugs seem to be a promising way for addicts to stay clean.
  • Naloxone and acamprosate are two candidates for anti-craving drugs that are already used for relapse prevention in alcoholic patients.
  • However, it has to be figured out if both drugs are also effective in opiate-addicts.
  • In order to evaluate their effectiveness, a conditioned place preference (CPP) paradigm was used in rats conditioned to 10 mg/kg, i.p., morphine.
  • As acamprosate and naloxone have been suggested to selectively affect different types of craving (withdrawal-craving versus reward-craving), we have tried to modulate craving-behaviour by maintaining two groups of rats under different conditions (isolated versus group-housed).
  • Thereafter, the effectiveness of acamprosate (200 mg/kg, i.p.) and naloxone (2 mg/kg, i.p.) in reducing morphine-CPP expression was evaluated.
  • As a result, isolation produced a weak reduction in morphine-CPP development.
  • Furthermore, acamprosate and naloxone had no effect on morphine-CPP expression.
  • Based on the present results, we assume that the anti-craving drugs acamprosate and naloxone may not be effective for relapse prevention in opiate-addicts.
  • [MeSH-major] Alcohol Deterrents / pharmacology. Conditioning, Operant / drug effects. Morphine / pharmacology. Naloxone / pharmacology. Narcotic Antagonists / pharmacology. Narcotics / pharmacology. Taurine / analogs & derivatives. Taurine / pharmacology
  • [MeSH-minor] Analysis of Variance. Animals. Behavior, Animal. Drug Interactions. Locomotion / drug effects. Male. Rats. Rats, Sprague-Dawley. Social Isolation. Spatial Behavior / drug effects

  • MedlinePlus Health Information. consumer health - Opioid Abuse and Addiction.
  • Hazardous Substances Data Bank. Taurine .
  • Hazardous Substances Data Bank. NALOXONE .
  • Hazardous Substances Data Bank. MORPHINE .
  • Hazardous Substances Data Bank. ACAMPROSATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15644276.001).
  • [ISSN] 0304-3940
  • [Journal-full-title] Neuroscience letters
  • [ISO-abbreviation] Neurosci. Lett.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Alcohol Deterrents; 0 / Narcotic Antagonists; 0 / Narcotics; 1EQV5MLY3D / Taurine; 36B82AMQ7N / Naloxone; 76I7G6D29C / Morphine; N4K14YGM3J / acamprosate
  •  go-up   go-down


26. Stubbe HD, Greiner C, Westphal M, Rickert CH, Aken HV, Eichel V, Wassmann H, Daudel F, Hinder F: Cerebral response to norepinephrine compared with fluid resuscitation in ovine traumatic brain injury and systemic inflammation. Crit Care Med; 2006 Oct;34(10):2651-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebral response to norepinephrine compared with fluid resuscitation in ovine traumatic brain injury and systemic inflammation.
  • OBJECTIVE: Traumatic brain injury is frequently accompanied by a systemic inflammatory response.
  • The present study investigated the cerebral effects of cerebral perfusion pressure (CPP) management performed by either fluid resuscitation or vasopressor treatment of low CPP induced by systemic inflammation.
  • At hour 10, one group (n = 6) was infused with hydroxyethyl starch until CPP reached 60-70 mm Hg.
  • A second group (n = 6) received norepinephrine for CPP elevation.
  • Head trauma increased intracranial pressure and decreased brain tissue oxygen tension.
  • Endotoxemia induced a hyperdynamic cardiovascular response with increased internal carotid blood flow in the presence of systemic hypotension and decreased CPP.
  • Hydroxyethyl starch infusion further increased internal carotid blood flow from (mean +/- sd) 247 +/- 26 (hour 10) to 342 +/- 42 mL/min (hour 13) and intracranial pressure from 20 +/- 4 (hour 10) to a maximum of 25 +/- 3 mm Hg (hour 12) but did not significantly affect brain tissue oxygen tension, sinus venous oxygen saturation and oxygen extraction fraction.
  • Norepinephrine increased internal carotid blood flow from 268 +/- 19 to 342 +/- 58 mL/min and intracranial pressure from 22 +/- 11 to 24 +/- 11 mm Hg (hour 10 vs. hour 13) but significantly increased sinus venous oxygen saturation from 49 +/- 4 (hour 10) to a maximum of 59 +/- 6 mm Hg (hour 12) and decreased oxygen extraction fraction.
  • The increase in brain tissue oxygen tension during norepinephrine treatment was not significant.
  • CONCLUSION: We conclude that despite identical carotid blood flows, only CPP management with norepinephrine reduced the cerebral oxygen deficit in this model.
  • [MeSH-major] Brain Injuries / therapy. Cerebrovascular Circulation. Fluid Therapy. Norepinephrine / therapeutic use. Systemic Inflammatory Response Syndrome / therapy. Vasoconstrictor Agents / therapeutic use
  • [MeSH-minor] Animals. Hemodynamics / drug effects. Intracranial Pressure / drug effects. Sheep

  • Hazardous Substances Data Bank. Norepinephrine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Crit Care Med. 2006 Oct;34(10):2697-8 [16983278.001]
  • (PMID = 16932232.001).
  • [ISSN] 0090-3493
  • [Journal-full-title] Critical care medicine
  • [ISO-abbreviation] Crit. Care Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vasoconstrictor Agents; X4W3ENH1CV / Norepinephrine
  •  go-up   go-down


27. Salluh JI, Martins GA, Santino MS, Araújo LV, Freitas GG, Verdeal JC: Early use of terlipressin in catecholamine-resistant shock improves cerebral perfusion pressure in severe traumatic brain injury. Acta Anaesthesiol Scand; 2007 Apr;51(4):505-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early use of terlipressin in catecholamine-resistant shock improves cerebral perfusion pressure in severe traumatic brain injury.
  • BACKGROUND: Maintaining adequate cerebral perfusion pressure is an essential aspect in the treatment of severe acute brain injury.
  • To accomplish this therapeutic goal vasopressors are usually required.
  • The patient had suffered severe traumatic brain injury, the Glasgow coma score (GCS) was four and there were signs of aspiration of gastric contents.
  • DISCUSSION: The present report illustrates the potential benefits of terlipressin in refractory shock in a patient with severe traumatic brain injury.
  • An increase in cerebral perfusion pressure (CPP) and a huge decrease in the dose of norepinephrine were observed.
  • In the setting of severe brain injury associated with refractory hypotension, terlipressin may improve mean arterial pressure and cerebral perfusion pressure.
  • CONCLUSION: In the setting of severe brain injury associated with refractory hypotension, terlipressin may have a role as a rescue therapy.
  • [MeSH-major] Brain Injuries / complications. Catecholamines / administration & dosage. Cerebrovascular Circulation / drug effects. Drug Resistance. Lypressin / analogs & derivatives. Shock / drug therapy
  • [MeSH-minor] Accidents, Traffic. Adolescent. Blood Pressure / drug effects. Fatal Outcome. Humans. Male. Motorcycles. Multiple Organ Failure / etiology. Norepinephrine / administration & dosage. Oxygen / blood. Respiratory Distress Syndrome, Adult / etiology. Severity of Illness Index. Systemic Inflammatory Response Syndrome / complications. Time Factors. Vasoconstrictor Agents / therapeutic use

  • MedlinePlus Health Information. consumer health - Shock.
  • Hazardous Substances Data Bank. Norepinephrine .
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Anaesthesiol Scand. 2007 Aug;51(7):957 [17635407.001]
  • (PMID = 17378791.001).
  • [ISSN] 0001-5172
  • [Journal-full-title] Acta anaesthesiologica Scandinavica
  • [ISO-abbreviation] Acta Anaesthesiol Scand
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Catecholamines; 0 / Vasoconstrictor Agents; 50-57-7 / Lypressin; 7Z5X49W53P / terlipressin; S88TT14065 / Oxygen; X4W3ENH1CV / Norepinephrine
  •  go-up   go-down


28. Maffeis C, Franceschi R, Moghetti P, Camilot M, Lauriola S, Tatò L: Circulating ghrelin levels in girls with central precocious puberty are reduced during treatment with LHRH analog. Eur J Endocrinol; 2007 Jan;156(1):99-103
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating ghrelin levels in girls with central precocious puberty are reduced during treatment with LHRH analog.
  • No data are available for girls with central precocious puberty (CPP).
  • AIMS: To explore ghrelin changes before, during, and after GnRH analog treatment in girls with CPP.
  • SUBJECTS AND METHODS: A sample of 20 Caucasian girls (8.08 +/- 0.65 years of age) with CPP was recruited.
  • Height and weight, bone age, LH, FSH, 17beta estradiol (E(2)), and ghrelin were measured before starting treatment with GnRH analog, 18 months after therapy began and again 6 months after therapy discontinuation.
  • RESULTS: LH and E(2) serum levels decreased significantly during treatment (2.45 +/- 2.03 vs 0.67 +/- 0.49 UI/l, P < 0.01 and 28.17 +/- 9.7 vs 15 pmol/l, P < 0.01 respectively), returning to baseline levels after the discontinuation of therapy (4.75 +/- 1.66 UI/l and 29.23 +/- 6.99 pmol/l respectively).
  • LH peaked following LHRH stimulation significantly (P < 0.01) decreased during treatment (24.45 +/- 14.17 vs 1.3 +/- 0.18 UI/l) and then increased after therapy discontinuation (12.58 +/- 6.09, P < 0.01).
  • Ghrelin decreased significantly (P < 0.05) during treatment (1849 +/- 322 vs 1207 +/- 637 pg/ml), and increased, though not significantly (P = 0.09) after therapy withdrawal (1567 +/- 629 pg/ml).
  • CONCLUSIONS: Contrary to what is expected in physiologic puberty, where ghrelin is progressively reduced, the prepubertal hormone milieau induced by GnRHa treatment in patients suffering from central precocious puberty (CPP) did not promote an increase in ghrelin circulating levels.
  • Therefore, in CPP, ghrelin secretion seems to be independent from pubertal development per se.
  • Concomitant estrogen suppression during treatment may play a potential role in the regulation of ghrelin secretion in these girls.

  • Genetic Alliance. consumer health - Precocious puberty.
  • Genetic Alliance. consumer health - Central precocious puberty.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17218731.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ghrelin; 0 / Gonadal Steroid Hormones; 0 / Peptide Hormones; 33515-09-2 / Gonadotropin-Releasing Hormone; 4TI98Z838E / Estradiol; 9002-67-9 / Luteinizing Hormone
  •  go-up   go-down


29. Beaumont A, Hayasaki K, Marmarou A, Barzo P, Fatouros P, Corwin F: Contrasting effects of dopamine therapy in experimental brain injury. J Neurotrauma; 2001 Dec;18(12):1359-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contrasting effects of dopamine therapy in experimental brain injury.
  • Management of cerebral perfusion pressure (CPP) is thought to be important for the treatment of traumatic brain injury (TBI).
  • Vasopressors have been advocated as a method of increasing mean arterial blood pressure (mABP) and cerebral perfusion pressure (CPP) in the face of rising intracranial pressure (ICP).
  • There are unresolved issues and theoretical risks about this therapy.
  • This study therefore examined the effects of dopamine on physiological and MRI/MRS parameters in (1) a rodent model of rapidly rising intracranial pressure, caused by diffuse injury with secondary insult and (2) a model of cortical contusion.
  • Dopamine was capable of restoring CPP in the model of rapidly rising ICP.
  • This CPP restoration was associated with a partial restoration of CBF.
  • MRI assessed tissue water content was increased four hours after injury and dopamine increased cerebral water content in both subgroups of injury; significantly in the group with a persistently low ADCw (p < 0.01).
  • This occurred in the absence of ADCw changes, except in the contralateral hippocampus, where both water content and ADCw values rose with treatment, suggesting extracellular accumulation of water.
  • In conclusion, although dopamine is capable of partially restoring CBF after injury, situations exist in which dopamine therapy worsens the swelling process.
  • It is possible therefore that subgroups of patients exist who experience adverse effects of vasopressor treatment, and consequently the effects of vasopressor therapy in the clinical setting need to be more carefully evaluated.
  • [MeSH-major] Brain Injuries / drug therapy. Dopamine / therapeutic use
  • [MeSH-minor] Animals. Brain Edema / chemically induced. Brain Edema / drug therapy. Brain Edema / physiopathology. Cerebrovascular Circulation / drug effects. Cerebrovascular Circulation / physiology. Intracranial Pressure / drug effects. Intracranial Pressure / physiology. Male. Rats. Rats, Sprague-Dawley

  • Hazardous Substances Data Bank. DOPAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11780866.001).
  • [ISSN] 0897-7151
  • [Journal-full-title] Journal of neurotrauma
  • [ISO-abbreviation] J. Neurotrauma
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] VTD58H1Z2X / Dopamine
  •  go-up   go-down


30. Howells T, Elf K, Jones PA, Ronne-Engström E, Piper I, Nilsson P, Andrews P, Enblad P: Pressure reactivity as a guide in the treatment of cerebral perfusion pressure in patients with brain trauma. J Neurosurg; 2005 Feb;102(2):311-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pressure reactivity as a guide in the treatment of cerebral perfusion pressure in patients with brain trauma.
  • OBJECT: The aim of this study was to compare the effects of two different treatment protocols on physiological characteristics and outcome in patients with brain trauma.
  • One protocol was primarily oriented toward reducing intracranial pressure (ICP), and the other primarily on maintaining cerebral perfusion pressure (CPP).
  • METHODS: A series of 67 patients in Uppsala were treated according to a protocol aimed at keeping ICP less than 20 mm Hg and, as a secondary target, CPP at approximately 60 mm Hg.
  • Another series of 64 patients in Edinburgh were treated according to a protocol aimed primarily at maintaining CPP greater than 70 mm Hg and, secondarily, ICP less than 25 mm Hg for the first 24 hours and 30 mm Hg subsequently.
  • The ICP and CPP insults were assessed as the percentage of monitoring time that ICP was greater than or equal to 20 mm Hg and CPP less than 60 mm Hg, respectively.
  • In patients treated according to the CPP-oriented protocol, even short durations of CPP insults were strong predictors of death.
  • In patients treated according to the ICP-oriented protocol, even long durations of CPP insult-mostly in the range of 50 to 60 mm Hg--were significant predictors of favorable outcome (GOS Score 4 or 5).
  • Among those who had undergone ICP-oriented treatment, pressure-passive patients (MABP/ICP slope > or = 0.13) had a better outcome.
  • Among those who had undergone CPP-oriented treatment, the more pressure-active (MABP/ICP slope < 0.13) patients had a better outcome.
  • CONCLUSION: Based on data from this study, the authors concluded that ICP-oriented therapy should be used in patients whose slope of the MABP/ICP regression line is at least 0.13, that is, in pressure-passive patients.
  • If the slope is less than 0.13, then hypertensive CPP therapy is likely to produce a better outcome.
  • [MeSH-major] Antihypertensive Agents / therapeutic use. Blood Pressure / physiology. Brain / blood supply. Brain Injuries / drug therapy. Brain Injuries / physiopathology. Hypnotics and Sedatives / therapeutic use. Vasoconstrictor Agents / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Critical Care. Female. Glasgow Coma Scale. Glasgow Outcome Scale. Homeostasis / drug effects. Homeostasis / physiology. Hospitals, University. Humans. Intracranial Pressure / drug effects. Intracranial Pressure / physiology. Linear Models. Male. Middle Aged. Monitoring, Physiologic. Prognosis. Scotland. Signal Processing, Computer-Assisted. Sweden. Treatment Outcome


31. Endoh T, Sisido M, Ohtsuki T: Cellular siRNA delivery mediated by a cell-permeant RNA-binding protein and photoinduced RNA interference. Bioconjug Chem; 2008 May;19(5):1017-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HIV-1 TAT peptide, which is a cell-penetrating peptide (CPP), was fused to the U1A RNA-binding domain (TatU1A) to generate a sequence-specific siRNA delivery system for mammalian cells.
  • Although most of the internalized siRNA seemed to be entrapped in endocytic compartments, efficient redistribution of the entrapped siRNAs was achieved by photostimulation of a fluorophore attached to TatU1A.
  • CLIP-RNAi is a promising strategy for RNAi experiments and for pinpoint RNAi therapy.
  • [MeSH-major] Drug Delivery Systems. RNA Interference. RNA, Small Interfering / metabolism
  • [MeSH-minor] AIDS Vaccines / chemistry. AIDS Vaccines / genetics. AIDS Vaccines / metabolism. Animals. CHO Cells. Cells, Cultured. Cricetinae. Cricetulus. Electrophoretic Mobility Shift Assay. Endosomes / drug effects. Endosomes / metabolism. Endosomes / radiation effects. Gene Silencing / drug effects. Green Fluorescent Proteins / drug effects. Green Fluorescent Proteins / genetics. Green Fluorescent Proteins / metabolism. Photochemistry. Receptor, Epidermal Growth Factor / drug effects. Receptor, Epidermal Growth Factor / genetics. Receptor, Epidermal Growth Factor / metabolism. Recombinant Fusion Proteins / chemistry. Recombinant Fusion Proteins / genetics. Recombinant Fusion Proteins / metabolism

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18442282.001).
  • [ISSN] 1520-4812
  • [Journal-full-title] Bioconjugate chemistry
  • [ISO-abbreviation] Bioconjug. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AIDS Vaccines; 0 / RNA, Small Interfering; 0 / Recombinant Fusion Proteins; 0 / human immunodeficiency virus type 1 Tat vaccine; 147336-22-9 / Green Fluorescent Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


32. Crinò A, Di Giorgio G, Schiaffini R, Fierabracci A, Spera S, Maggioni A, Gattinara GC: Central precocious puberty and growth hormone deficiency in a boy with Prader-Willi syndrome. Eur J Pediatr; 2008 Dec;167(12):1455-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Only a few cases of central precocious puberty (CPP) have been reported.
  • We describe an 8.8-year-old PWS boy, with microdeletion of chromosome 15q, who developed CPP.
  • LHRH analogue therapy (Leuproreline 3.75 mg/28 days i.m.) was started at 8.9 years and discontinued at 11.3 years, when the patient had bone age of 13 years.
  • During therapy, growth velocity, testosterone, FSH, and LH peak decreased significantly, with no pubertal progression.
  • Growth hormone therapy (0.24 mg/kg/week) was started at 9.5 years and discontinued at 15.3 years because the patient had bone age of 17 years.
  • After interrupting LHRH therapy the patient demonstrated spontaneous pubertal progression with pubertal gonadotropin and testosterone.
  • To our knowledge this is the fourth male patient with genetically-confirmed PWS demonstrating CPP and GHD and the first with a long follow-up to young adulthood.
  • [MeSH-major] Human Growth Hormone / deficiency. Hypogonadism / etiology. Hypothalamic Diseases / complications. Prader-Willi Syndrome / complications. Puberty, Precocious / etiology
  • [MeSH-minor] Child. Drug Therapy, Combination. Gonadotropin-Releasing Hormone / analogs & derivatives. Humans. Male. Treatment Outcome


33. Turk DC, Swanson KS, Gatchel RJ: Predicting opioid misuse by chronic pain patients: a systematic review and literature synthesis. Clin J Pain; 2008 Jul-Aug;24(6):497-508
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, a minority may develop aberrant drug behaviors.
  • OBJECTIVE: To synthesize the evidence of published strategies for identifying at-risk patients to guide clinicians' decisions and practices for prescribing opioid treatment for chronic pain patients (CPP).
  • Studies were limited to human studies in the English language related to screening for predictors of aberrant drug behaviors in CPP who were prescribed long-term opioids.
  • We included studies reviewing, developing measures, or investigating outcomes related to screening for aberrant opioid behaviors in CPP.
  • RESULTS: We identified 6 published articles addressing clinician-based predictors of substance misuse of opioids and 9 published studies evaluating the predictive ability of clinical interviews and self-report measures for aberrant opioid behaviors in CPP.
  • CONCLUSION: Review of the published studies reveals that no one procedure or set of predictor variables is sufficient to identify CPP at-risk for opioid misuse or abuse.
  • Strong predictors include a personal history of illicit drug and alcohol abuse.
  • Prospective studies, especially ones with CPP who have not already been started on chronic opioid therapy, are needed.
  • [MeSH-major] Analgesics, Opioid / adverse effects. Opioid-Related Disorders / etiology. Pain / drug therapy
  • [MeSH-minor] Chronic Disease. Humans. MEDLINE / statistics & numerical data. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18574359.001).
  • [ISSN] 1536-5409
  • [Journal-full-title] The Clinical journal of pain
  • [ISO-abbreviation] Clin J Pain
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / 5K23GM071400-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid
  • [Number-of-references] 64
  •  go-up   go-down


34. Meybohm P, Cavus E, Bein B, Steinfath M, Brand PA, Scholz J, Dörges V: Cerebral metabolism assessed with microdialysis in uncontrolled hemorrhagic shock after penetrating liver trauma. Anesth Analg; 2006 Oct;103(4):948-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a porcine model of uncontrolled hemorrhagic shock, we evaluated the effects of fluid resuscitation versus arginine vasopressin (AVP) combined with hypertonic-hyperoncotic hydroxyethyl starch solution (HHS) on cerebral perfusion pressure (CPP) and on cerebral metabolism using intracerebral microdialysis.
  • Thirty minutes after drug administration, bleeding was controlled by manual compression, and colloid and crystalloid solutions were administered in both groups.
  • After hemodynamic decompensation, fluid resuscitation resulted in a smaller increase of CPP than did AVP/HHS (mean +/- sem; 24 +/- 5 vs 45 +/- 7 mm Hg; P < 0.01).
  • In conclusion, AVP/HHS proved to be superior to fluid in the initial phase of therapy with respect to CPP and cerebral oxygenation, but was comparable to fluid regarding cerebral metabolism and secondary cell damage in surviving animals.
  • [MeSH-major] Cerebral Cortex / metabolism. Cerebrovascular Circulation / physiology. Shock, Hemorrhagic / metabolism. Shock, Hemorrhagic / therapy
  • [MeSH-minor] Animals. Arginine Vasopressin / pharmacology. Carbon Dioxide / blood. Disease Models, Animal. Female. Fluid Therapy / methods. Hemodynamics. Intracranial Pressure. Liver / injuries. Male. Microdialysis. Oxygen / blood. Partial Pressure. Swine. Wounds and Injuries / blood. Wounds and Injuries / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carbon dioxide .
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17000810.001).
  • [ISSN] 1526-7598
  • [Journal-full-title] Anesthesia and analgesia
  • [ISO-abbreviation] Anesth. Analg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 113-79-1 / Arginine Vasopressin; 142M471B3J / Carbon Dioxide; S88TT14065 / Oxygen
  •  go-up   go-down


35. Tseng MY, Al-Rawi PG, Czosnyka M, Hutchinson PJ, Richards H, Pickard JD, Kirkpatrick PJ: Enhancement of cerebral blood flow using systemic hypertonic saline therapy improves outcome in patients with poor-grade spontaneous subarachnoid hemorrhage. J Neurosurg; 2007 Aug;107(2):274-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhancement of cerebral blood flow using systemic hypertonic saline therapy improves outcome in patients with poor-grade spontaneous subarachnoid hemorrhage.
  • METHODS: Thirty-five patients with poor-grade spontaneous SAH received 2 ml/kg 23.5% hypertonic saline intravenously, and they underwent bedside transcranial Doppler (TCD) ultrasonography and intracranial pressure (ICP) monitoring.
  • Seventeen of them underwent Xe-enhanced computed tomography (CT) scanning for measuring CBF.
  • RESULTS: The authors observed a maximum increase in blood pressure by 10.3% (p < 0.05) and cerebral perfusion pressure (CPP) by 21.2% (p < 0.01) at 30 minutes, followed by a maximum decrease in ICP by 93.1% (p < 0.01) at 60 minutes.
  • Changes in ICP and CPP persisted for longer than 180 and 90 minutes, respectively.
  • A dose-dependent effect of CBF increments on favorable outcome was seen on Xe-CT scans (mRS Score 1-3, odds ratio 1.27 per 1 ml/100 g tissue x min, p = 0.045).
  • CONCLUSIONS: Bolus systemic hypertonic saline therapy may be used for reversal of cerebral ischemia to normal perfusion in patients with poor-grade SAH.
  • [MeSH-major] Cerebrovascular Circulation / drug effects. Homeostasis / drug effects. Saline Solution, Hypertonic / administration & dosage. Subarachnoid Hemorrhage / physiopathology. Subarachnoid Hemorrhage / therapy
  • [MeSH-minor] Adult. Aged. Blood Flow Velocity / drug effects. Blood Pressure / drug effects. Female. Follow-Up Studies. Humans. Injections, Intravenous. Intracranial Pressure / drug effects. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg. 2008 Mar;108(3):632; author reply 632-3 [18312116.001]
  • (PMID = 17695380.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0001237; United Kingdom / Medical Research Council / / G0600986; United Kingdom / Medical Research Council / / G9439390
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Saline Solution, Hypertonic
  •  go-up   go-down


36. Vercellini P, Viganò P, Somigliana E, Abbiati A, Barbara G, Fedele L: Medical, surgical and alternative treatments for chronic pelvic pain in women: a descriptive review. Gynecol Endocrinol; 2009 Apr;25(4):208-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medical, surgical and alternative treatments for chronic pelvic pain in women: a descriptive review.
  • Several causes of chronic pelvic pain (CPP) are recognised, but in many women a definite diagnosis cannot be made.
  • Few randomised controlled trials on treatment of CPP have been conducted.
  • The aim of this descriptive review is to describe the management of CPP, which can focus on treating the pain itself, the underlying cause, or both.
  • Combination drug therapy with medications with different mechanisms of action may improve therapeutic results.
  • Several alternative non-invasive treatments have been proposed including exercise programmes, cognitive and behavioural medicine, physical therapy, dietary modification, massage and acupuncture.
  • Treatment of CPP, generally, requires acceptance of the concept of managing rather than curing symptoms.
  • [MeSH-major] Complementary Therapies. Pelvic Pain / drug therapy. Pelvic Pain / surgery
  • [MeSH-minor] Chronic Disease. Female. Humans

  • MedlinePlus Health Information. consumer health - Complementary and Integrative Medicine.
  • MedlinePlus Health Information. consumer health - Pelvic Pain.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19296329.001).
  • [ISSN] 1473-0766
  • [Journal-full-title] Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • [ISO-abbreviation] Gynecol. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 98
  •  go-up   go-down


37. Martínez-León MI, Weil-Lara B, Herrero-Hernández A: [Papilloma and carcinoma of the choroid plexus in pediatric patients]. Radiologia; 2007 Jul-Aug;49(4):279-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Papilloma and carcinoma of the choroid plexus in pediatric patients].
  • [Transliterated title] Papiloma y carcinoma de plexos coroideos en la edad pediátrica.
  • Papillomas of the choroid plexus are rare tumors of neuroectodermal origin; they represent less than 5% of all central nervous system (CNS) tumors in pediatric patients.
  • Choroid plexus carcinomas are even rarer.
  • We reviewed the incidence of these neoplasms at our reference hospital and found six tumors of the choroid plexus (five papillomas and one carcinoma) in five patients.
  • All five patients underwent computed tomography (CT) examination.
  • All patients had tumors located in the lateral ventricles, and one patient had a second tumor located in the third ventricle.
  • All patients underwent surgery; total resection was achieved in the five papillomas, whereas the carcinoma was partially resected and the patient is currently undergoing chemotherapy.
  • The three patients with a single papilloma are disease free at follow-up (range 7 months to 11 years).
  • The patient with two papillomas shows good recovery at follow-up, whereas the patient with carcinoma of the choroid plexus has a poor prognosis.
  • [MeSH-major] Carcinoma. Choroid Plexus Neoplasms. Papilloma
  • [MeSH-minor] Female. Humans. Infant. Infant, Newborn. Male. Prenatal Diagnosis


38. Stoner J, Martin G, O'Mara K, Ehlers J, Tomlanovich M: Amiodarone and bretylium in the treatment of hypothermic ventricular fibrillation in a canine model. Acad Emerg Med; 2003 Mar;10(3):187-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amiodarone and bretylium in the treatment of hypothermic ventricular fibrillation in a canine model.
  • Despite mixed experimental data, some authors view bretylium as the drug of choice in hypothermic VF.
  • OBJECTIVES: To compare defibrillation rates from hypothermic VF after drug therapy with amiodarone, bretylium, and placebo.
  • Thirty anesthetized dogs were mechanically ventilated and instrumented to monitor coronary perfusion pressure (CPP), rectal core temperature, and electrocardiogram (ECG).
  • Ventricular fibrillation was induced as needed with a transthoracic AC current.
  • Return of spontaneous circulation (ROSC) was defined as a sustainable ECG rhythm generating a corresponding arterial pressure tracing lasting a minimum of 15 minutes.
  • RESULTS: CPR was adequate based on CPP > 15 mm Hg in all animals.
  • Mean (+/-SD) CPP was 35.3 +/- 18.8 mm Hg with an overall lower trend in the amiodarone group (p = 0.06).
  • [MeSH-major] Amiodarone / therapeutic use. Anti-Arrhythmia Agents / therapeutic use. Bretylium Compounds / therapeutic use. Ventricular Fibrillation / drug therapy
  • [MeSH-minor] Animals. Disease Models, Animal. Dogs. Hypothermia, Induced. Random Allocation

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12615580.001).
  • [ISSN] 1069-6563
  • [Journal-full-title] Academic emergency medicine : official journal of the Society for Academic Emergency Medicine
  • [ISO-abbreviation] Acad Emerg Med
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Arrhythmia Agents; 0 / Bretylium Compounds; N3RQ532IUT / Amiodarone; RZR75EQ2KJ / bretylium
  •  go-up   go-down


39. Endoh T, Ohtsuki T: Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape. Adv Drug Deliv Rev; 2009 Jul 25;61(9):704-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RNAi-mediated silencing of specific genes is a promising strategy for gene therapy.
  • To utilize RNAi for therapy, an efficient and safe method for delivery of RNA into the cell cytosol is necessary.
  • This review focuses on CPP-based RNA delivery strategies.
  • In using CPP-based RNA delivery, most of the RNA internalized by the cell is entrapped in endosomes.
  • [MeSH-minor] Amino Acid Sequence. Animals. Drug Carriers. Fluorescent Dyes. Gene Silencing. Genetic Therapy. Humans. Molecular Sequence Data. Photosensitizing Agents / pharmacology. RNA Interference. RNA-Binding Proteins / chemistry. RNA-Binding Proteins / metabolism

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19383521.001).
  • [ISSN] 1872-8294
  • [Journal-full-title] Advanced drug delivery reviews
  • [ISO-abbreviation] Adv. Drug Deliv. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Drug Carriers; 0 / Fluorescent Dyes; 0 / Peptides; 0 / Photosensitizing Agents; 0 / RNA, Small Interfering; 0 / RNA-Binding Proteins
  • [Number-of-references] 74
  •  go-up   go-down


40. Himmelseher S, Pfenninger E: [Neuroprotection in neuroanesthesia: current practices in Germany]. Anaesthesist; 2000 May;49(5):412-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since the questions concerning "neuroprotective therapy" were linked to a general survey on clinical neuroanesthesia performed by the scientific neuroanesthesia working group of the DGAI, the only departments that were assessed were those which had participated in an earlier study on neuroanesthesia in 1991.
  • Therapy varied considerably between departments.
  • Following head trauma 69% of injured patients were managed with enhanced cerebral perfusion pressure (CPP) within the range of 70-90 mmHg.
  • If necessary, CPP increase was induced by vasopressors (exogenous supply of catecholamines in 100% of instances) and the administration of fluids (97% of instances).
  • The most commonly used therapeutic approaches to treat intracranial hypertension were mannitol (95% of instances), hyperventilation (91% of instances), cerebrospinal fluid drainage (89% of instances), and barbiturates (86% of instances).
  • Tris (hydroxymethyl)-aminomethane was administered in almost 49%, mild hypothermia in 37%, and hypertonic-hyperoncotic solutions in 28% of patients treated for an increase in intracranial pressure.
  • Following intracranial aneurysm surgery "triple-H" therapy was used in 74% of patients, applied as hemodilution in 94% and as hypervolemia and hypertension in 87% of instances.
  • It was used in 83% of patients during perioperative care and in 52% of patients during intensive care therapy.
  • Specific neuroprotective drugs were applied in 68% of departments, with barbiturates (38% of instances), nimodipine (23% of instances), and corticosteroids (10% of instances) as the main agents named.
  • These brain-protective medications were administered especially in intracranial hypertension in 30%, in intracranial aneurysms in 21%, and in subarachnoid hemorrhages subsequent to head trauma in 18% of instances described.
  • CONCLUSION: These findings demonstrate that the neuroprotective therapy administered in anesthesiological departments in Germany is not yet standardized, i.e., there is a wide variation.
  • [MeSH-minor] Blood Pressure / physiology. Cerebrovascular Circulation / drug effects. Cerebrovascular Circulation / physiology. Craniocerebral Trauma / surgery. Data Collection. Germany. Humans. Hypothermia, Induced. Intracranial Aneurysm / surgery. Intracranial Hypertension / prevention & control. Intracranial Hypertension / therapy. Neuroprotective Agents / therapeutic use. Respiration, Artificial. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Anesthesia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10883355.001).
  • [ISSN] 0003-2417
  • [Journal-full-title] Der Anaesthesist
  • [ISO-abbreviation] Anaesthesist
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Neuroprotective Agents
  •  go-up   go-down


41. Theochari E, Xanthos T, Papadimitriou D, Demestiha T, Condilis N, Tsirikos-Karapanos N, Tsiftsi K, Papadimitriou L: Selective beta blockade improves the outcome of cardiopulmonary resuscitation in a swine model of cardiac arrest. Ann Ital Chir; 2008 Nov-Dec;79(6):409-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND OBJECTIVES: Epinephrine has been the mainstay drug of choice for cardiac resuscitation for more than 30 years.
  • RESULTS: Seven animals (87.5%) restored cardiac rhythm compatible with a pulse in the Esmolol group, compared to 2 animals (33.3%) in the control group (p = 0.018).
  • The average time until restoration of circulation was 16 +/- 3.2 minutes in our control group and 12.8 +/- 1.4 minutes in Esmolol group (p = 0.059).
  • Coronary perfusion pressure (CPP) was significantly higher in the Esmolol group.
  • CONCLUSIONS: Esmolol improves significantly the outcome of cardiopulmonary resuscitation and the average time of restoration of circulation, while in the proposed dosage does not alter the CPP at the beginning of CPR.
  • However, it augments CPP from the sixth minute of CPR and afterwards.
  • [MeSH-major] Adrenergic Agonists / administration & dosage. Adrenergic beta-Antagonists / administration & dosage. Cardiopulmonary Resuscitation / methods. Epinephrine / administration & dosage. Propanolamines / administration & dosage. Ventricular Fibrillation / drug therapy
  • [MeSH-minor] Animals. Disease Models, Animal. Drug Evaluation, Preclinical / methods. Drug Therapy, Combination. Heart Rate / drug effects. Random Allocation. Survival Analysis. Swine

  • MedlinePlus Health Information. consumer health - CPR.
  • Hazardous Substances Data Bank. EPINEPHRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19354034.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Adrenergic Agonists; 0 / Adrenergic beta-Antagonists; 0 / Propanolamines; MDY902UXSR / esmolol; YKH834O4BH / Epinephrine
  •  go-up   go-down


42. Oddo M, Levine JM, Frangos S, Carrera E, Maloney-Wilensky E, Pascual JL, Kofke WA, Mayer SA, LeRoux PD: Effect of mannitol and hypertonic saline on cerebral oxygenation in patients with severe traumatic brain injury and refractory intracranial hypertension. J Neurol Neurosurg Psychiatry; 2009 Aug;80(8):916-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of mannitol and hypertonic saline on cerebral oxygenation in patients with severe traumatic brain injury and refractory intracranial hypertension.
  • BACKGROUND: The impact of osmotic therapies on brain oxygen has not been extensively studied in humans.
  • We examined the effects on brain tissue oxygen tension (PbtO(2)) of mannitol and hypertonic saline (HTS) in patients with severe traumatic brain injury (TBI) and refractory intracranial hypertension.
  • METHODS: 12 consecutive patients with severe TBI who underwent intracranial pressure (ICP) and PbtO(2) monitoring were studied.
  • PbtO(2), ICP, mean arterial pressure, cerebral perfusion pressure (CPP), central venous pressure and cardiac output were monitored continuously.
  • RESULTS: 42 episodes of intracranial hypertension, treated with mannitol (n = 28 boluses) or HTS (n = 14 boluses), were analysed.
  • HTS treatment was associated with an increase in PbtO(2) (from baseline 28.3 (13.8) mm Hg to 34.9 (18.2) mm Hg at 30 min, 37.0 (17.6) mm Hg at 60 min and 41.4 (17.7) mm Hg at 120 min; all p<0.01) while mannitol did not affect PbtO(2) (baseline 30.4 (11.4) vs 28.7 (13.5) vs 28.4 (10.6) vs 27.5 (9.9) mm Hg; all p>0.1).
  • Compared with mannitol, HTS was associated with lower ICP and higher CPP and cardiac output.
  • CONCLUSIONS: In patients with severe TBI and elevated ICP refractory to previous mannitol treatment, 7.5% hypertonic saline administered as second tier therapy is associated with a significant increase in brain oxygenation, and improved cerebral and systemic haemodynamics.
  • [MeSH-major] Brain Chemistry / drug effects. Brain Injuries / drug therapy. Diuretics / pharmacology. Intracranial Hypertension / drug therapy. Mannitol / pharmacology. Oxygen Consumption / drug effects. Saline Solution, Hypertonic / pharmacology
  • [MeSH-minor] Adult. Data Interpretation, Statistical. Female. Glasgow Coma Scale. Hemodynamics / drug effects. Humans. Intracranial Pressure / physiology. Male. Recurrence


43. Bertelloni S, Mul D: Treatment of central precocious puberty by GnRH analogs: long-term outcome in men. Asian J Androl; 2008 Jul;10(4):525-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of central precocious puberty by GnRH analogs: long-term outcome in men.
  • In boys, central precocious puberty (CPP) is the appearance of secondary sex characteristics driven by pituitary gonadotropin secretion before the age of 9 years.
  • In the last years, relevant improvements in the treatment of CPP have been achieved.
  • Because CPP is rare in boys, the majority of papers on this issue focus on girls and do not address specific features of male patients regarding end results and safety.
  • In the present paper, recent advances of CPP management with GnRH analogs in men are summarized.
  • End results in untreated and treated patients are also reviewed by an analysis of the recently published literature on treatment of CPP in men.
  • The available data indicate that therapy with GnRH analogs can improve final height into the range of target height without significant adverse short-term and long-term effects, but longer follow-up of larger series of patients is still required to draw definitive conclusions.
  • [MeSH-major] Gonadotropin-Releasing Hormone / analogs & derivatives. Gonadotropin-Releasing Hormone / therapeutic use. Puberty, Precocious / drug therapy
  • [MeSH-minor] Adolescent. Adult. Body Height / drug effects. Body Height / physiology. Child. Dose-Response Relationship, Drug. Humans. Male. Sex Characteristics. Treatment Outcome


44. Lee HJ, Wang CJ, Kuo HC, Chou FP, Jean LF, Tseng TH: Induction apoptosis of luteolin in human hepatoma HepG2 cells involving mitochondria translocation of Bax/Bak and activation of JNK. Toxicol Appl Pharmacol; 2005 Mar 1;203(2):124-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since hepatocellular carcinoma remains a major challenging clinical problem in many parts of the world including Eastern Asia and Southern Africa, it is imperative to develop more effective chemopreventive and chemotherapy agents.
  • We found that Bax and Bak translocated to mitochondria apparently, whereas Fas ligand (FasL) was unchanged after a treatment with luteolin for 3 h.
  • In addition, it showed that c-Jun NH2-terminal kinase (JNK) was activated after the treatment of luteolin for 3-12 h.
  • Further investigation showed that a specific JNK inhibitor, SP600125, reduced the activation of CPP 32, the mitochondrial translocation of Bax, as well as the cytosolic release of cytochrome c that induced by luteolin.
  • [MeSH-major] Anticarcinogenic Agents / pharmacology. Apoptosis / drug effects. JNK Mitogen-Activated Protein Kinases / metabolism. Luteolin / pharmacology. p38 Mitogen-Activated Protein Kinases / metabolism
  • [MeSH-minor] Caspase 3. Caspases / metabolism. Cell Line, Tumor. Cytochromes c / metabolism. Humans. Membrane Proteins / metabolism. Mitochondria / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. bcl-2 Homologous Antagonist-Killer Protein. bcl-2-Associated X Protein

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15710173.001).
  • [ISSN] 0041-008X
  • [Journal-full-title] Toxicology and applied pharmacology
  • [ISO-abbreviation] Toxicol. Appl. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / BAK1 protein, human; 0 / BAX protein, human; 0 / Membrane Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2 Homologous Antagonist-Killer Protein; 0 / bcl-2-Associated X Protein; 9007-43-6 / Cytochromes c; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases; KUX1ZNC9J2 / Luteolin
  •  go-up   go-down


45. El-Gaidi MA, Eissa EM: Infantile intracranial neoplasms: characteristics and surgical outcomes of a contemporary series of 21 cases in an Egyptian referral center. Pediatr Neurosurg; 2010;46(4):272-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infantile intracranial neoplasms: characteristics and surgical outcomes of a contemporary series of 21 cases in an Egyptian referral center.
  • OBJECTIVE: To investigate the demographic, clinical, radiological, pathological and surgical features and outcomes of infantile intracranial neoplasms, the second most common neoplasm in infants.
  • RESULTS: Out of 451 patients with primary intracranial neoplasms (age 0-14 years), 21 infants (<1 year) underwent surgery, representing 4.7% of total cases.
  • The most common tumor was choroid plexus papilloma (23.8%), followed by teratoma (19%) then astrocytoma and ependymoma (14.3% each).
  • Three patients received chemotherapy, but none received radiotherapy.
  • The statistically significant predictors of prognosis were the extent of resection and tumor grade.
  • CONCLUSION: Although the prognosis for infantile intracranial neoplasms is worse than for older children, an overall promising outcome with low operative morbidity and mortality was achieved using gross total excision and appropriate adjuvant chemotherapy as part of a multidisciplinary approach.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / surgery. Papilloma, Choroid Plexus / mortality. Papilloma, Choroid Plexus / surgery
  • [MeSH-minor] Adolescent. Astrocytoma / drug therapy. Astrocytoma / mortality. Astrocytoma / surgery. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Egypt / epidemiology. Ependymoma / drug therapy. Ependymoma / mortality. Ependymoma / surgery. Female. Humans. Infant. Infant, Newborn. Male. Medulloblastoma / drug therapy. Medulloblastoma / mortality. Medulloblastoma / surgery. Morbidity. Neurilemmoma / drug therapy. Neurilemmoma / mortality. Neurilemmoma / surgery. Prognosis. Quality of Life. Referral and Consultation / statistics & numerical data. Retrospective Studies. Teratoma / drug therapy. Teratoma / mortality. Teratoma / surgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 21160236.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


46. Lewis KA, Eugster EA: Experience with the once-yearly histrelin (GnRHa) subcutaneous implant in the treatment of central precocious puberty. Drug Des Devel Ther; 2009;3:1-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experience with the once-yearly histrelin (GnRHa) subcutaneous implant in the treatment of central precocious puberty.
  • In 2007, a hydrogel histrelin implant was approved for the treatment of children with central precocious puberty (CPP).
  • Children with CPP commonly have reduced height potential due to premature closure of the epiphyseal growth plates from exposure to sex steroids.
  • Gonadotropin-releasing hormone analog (GnRHa) treatment halts puberty and allows for improvement of adult height.
  • A hydrogel implant delivery system utilizing the potent GnRHa, histrelin, was first developed for use in men with prostate cancer.
  • A once yearly histrelin subcutaneous implant was subsequently developed for the treatment of children with CPP.
  • Studies to date have demonstrated safety, tolerability, and effectiveness of this treatment option in patients treated up to 2 years.
  • Cost of this treatment seems comparable to somewhat higher than the commonly used GnRHa treatment option, depot leuprolide.
  • While long term studies are needed to establish continued efficacy and safety beyond 2 years of treatment, the histrelin implant appears to be an attractive option for GnRHa treatment in patients with CPP.

  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr. 1986 Jan;108(1):47-54 [3080571.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Jan;84(1):44-9 [9920060.001]
  • [Cites] J Urol. 2000 Mar;163(3):838-44 [10687989.001]
  • [Cites] Eur J Pediatr. 2000 May;159(5):369-74 [10834524.001]
  • [Cites] Urology. 2001 Oct;58(4):578-82 [11597543.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Oct;86(10):4711-6 [11600530.001]
  • [Cites] Asian J Androl. 2008 Jul;10(4):525-34 [18478155.001]
  • [Cites] Pediatrics. 2005 Dec;116(6):e798-802 [16322137.001]
  • [Cites] J Urol. 2006 Apr;175(4):1353-8 [16515997.001]
  • [Cites] Curr Probl Pediatr Adolesc Health Care. 2007 Feb;37(2):50-72 [17223057.001]
  • [Cites] J Clin Endocrinol Metab. 2007 May;92(5):1697-704 [17327379.001]
  • [Cites] J Pediatr Endocrinol Metab. 2007 Nov;20(11):1189-98 [18183790.001]
  • [Cites] J Clin Pharmacol. 2005 Nov;45(11):1245-9 [16239357.001]
  • (PMID = 19920916.001).
  • [ISSN] 1177-8881
  • [Journal-full-title] Drug design, development and therapy
  • [ISO-abbreviation] Drug Des Devel Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2769233
  • [Keywords] NOTNLM ; central precocious puberty / gonadotropin-releasing-hormone analogs / histrelin / implant
  •  go-up   go-down


47. Schulz D, Buddenberg T, Huston JP: Extinction-induced "despair" in the water maze, exploratory behavior and fear: effects of chronic antidepressant treatment. Neurobiol Learn Mem; 2007 May;87(4):624-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extinction-induced "despair" in the water maze, exploratory behavior and fear: effects of chronic antidepressant treatment.
  • Specifically, the removal of a hidden platform in the water maze induced extinction of previously reinforced escape behavior and behavioral immobility, indicative of "despair", which also correlated with indices of fear.
  • Here, we tested the effects of antidepressants on extinction in the water maze, and expected that such drugs would attenuate the rate of extinction of a conditioned place preference (CPP) and also any emotionally relevant behavior that is induced by the loss of reinforcement, such as immobility.
  • Daily treatment with desipramine hydrochloride (DMI, 10mg/kg) or fluoxetine (FLX, 10 mg/kg) commenced 1 day before the first of 11 extinction trials without the platform, administered 48 h apart, and continued thereafter, as the rats were tested in an open field and elevated-plus maze.
  • As compared to controls, DMI increased the resistance-to-extinction of CPP, attenuated immobility, and increased wall climbing behavior.
  • [MeSH-major] Antidepressive Agents / pharmacology. Exploratory Behavior / drug effects. Extinction, Psychological / physiology. Fear / drug effects. Maze Learning / drug effects
  • [MeSH-minor] Affect. Animals. Conditioning, Classical / drug effects. Conditioning, Classical / physiology. Depressive Disorder / drug therapy. Desipramine / pharmacology. Disease Models, Animal. Drug Administration Schedule. Escape Reaction. Fluoxetine / pharmacology. Immobility Response, Tonic / drug effects. Immobility Response, Tonic / physiology. Male. Rats. Rats, Wistar. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Antidepressants.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DESIPRAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17223365.001).
  • [ISSN] 1074-7427
  • [Journal-full-title] Neurobiology of learning and memory
  • [ISO-abbreviation] Neurobiol Learn Mem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antidepressive Agents; 01K63SUP8D / Fluoxetine; TG537D343B / Desipramine
  •  go-up   go-down


48. Bentsen G, Breivik H, Lundar T, Stubhaug A: Predictable reduction of intracranial hypertension with hypertonic saline hydroxyethyl starch: a prospective clinical trial in critically ill patients with subarachnoid haemorrhage. Acta Anaesthesiol Scand; 2004 Oct;48(9):1089-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictable reduction of intracranial hypertension with hypertonic saline hydroxyethyl starch: a prospective clinical trial in critically ill patients with subarachnoid haemorrhage.
  • BACKGROUND: After head trauma, hypertonic saline lowers intracranial pressure (ICP) and preserves or increases cerebral perfusion pressure (CPP).
  • The aim of this study was to evaluate the effects on elevated ICP and on CPP in patients critically ill from SAH.
  • METHODS: Critically ill SAH-patients needing urgent treatment for an elevated ICP, but otherwise stable, were included in this study.
  • Our primary outcome variables were changes in ICP and CPP during and for 3 h after this infusion.
  • RESULTS: All interventions resulted in decreased ICP and elevation of CPP.
  • The mean percent peak increase in CPP was 26% (range 16-32%, P = 0.002).
  • CONCLUSIONS: 7.2% saline in 6% hydroxyethyl starch is an effective and safe therapy for intracranial hypertension after SAH.
  • We demonstrate that an infusion of 2 ml kg(-1) during 20 min has a predictable and clinically significant beneficial effect on ICP and CPP.
  • [MeSH-major] Hydroxyethyl Starch Derivatives / therapeutic use. Intracranial Hypertension / drug therapy. Plasma Substitutes / therapeutic use. Subarachnoid Hemorrhage / drug therapy
  • [MeSH-minor] Adult. Blood Volume / drug effects. Cerebrovascular Circulation / drug effects. Critical Illness. Extravascular Lung Water / drug effects. Female. Hemodynamics / drug effects. Humans. Male. Middle Aged. Osmolar Concentration. Prospective Studies. Saline Solution, Hypertonic

  • Genetic Alliance. consumer health - Intracranial Hypertension.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15352953.001).
  • [ISSN] 0001-5172
  • [Journal-full-title] Acta anaesthesiologica Scandinavica
  • [ISO-abbreviation] Acta Anaesthesiol Scand
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Hydroxyethyl Starch Derivatives; 0 / Plasma Substitutes; 0 / Saline Solution, Hypertonic
  •  go-up   go-down


49. Eun JS, Bae K, Yun YP, Hong JT, Kwon HN, Oh KW: Inhibitory effects of paeonol on morphine-induced locomotor sensitization and conditioned place preference in mice. Arch Pharm Res; 2006 Oct;29(10):904-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The inhibitory effects of paeonol, a major compound of Paeoniae radix, on the development of locomotor sensitization, conditioned place preference (CPP) and dopamine receptor supersensitivity induced by the repeated administration of morphine were investigated through behavioral experiments.
  • Repeated administration of morphine develops sensitization (reverse tolerance), a progressive enhancement of locomotion, which is used as a model for studying the drug-induced drug-seeking behaviors, and CPP, which is used as a model for studying drug reinforcement.
  • Paeonol inhibited morphine-induced hyperlocomotion, sensitization and CPP.
  • In addition, paeonol inhibited the development of postsynaptic dopamine receptors supersensitivity, which may be an underlying common mechanism that mediates the morphine-induced dopaminergic behaviors such as sensitization and CPP.
  • These results provide evidence that paeonol exerts anti-dopaminergic activity, and it is suggested that paeonol may be useful for the prevention and therapy of these adverse actions of morphine.
  • [MeSH-major] Acetophenones / pharmacology. Conditioning (Psychology) / drug effects. Morphine / antagonists & inhibitors. Motor Activity / drug effects. Spatial Behavior / drug effects
  • [MeSH-minor] Administration, Oral. Animals. Behavior, Animal / drug effects. Dopamine Antagonists / administration & dosage. Dopamine Antagonists / pharmacology. Dose-Response Relationship, Drug. Injections, Subcutaneous. Male. Mice. Mice, Inbred ICR. Paeonia / chemistry. Plant Roots / chemistry. Receptors, Dopamine / physiology

  • Hazardous Substances Data Bank. MORPHINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17121187.001).
  • [ISSN] 0253-6269
  • [Journal-full-title] Archives of pharmacal research
  • [ISO-abbreviation] Arch. Pharm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Acetophenones; 0 / Dopamine Antagonists; 0 / Receptors, Dopamine; 3R834EPI82 / paeonol; 76I7G6D29C / Morphine
  •  go-up   go-down


50. Courteix C, Privat AM, Pélissier T, Hernandez A, Eschalier A, Fialip J: Agmatine induces antihyperalgesic effects in diabetic rats and a superadditive interaction with R(-)-3-(2-carboxypiperazine-4-yl)-propyl-1-phosphonic acid, a N-methyl-D-aspartate-receptor antagonist. J Pharmacol Exp Ther; 2007 Sep;322(3):1237-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Agmatine induces antihyperalgesic effects in diabetic rats and a superadditive interaction with R(-)-3-(2-carboxypiperazine-4-yl)-propyl-1-phosphonic acid, a N-methyl-D-aspartate-receptor antagonist.
  • Agmatine, an endogenous cationic amine resulting from the decarboxylation of L-arginine, produces antihyperalgesic and antiallodynic effects in animal models of chronic neuropathic and inflammatory pain.
  • To determine its mechanism of action and the potential interest of some of its combinations, the antihyperalgesic effect of agmatine was challenged with alpha(2)-adrenergic imidazoline and opioid-receptor antagonists, and its interaction with the opioid-receptor agonist morphine, the competitive N-methyl-D-aspartate receptor antagonist D-CPP [R(-)-3-(2-carboxypiperazine-4-yl)-propyl-1-phosphonic acid], and the nitric-oxide synthase inhibitor L-NAME (L-N(G)-nitro-L-arginine methyl ester) were examined.
  • In diabetic rats, an isobolographic analysis showed that combinations of i.t. agmatine with i.v.
  • L-NAME or with i.t. morphine resulted in an additive antihyperalgesic effect, whereas the agmatine/D-CPP i.t. combination was superadditive.
  • Moreover, agmatine combined with D-CPP produces an antinociceptive synergy in experimental neuropathy, opening opportunities in the development of new strategies for pain therapy.
  • [MeSH-major] Agmatine / pharmacology. Hyperalgesia / drug therapy. Pain / drug therapy. Piperazines / pharmacology. Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors
  • [MeSH-minor] Animals. Anticonvulsants / pharmacology. Diabetes Mellitus, Experimental / complications. Drug Interactions. Excitatory Amino Acid Antagonists / pharmacology. Rats. Streptozocin

  • MedlinePlus Health Information. consumer health - Pain.
  • Hazardous Substances Data Bank. STREPTOZOTOCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17551093.001).
  • [ISSN] 0022-3565
  • [Journal-full-title] The Journal of pharmacology and experimental therapeutics
  • [ISO-abbreviation] J. Pharmacol. Exp. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Excitatory Amino Acid Antagonists; 0 / Piperazines; 0 / Receptors, N-Methyl-D-Aspartate; 100828-16-8 / 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid; 5W494URQ81 / Streptozocin; 70J407ZL5Q / Agmatine
  •  go-up   go-down


51. Pillai A, Rajeev K, Chandi S, Unnikrishnan M: Intrinsic brainstem choroid plexus papilloma. Case report. J Neurosurg; 2004 Jun;100(6):1076-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrinsic brainstem choroid plexus papilloma. Case report.
  • The authors report an intrinsic brainstem lesion that was diagnosed initially as a pontine cavernoma, which finally proved to be a choroid plexus papilloma.
  • Choroid plexus papillomas are rare tumors of the central nervous system and are usually intraventricular in location.
  • The occurrence of this tumor in an intraparenchymal location is extremely rare, and its occurrence within the brainstem is previously unreported.
  • The authors also report a trial of chemotherapy with lomustine in the management of the residual tumor.
  • [MeSH-major] Brain Stem Neoplasms / pathology. Choroid Plexus Neoplasms / pathology. Glioma / pathology
  • [MeSH-minor] Antineoplastic Agents, Alkylating / therapeutic use. Female. Humans. Lomustine / therapeutic use. Middle Aged

  • Genetic Alliance. consumer health - Choroid Plexus Papilloma.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15200124.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7BRF0Z81KG / Lomustine
  •  go-up   go-down


52. Krstevska-Konstantinova M, Jancevska A, Gucev Z: Autoimmune thyroiditis and diabetes mellitus type 1 after long-term gonadotropin-releasing hormone agonist treatment for central precocious puberty: evolution or coincidence? J Pediatr Endocrinol Metab; 2010 Apr;23(4):403-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autoimmune thyroiditis and diabetes mellitus type 1 after long-term gonadotropin-releasing hormone agonist treatment for central precocious puberty: evolution or coincidence?
  • Very few abnormalities in endocrine function have been reported during long term gonadotropin-releasing hormone agonist (GnRHa) treatment in girls.
  • Most authors agree that this therapy is safe and effective.
  • We present an unusual outcome of long term GnRHa therapy in two girls with central precocious puberty(CPP) of idiopathic or organic origin.
  • They have received monthly depot injections of triptorelin acetate for a time period of 8 years.
  • Another girl with a hypothalamic hamartoma developed diabetes mellitus at the age of 9 years.
  • Both of these girls were early diagnosed for CPP, at 6 months and 8 months respectively, and given GnRHa treatment.
  • So far, it is not known whether these autoimmune diseases are related to the GnRHa treatment or are simply a coincidence.
  • However, we suggest a closer monitoring of girls with CPP who have had a long period of treatment.
  • [MeSH-major] Diabetes Mellitus, Type 1 / etiology. Puberty, Precocious / drug therapy. Thyroiditis, Autoimmune / etiology. Triptorelin Pamoate / therapeutic use
  • [MeSH-minor] Child. Female. Hamartoma / complications. Hamartoma / drug therapy. Humans. Luteolytic Agents / therapeutic use. Pituitary Diseases / complications. Pituitary Diseases / drug therapy


53. Houchi H, Warnault V, Barbier E, Dubois C, Pierrefiche O, Ledent C, Daoust M, Naassila M: Involvement of A2A receptors in anxiolytic, locomotor and motivational properties of ethanol in mice. Genes Brain Behav; 2008 Nov;7(8):887-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We aimed to investigate if the increased propensity of A2A(-/-) mice to consume ethanol is associated with an altered sensitivity in the motivational properties of ethanol in the conditioned place preference (CPP) and conditioned taste aversion (CTA) paradigms and with an altered development of sensitization to the locomotor effects of ethanol.
  • Our results show that A2A(-/-) mice produced on a CD1 background displayed a reduced ethanol-induced CPP and an increased sensitivity to the anxiolytic and locomotorstimulant effects of ethanol, but they did not show alteration in ethanol-induced CTA and locomotor sensitization.
  • Ethanol-induced CPP, ethanol consumption and the locomotor effects of ethanol were also tested in A2A(-/-) mice produced on a C57BL/6J background.
  • Our results emphasized the importance of the genetic background because alteration in ethanol consumption and preference, ethanol-induced CPP and locomotor-stimulant effects were not found in knockout mice produced on the alcohol-preferring C57BL/6J genetic background.
  • In conclusion, A2AR deficiency in mice generated on a CD1 background leads to high ethanol consumption that is associated with an increased sensitivity to the locomotor-stimulant/anxiolytic effects of ethanol and a decrease in ethanol-induced CPP.
  • [MeSH-major] Adenosine / metabolism. Alcohol-Induced Disorders, Nervous System / genetics. Brain / drug effects. Ethanol / pharmacology. Receptor, Adenosine A2A / drug effects
  • [MeSH-minor] Animals. Anti-Anxiety Agents / pharmacology. Anxiety / drug therapy. Anxiety / genetics. Anxiety / metabolism. Behavior, Animal / drug effects. Behavior, Animal / physiology. Central Nervous System Depressants / pharmacology. Conditioning (Psychology) / drug effects. Conditioning (Psychology) / physiology. Disease Models, Animal. Drug Resistance / drug effects. Drug Resistance / genetics. Genotype. Male. Mice. Mice, Inbred C57BL. Mice, Knockout. Motivation. Motor Activity / drug effects. Motor Activity / physiology. Species Specificity

  • Hazardous Substances Data Bank. Adenosine .
  • Hazardous Substances Data Bank. ETHANOL .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19097273.001).
  • [ISSN] 1601-183X
  • [Journal-full-title] Genes, brain, and behavior
  • [ISO-abbreviation] Genes Brain Behav.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Anxiety Agents; 0 / Central Nervous System Depressants; 0 / Receptor, Adenosine A2A; 3K9958V90M / Ethanol; K72T3FS567 / Adenosine
  •  go-up   go-down


54. Nomura Y, Yasumoto S, Yanai F, Akiyoshi H, Inoue T, Nibu K, Tsugu H, Fukushima T, Hirose S: Survival and late effects on development of patients with infantile brain tumor. Pediatr Int; 2009 Jun;51(3):337-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival and late effects on development of patients with infantile brain tumor.
  • BACKGROUND: Most infants with brain tumor may have a poor prognosis.
  • The aim of the present study was to retrospectively analyze the survival and outcome with regard to mental and physical development in 11 subjects with brain tumor; these tumors were diagnosed when the patients were under 1 year of age.
  • METHODS: The histological diagnoses of these tumors were astrocytoma, n = 3; pineocytoma, n = 2; teratoma, n = 1; ependymoma, n = 1; atypical teratoid/rhabdoid tumor, n = 1; glioblastoma, n = 1; medulloblastoma, n = 1; and choroid plexus papilloma, n = 1.
  • Surgical resection was performed in eight patients, and adjuvant chemotherapy was administered to all except one patient with choroid plexus papilloma.
  • Radiotherapy was additionally performed for four of the 10 chemotherapy patients.
  • Among the surviving patients, five were under no treatment for 50-167 months after the diagnosis (median duration, 89 months), while one received chemotherapy for 20 months.
  • Five patients exhibited mental retardation, and one patient experienced normal development after surgical removal of his choroid plexus papilloma.
  • Diencephalic syndrome developed in one patient with pilomyxoid astrocytoma that necessitated hormone replacement therapy, and bodyweight over +2 SD was observed in two patients.
  • The remaining five patients died 11-111 months after diagnosis (median duration, 24 months).
  • CONCLUSION: The prognosis of infantile brain tumor with regard to mortality and developmental outcome remains poor.
  • [MeSH-major] Astrocytoma / mortality. Brain Neoplasms / mortality. Child Development. Pinealoma / mortality
  • [MeSH-minor] Chemotherapy, Adjuvant. Female. Humans. Infant. Infant, Newborn. Magnetic Resonance Imaging. Male. Prognosis. Quality of Life. Radiotherapy, Adjuvant


55. Anpalagan A, Condous G: Is there a role for use of levonorgestrel intrauterine system in women with chronic pelvic pain? J Minim Invasive Gynecol; 2008 Nov-Dec;15(6):663-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This review focuses on the available evidence for the use of levonorgestrel (LNG) intrauterine system (IUS) in women with chronic pelvic pain (CPP).
  • Laparoscopic surgery was shown to be useful in clarifying the underlying cause in women with CPP, with 70% having abnormal findings at laparoscopy.
  • Up to 36% need repeated surgery during a 5-year period after the primary procedure.
  • The absolute reduction in recurrence of dysmenorrhea in women who also had the LNG IUS inserted at the time of surgery was 35% (95% CI 9%-61%).
  • Insertion of the LNG IUS at the time of primary laparoscopic surgery in women with CPP caused by endometriosis has the potential to reduce postoperative pain scores.
  • This nonsurgical option could potentially reduce the rate of repeated laparoscopies in women with CPP and, in turn, reduce overall intervention rates.
  • [MeSH-major] Contraceptive Agents, Female / therapeutic use. Levonorgestrel / therapeutic use. Pelvic Pain / drug therapy
  • [MeSH-minor] Clinical Trials as Topic. Dysmenorrhea / drug therapy. Female. Humans. Menstruation Disturbances / complications. Menstruation Disturbances / diagnosis

  • MedlinePlus Health Information. consumer health - Pelvic Pain.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LEVONORGESTREL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18774757.001).
  • [ISSN] 1553-4650
  • [Journal-full-title] Journal of minimally invasive gynecology
  • [ISO-abbreviation] J Minim Invasive Gynecol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contraceptive Agents, Female; 5W7SIA7YZW / Levonorgestrel
  • [Number-of-references] 21
  •  go-up   go-down


56. Municchi G, Marconcini S, D'Ambrosio A, Berardi R, Acquaviva A: Central precocious puberty in multisystem Langerhans cell histiocytosis: a case report. Pediatr Hematol Oncol; 2002 Jun;19(4):273-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors describe a girl with multisystem Langerhans cell histiocytosis (LCH) who developed central precocious puberty (CPP).
  • She subsequently developed diabetes insipidus with a documented lesion of the pituitary stalk; she received chemotherapy and began therapy with l-desamino-8-D-argininevasopressin.
  • Growth hormone deficiency was diagnosed at the age of 4.4 years and GH replacement therapy started.
  • The patient has been off therapy for LCH since the age of 6.
  • Signs of pubertal development appeared at 7.5 years (bone age 8 years) and gonadotropin-releasing hormone analog (GnRHa) treatment was started.
  • During the observation period she developed central hypothyroidism.
  • Development of CPP during LCH is extremely rare; to the authors 'knowledge, no patient has been described so far.
  • The authors believe that CPP was secondary to LCH and did not represent a casual finding, even in the absence of hypothalamic-pituitary axis involvement.
  • The possibility of CPP development should be considered during the follow-up of these patients.


57. Decker P, Muller S: Modulating poly (ADP-ribose) polymerase activity: potential for the prevention and therapy of pathogenic situations involving DNA damage and oxidative stress. Curr Pharm Biotechnol; 2002 Sep;3(3):275-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modulating poly (ADP-ribose) polymerase activity: potential for the prevention and therapy of pathogenic situations involving DNA damage and oxidative stress.
  • PARP is activated at an intermediate stage of apoptosis and is then cleaved and inactivated at a late stage by apoptotic proteases, namely caspase-3/CPP-32/Yama/apopain and caspase-7.
  • With regard to the increasing interest towards PARP, the aim of this review is to explain the cellular role of PARP and the advantages of modulating its activity in diverse preventive or therapeutic strategies.
  • [MeSH-minor] Animals. Apoptosis / drug effects. Apoptosis / physiology. Enzyme Inhibitors / pharmacology. Humans. Poly Adenosine Diphosphate Ribose / biosynthesis. Poly(ADP-ribose) Polymerase Inhibitors. Tumor Cells, Cultured / drug effects. Tumor Cells, Cultured / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12164482.001).
  • [ISSN] 1389-2010
  • [Journal-full-title] Current pharmaceutical biotechnology
  • [ISO-abbreviation] Curr Pharm Biotechnol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Poly(ADP-ribose) Polymerase Inhibitors; 26656-46-2 / Poly Adenosine Diphosphate Ribose; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases
  • [Number-of-references] 100
  •  go-up   go-down


58. Berrada M, Yang Z, Lehnert S: Tumor treatment by sustained intratumoral release of 5-fluorouracil: effects of drug alone and in combined treatments. Int J Radiat Oncol Biol Phys; 2002 Dec 1;54(5):1550-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor treatment by sustained intratumoral release of 5-fluorouracil: effects of drug alone and in combined treatments.
  • PURPOSE: To evaluate an intratumoral polymer implant for sustained delivery of 5-fluorouracil (5-FU) in a mouse tumor model.
  • METHODS AND MATERIALS: 5-FU was incorporated into a polyanhydride-based polymer, bis(p-carboxyphenoxy)propane sebacic acid (CPP:SA) and implanted in RIF-1 mouse fibrosarcoma growing s.c.
  • The effectiveness of treatment was evaluated by tumor growth delay.
  • A second drug, cis-diamminedichloroplatinum (cis-DDP), was administered by intraperitoneal injection or by osmotic pump.
  • RESULTS: For drug/polymer implant alone, the tumor growth delay was proportional to the amount of drug in the implant.
  • The 5-FU polymer implant was most effective when combined with cis-DDP or with acute or fractionated radiation, and in some cases, the effects of combined treatments were greater than additive.
  • CONCLUSION: Results indicate that 5-FU can be effectively delivered by polymer implant and that this mode of delivery is particularly appropriate for combined treatments.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fluorouracil / administration & dosage. Fluorouracil / therapeutic use. Neoplasms / drug therapy. Neoplasms / radiotherapy
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Cobalt Radioisotopes. Combined Modality Therapy. Iodine Radioisotopes / therapeutic use. Mice. Neoplasm Transplantation. Organoplatinum Compounds. Polymers / therapeutic use. Radiation-Sensitizing Agents / therapeutic use. Radiometry. Time Factors. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12459384.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cobalt Radioisotopes; 0 / Iodine Radioisotopes; 0 / Organoplatinum Compounds; 0 / Polymers; 0 / Radiation-Sensitizing Agents; 78022-86-3 / diammine platinum(II) dilactate; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


59. Abekawa T, Ito K, Koyama T: Role of the simultaneous enhancement of NMDA and dopamine D1 receptor-mediated neurotransmission in the effects of clozapine on phencyclidine-induced acute increases in glutamate levels in the rat medial prefrontal cortex. Naunyn Schmiedebergs Arch Pharmacol; 2006 Dec;374(3):177-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clozapine (CLZ) can improve both the positive and negative symptoms of treatment-resistant schizophrenia (TRS), which does not respond to typical antipsychotics.
  • This suggests that elucidation of the pharmacological mechanism for CLZ could lead to further clarification of the pathophysiology of TRS.
  • This study examined the effects of CLZ on phencyclidine (PCP)-induced hyperlocomotion and on the acute increases in glutamate levels that occur in the medial prefrontal cortex (mPFC) in order to test the hypothesis that CLZ effect is associated with the simultaneous enhancement of N-methyl-D: -aspartate (NMDA) and dopamine D(1) receptor-mediated neurotransmission.
  • CLZ also blocked, in a dose-related manner, acute increases in glutamate levels in the mPFC that were induced by local perfusion with a competitive NMDA receptor antagonist, CPP, in this region.
  • Although an enhanced blocking effect of the sub-threshold concentration of NMDA perfusion on PCP-induced acute increases in glutamate levels in the mPFC was noted after co-perfusion with a dopamine D(1) receptor agonist, SKF-38393, perfusion with SKF-38393 did not reverse the CLZ blocking of PCP-induced increases in glutamate levels.
  • [MeSH-major] Antipsychotic Agents / pharmacology. Behavior, Animal / drug effects. Clozapine / pharmacology. Glutamic Acid / metabolism. Receptors, Dopamine D1 / drug effects. Receptors, N-Methyl-D-Aspartate / drug effects
  • [MeSH-minor] Analysis of Variance. Animals. Dose-Response Relationship, Drug. Drug Resistance. Haloperidol / pharmacology. Humans. Male. Microdialysis. Motor Activity / drug effects. Phencyclidine. Prefrontal Cortex / metabolism. Rats. Rats, Sprague-Dawley. Schizophrenia / drug therapy. Schizophrenia / physiopathology

  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • Hazardous Substances Data Bank. HALOPERIDOL .
  • Hazardous Substances Data Bank. CLOZAPINE .
  • Hazardous Substances Data Bank. PHENCYCLIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci. 1998 Jul 15;18(14):5545-54 [9651235.001]
  • [Cites] Arch Gen Psychiatry. 1988 Sep;45(9):789-96 [3046553.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jan;28(1):173-80 [14687871.001]
  • [Cites] Psychopharmacology (Berl). 2003 Sep;169(3-4):215-33 [12955285.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1349-52 [9721099.001]
  • [Cites] J Neurosci. 2003 Feb 1;23(3):867-75 [12574415.001]
  • [Cites] J Neurochem. 1998 Jan;70(1):198-209 [9422363.001]
  • [Cites] Neuropsychopharmacology. 1996 May;14(5):301-7 [8703299.001]
  • [Cites] Brain Res Bull. 2002 Mar 15;57(5):623-30 [11927365.001]
  • [Cites] Pharmacol Toxicol. 1999 May;84(5):193-6 [10361974.001]
  • [Cites] Eur J Pharmacol. 1979 Nov 16;59(3-4):169-79 [575093.001]
  • [Cites] J Comp Neurol. 1992 Feb 15;316(3):314-47 [1577988.001]
  • [Cites] NIDA Res Monogr. 1978 Aug;(21):241-53 [101872.001]
  • [Cites] Brain Res. 2000 Jun 9;867(1-2):250-4 [10837822.001]
  • [Cites] Arch Gen Psychiatry. 1994 Mar;51(3):199-214 [8122957.001]
  • [Cites] Eur J Pharmacol. 1976 Nov;40(1):45-56 [1033072.001]
  • [Cites] J Pharmacol Exp Ther. 1997 Oct;283(1):226-34 [9336328.001]
  • [Cites] Eur J Neurosci. 2003 Mar;17(6):1306-12 [12670320.001]
  • [Cites] J Neurophysiol. 2002 May;87(5):2324-36 [11976371.001]
  • [Cites] J Pharmacol Exp Ther. 2005 May;313(2):594-603 [15659539.001]
  • [Cites] Synapse. 1997 Nov;27(3):242-61 [9329159.001]
  • [Cites] J Pharmacol Exp Ther. 2000 Feb;292(2):731-6 [10640312.001]
  • [Cites] J Clin Psychiatry. 1994 Sep;55 Suppl B:8-14 [7961581.001]
  • [Cites] Am J Psychiatry. 2002 Feb;159(2):255-62 [11823268.001]
  • [Cites] Br J Pharmacol. 1998 May;124(2):377-85 [9641556.001]
  • [Cites] Psychopharmacology (Berl). 1998 Jul;138(1):89-95 [9694531.001]
  • [Cites] Neuropsychopharmacology. 1998 Mar;18(3):197-209 [9471117.001]
  • [Cites] Biol Psychiatry. 1997 Oct 15;42(8):664-8 [9325559.001]
  • [Cites] Am J Psychiatry. 1991 Oct;148(10):1301-8 [1654746.001]
  • [Cites] Psychopharmacology (Berl). 2003 Sep;169(3-4):247-56 [12898123.001]
  • [Cites] J Neurochem. 2004 Oct;91(1):189-99 [15379899.001]
  • [Cites] Biol Psychiatry. 2001 Nov 15;50(10 ):750-7 [11720693.001]
  • [Cites] Cereb Cortex. 2001 May;11(5):452-62 [11313297.001]
  • [Cites] J Neurosci Methods. 1995 Mar;57(1):93-9 [7791370.001]
  • [Cites] Neuroscience. 1981;6(5):863-73 [6113562.001]
  • [Cites] J Pharmacol Exp Ther. 1993 May;265(2):498-508 [7684443.001]
  • [Cites] Neuropsychopharmacology. 1995 Aug;13(1):9-19 [8526975.001]
  • [Cites] Synapse. 2003 May;48(2):66-79 [12619040.001]
  • [Cites] Eur J Pharmacol. 1998 Jan 2;341(1):45-56 [9489855.001]
  • (PMID = 17103144.001).
  • [ISSN] 0028-1298
  • [Journal-full-title] Naunyn-Schmiedeberg's archives of pharmacology
  • [ISO-abbreviation] Naunyn Schmiedebergs Arch. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antipsychotic Agents; 0 / Receptors, Dopamine D1; 0 / Receptors, N-Methyl-D-Aspartate; 3KX376GY7L / Glutamic Acid; J1DOI7UV76 / Phencyclidine; J60AR2IKIC / Clozapine; J6292F8L3D / Haloperidol
  •  go-up   go-down


60. Pak AC, Ashby CR Jr, Heidbreder CA, Pilla M, Gilbert J, Xi ZX, Gardner EL: The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions. Int J Neuropsychopharmacol; 2006 Oct;9(5):585-602
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions.
  • Increasing evidence suggests that enhanced dopamine (DA) neurotransmission in the nucleus accumbens (NAc) may play a role in mediating the reward and reinforcement produced by addictive drugs and in the attentional processing of drug-associated environmental cues.
  • The meso-accumbens DA system is selectively enriched with DA D3 receptors, a DA receptor subtype increasingly implicated in reward-related brain and behavioural processes.
  • From a variety of evidence, it has been suggested that selective DA D3 receptor antagonism may be a useful pharmacotherapeutic approach for treating addiction.
  • The present experiments tested the efficacy of SB-277011A, a selective DA D3 receptor antagonist, in rat models of nicotine-enhanced electrical brain-stimulation reward (BSR), nicotine-induced conditioned locomotor activity (LMA), and nicotine-induced conditioned place preference (CPP).
  • SB-277011A, given intraperitoneally within the dose range of 1-12 mg/kg, dose-dependently reduced nicotine-enhanced BSR, nicotine-induced conditioned LMA, and nicotine-induced CPP.
  • The results suggest that selective D3 receptor antagonism constitutes a new and promising pharmacotherapeutic approach to the treatment of nicotine dependence.
  • [MeSH-major] Brain / drug effects. Conditioning, Operant / drug effects. Dopamine Antagonists / pharmacology. Nicotine / pharmacology. Nicotinic Agonists / pharmacology. Nitriles / pharmacology. Reward. Tetrahydroisoquinolines / pharmacology
  • [MeSH-minor] Analysis of Variance. Animals. Area Under Curve. Association Learning / drug effects. Behavior, Animal / drug effects. Cues. Dose-Response Relationship, Drug. Drug Interactions. Male. Motor Activity / drug effects. Rats. Rats, Long-Evans

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. NICOTINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pharmacol Exp Ther. 2000 Sep;294(3):1154-65 [10945872.001]
  • [Cites] Synapse. 1998 May;29(1):72-9 [9552176.001]
  • [Cites] Neuropsychopharmacology. 2003 Feb;28(2):329-38 [12589386.001]
  • [Cites] Behav Brain Res. 1998 Nov;96(1-2):185-8 [9821554.001]
  • [Cites] Annu Rev Psychol. 1989;40:191-225 [2648975.001]
  • [Cites] Pharmacol Biochem Behav. 1993 Oct;46(2):453-7 [8265701.001]
  • [Cites] Psychopharmacology (Berl). 2003 Dec;170(4):409-22 [12955296.001]
  • [Cites] Neuropsychopharmacology. 2003 Jun;28(6):1150-9 [12700684.001]
  • [Cites] Behav Neurosci. 1987 Apr;101(2):209-14 [3580122.001]
  • [Cites] Prog Neurobiol. 1998 Dec;56(6):613-72 [9871940.001]
  • [Cites] Eur J Pharmacol. 2001 Aug 24;426(1-2):R1-2 [11525784.001]
  • [Cites] Life Sci. 1996;58(25):PL365-72 [8649214.001]
  • [Cites] Psychopharmacology (Berl). 1995 Jul;120(1):10-20 [7480530.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 1989 Jan-Feb;339(1-2):208-13 [2725697.001]
  • [Cites] Nature. 1996 Jul 18;382(6588):255-7 [8717040.001]
  • [Cites] Science. 1975 Feb 14;187(4176):547-9 [1114313.001]
  • [Cites] Synapse. 1995 Oct;21(2):140-8 [8584975.001]
  • [Cites] Behav Pharmacol. 1995 Jun;6(4):333-347 [11224342.001]
  • [Cites] Behav Brain Res. 2000 Aug;113(1-2):97-103 [10942036.001]
  • [Cites] Ciba Found Symp. 1990;152:153-62; discussion 162-8 [2209252.001]
  • [Cites] Exp Clin Psychopharmacol. 1999 Feb;7(1):72-8 [10036612.001]
  • [Cites] Neuropharmacology. 2004;47 Suppl 1:190-201 [15464137.001]
  • [Cites] Synapse. 2003 Mar;47(3):176-83 [12494400.001]
  • [Cites] Neuroreport. 2003 Jan 20;14(1):93-8 [12544838.001]
  • [Cites] Synapse. 2002 May;44(2):61-3 [11891877.001]
  • [Cites] Eur J Pharmacol. 2000 Oct 27;407(1-2):47-51 [11050289.001]
  • [Cites] Eur J Pharmacol. 1988 Jul 7;151(2):233-42 [2844553.001]
  • [Cites] Respiration. 2002;69(5):381-4 [12232442.001]
  • [Cites] Pharmacol Rev. 1997 Sep;49(3):231-52 [9311022.001]
  • [Cites] Eur J Pharmacol. 2000 Mar 30;393(1-3):295-314 [10771025.001]
  • [Cites] Brain Res Brain Res Rev. 2005 Jul;49(1):77-105 [15960988.001]
  • [Cites] Eur J Pharmacol. 1987 Sep 23;141(3):395-9 [3666033.001]
  • [Cites] J Med Chem. 2000 May 4;43(9):1878-85 [10794704.001]
  • [Cites] Psychopharmacology (Berl). 1996 Feb;123(3):280-8 [8833421.001]
  • [Cites] Psychiatr Med. 1985;3(4):445-60 [2893431.001]
  • [Cites] Recent Adv Biol Psychiatry. 1961;4:288-309 [13916635.001]
  • [Cites] Synapse. 2000 Feb;35(2):160-2 [10611642.001]
  • [Cites] Neuropsychopharmacology. 2003 May;28(5):839-49 [12637956.001]
  • [Cites] J Neurosci. 2002 Nov 1;22(21):9595-603 [12417684.001]
  • [Cites] Behav Brain Res. 2003 Jul 14;143(1):65-74 [12842297.001]
  • [Cites] Neurosci Biobehav Rev. 1989 Summer-Fall;13(2-3):123-8 [2530477.001]
  • [Cites] Synapse. 2003 Jun 1;48(3):154-6 [12645041.001]
  • [Cites] Neuropharmacology. 2005 Sep;49(4):525-41 [15963538.001]
  • [Cites] Am J Addict. 2000 Fall;9(4):285-313 [11155784.001]
  • [Cites] Nicotine Tob Res. 2002 Aug;4(3):259-66 [12215234.001]
  • [Cites] Behav Brain Res. 1987 Oct;26(1):57-62 [3675835.001]
  • [Cites] NIDA Res Monogr. 1994;145:191-206 [8742814.001]
  • [Cites] Neuropsychopharmacology. 2003 Jul;28(7):1272-80 [12700694.001]
  • [Cites] Neuropsychobiology. 2002;45(2):87-94 [11893865.001]
  • [Cites] Synapse. 1997 May;26(1):93-4 [9097409.001]
  • [Cites] Pharmacol Biochem Behav. 1999 Apr;62(4):659-72 [10208371.001]
  • [Cites] Pharmacol Biochem Behav. 2005 May;81(1):190-7 [15894078.001]
  • [Cites] Psychopharmacology (Berl). 1976 Aug 17;48(3):311-8 [823588.001]
  • [Cites] Mol Psychiatry. 2003 Feb;8(2):225-30 [12610655.001]
  • [Cites] Physiol Behav. 1985 Sep;35(3):395-403 [3840902.001]
  • [Cites] Ann N Y Acad Sci. 1992 Jun 28;654:192-8 [1632583.001]
  • [Cites] J Neurosci. 1997 Nov 1;17(21):8580-7 [9334429.001]
  • [Cites] Synapse. 1998 Oct;30(2):181-93 [9723788.001]
  • [Cites] Drug Discov Today. 2005 Jul 1;10(13):917-25 [15993811.001]
  • [Cites] Br J Pharmacol. 1989 Sep;98(1):135-40 [2804543.001]
  • [Cites] Synapse. 1999 Jan;31(1):76-86 [10025686.001]
  • [Cites] Synapse. 2005 Jul;57(1):17-28 [15858839.001]
  • [Cites] Psychopharmacology (Berl). 2002 Feb;160(1):56-66 [11862374.001]
  • [Cites] Science. 1993 Jun 18;260(5115):1814-6 [8099761.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1976-81 [11172061.001]
  • [Cites] Curr Opin Pharmacol. 2005 Feb;5(1):107-18 [15661634.001]
  • [Cites] Behav Pharmacol. 2003 May;14(3):191-8 [12799520.001]
  • [Cites] J Neurosci. 2001 Aug 1;21(15):5841-6 [11466456.001]
  • [Cites] Pharmacol Biochem Behav. 1991 Jun;39(2):465-8 [1682950.001]
  • [Cites] Eur J Neurosci. 2005 Jun;21(12):3427-38 [16026480.001]
  • [Cites] Psychopharmacologia. 1960 Feb 12;1:251-6 [13834123.001]
  • [Cites] Eur J Pharmacol. 2001 Jul 20;424(2):85-90 [11476753.001]
  • [Cites] Psychopharmacology (Berl). 2000 May;149(4):388-96 [10867966.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4321-6 [10760299.001]
  • [Cites] Eur J Pharmacol. 1986 Dec 16;132(2-3):337-8 [3816984.001]
  • [Cites] Drugs Today (Barc). 2004 Apr;40(4):355-65 [15190388.001]
  • [Cites] Psychopharmacology (Berl). 1982;78(3):204-9 [6296898.001]
  • [Cites] Pharmacol Biochem Behav. 2001 Jan;68(1):135-45 [11274718.001]
  • [Cites] Pharmacol Biochem Behav. 1992 Apr;41(4):755-9 [1594644.001]
  • [Cites] Nature. 1999 Jul 22;400(6742):371-5 [10432116.001]
  • [Cites] Addiction. 2000 Aug;95(8):1173-83 [11092065.001]
  • [Cites] J Med Chem. 2005 Jun 2;48(11):3663-79 [15916415.001]
  • [Cites] Pharmacol Biochem Behav. 1994 Aug;48(4):853-62 [7972288.001]
  • [Cites] Pharmacol Biochem Behav. 1997 Aug;57(4):915-21 [9259024.001]
  • [Cites] Neuropsychopharmacology. 2003 Nov;28(11):1903-15 [12915863.001]
  • [Cites] Nat Med. 2003 Jun;9(6):762-7 [12740572.001]
  • [Cites] Psychopharmacology (Berl). 2005 May;179(3):567-75 [15619116.001]
  • [Cites] Behav Neurosci. 1993 Feb;107(1):161-5 [8095392.001]
  • [Cites] Psychopharmacology (Berl). 2005 Apr;178(4):481-92 [15765262.001]
  • [Cites] Psychopharmacology (Berl). 2004 Oct;176(1):57-65 [15083257.001]
  • [Cites] Brain Res. 1994 Aug 8;653(1-2):278-84 [7982062.001]
  • [Cites] Neuroreport. 1997 Jul 7;8(9-10):2373-7 [9243643.001]
  • [Cites] Neuropsychopharmacology. 2005 Apr;30(4):720-30 [15562293.001]
  • [Cites] Psychopharmacology (Berl). 1992;107(2-3):285-9 [1615127.001]
  • [Cites] Trends Pharmacol Sci. 1991 Dec;12(12):467-73 [1792691.001]
  • [Cites] Psychopharmacology (Berl). 1997 Nov;134(2):187-92 [9399383.001]
  • [Cites] J Pharmacol Exp Ther. 1994 Oct;271(1):294-301 [7965727.001]
  • [Cites] Can J Psychol. 1977 Dec;31(4):195-203 [608135.001]
  • (PMID = 16942635.001).
  • [ISSN] 1461-1457
  • [Journal-full-title] The international journal of neuropsychopharmacology
  • [ISO-abbreviation] Int. J. Neuropsychopharmacol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 DA999999
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dopamine Antagonists; 0 / Nicotinic Agonists; 0 / Nitriles; 0 / SB 277011; 0 / Tetrahydroisoquinolines; 6M3C89ZY6R / Nicotine
  • [Other-IDs] NLM/ NIHMS493706; NLM/ PMC3732043
  •  go-up   go-down


61. Glantz L, Godovic G, Lekar M, Kramer M, Eidelman LA: Efficacy of transdermal nitroglycerin combined with etodolac for the treatment of chronic post-thoracotomy pain: an open-label prospective clinical trial. J Pain Symptom Manage; 2004 Mar;27(3):277-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of transdermal nitroglycerin combined with etodolac for the treatment of chronic post-thoracotomy pain: an open-label prospective clinical trial.
  • Chronic post-thoracotomy pain (CPP) is associated with surgical intercostal nerve injury.
  • Like other forms of neuropathic pain, there is no ideal treatment.
  • The present study investigated the efficacy of NTG combined with the nonsteroidal anti-inflammatory drug etodolac for the treatment of CPP.
  • NTG, 5 mg/day, was added to the treatment.
  • A significant reduction in VAS was observed on day 14 of treatment (from 66.7 +/- 11 to 42.1 +/- 5, P< 0.05).
  • We conclude that NTG added to etodolac appears to be effective for the treatment of CPP, with minimal side effects.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Etodolac / administration & dosage. Nitroglycerin / administration & dosage. Pain, Postoperative / drug therapy. Thoracotomy / adverse effects. Vasodilator Agents / administration & dosage
  • [MeSH-minor] Administration, Cutaneous. Aged. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Prospective Studies

  • Hazardous Substances Data Bank. NITROGLYCERIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15038339.001).
  • [ISSN] 0885-3924
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Vasodilator Agents; 2M36281008 / Etodolac; G59M7S0WS3 / Nitroglycerin
  •  go-up   go-down


62. Wang B, Luo F, Xia YQ, Han JS: Peripheral electric stimulation inhibits morphine-induced place preference in rats. Neuroreport; 2000 Apr 7;11(5):1017-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Conditioned place preference (CPP) is a commonly used model to detect rewarding effect of drugs.
  • To observe the effect of peripheral electric stimulation (PES) on morphine-induced CPP, we trained the rats with morphine in a CPP paradigm.
  • PES of 2 and 2/100 Hz significantly decreased CPP in morphine-trained animals in a naloxone reversible manner, while PES of 100 Hz, foot shock, needle insertion, or plain restraining, showed no effect.
  • Thus, PES with a low-frequency component (2 Hz) could specifically inhibit the expression of morphine-induced CPP, presumably via activation of opioid receptors.
  • [MeSH-major] Acupuncture Therapy / methods. Analgesics, Opioid / pharmacology. Conditioning (Psychology) / drug effects. Morphine / pharmacology. Morphine Dependence / therapy. Peripheral Nerves / physiology
  • [MeSH-minor] Animals. Dose-Response Relationship, Drug. Male. Rats. Rats, Sprague-Dawley. Time Factors. Transcutaneous Electric Nerve Stimulation

  • MedlinePlus Health Information. consumer health - Acupuncture.
  • Hazardous Substances Data Bank. MORPHINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10790875.001).
  • [ISSN] 0959-4965
  • [Journal-full-title] Neuroreport
  • [ISO-abbreviation] Neuroreport
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 76I7G6D29C / Morphine
  •  go-up   go-down


63. Fishbain DA, Lewis JE, Gao J, Cole B, Rosomoff RS: Alleged medical abandonment in chronic opioid analgesic therapy: case report. Pain Med; 2009 May-Jun;10(4):722-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alleged medical abandonment in chronic opioid analgesic therapy: case report.
  • 1) present details of a chronic pain patient (CPP) on chronic opioid analgesic therapy (COAT), who diverted her opioids and was terminated from treatment, and subsequently committed suicide;.
  • METHODS: This is a case report of a CPP treated by a pain physician who demonstrated aberrant drug-related behaviors and required large doses of controlled-release oxycodone.
  • [MeSH-major] Analgesics, Opioid / adverse effects. Malpractice / legislation & jurisprudence. Pain, Intractable / drug therapy. Physician-Patient Relations. Refusal to Treat / legislation & jurisprudence. Suicide / legislation & jurisprudence
  • [MeSH-minor] Abdominal Pain / drug therapy. Abdominal Pain / etiology. Abdominal Pain / physiopathology. Adult. Alcoholism / complications. Alprazolam / administration & dosage. Crime. Drug Administration Schedule. Fatal Outcome. Female. Humans. Hypnotics and Sedatives / administration & dosage. Opioid-Related Disorders / etiology. Opioid-Related Disorders / psychology. Oxycodone / administration & dosage. Oxycodone / adverse effects. Pancreatitis, Chronic / complications. Pancreatitis, Chronic / physiopathology. Patient Compliance. Self Medication / psychology


64. Manoharan C, Singh J: Evaluation of polyanhydride microspheres for basal insulin delivery: Effect of copolymer composition and zinc salt on encapsulation, in vitro release, stability, in vivo absorption and bioactivity in diabetic rats. J Pharm Sci; 2009 Nov;98(11):4237-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The potential of poly 1,3-bis-(p-carboxyphenoxy) propane-co-sebacic acid (p(CPP:SA)) microspheres was investigated for controlled delivery of basal insulin.
  • CPP:SA copolymers with molar compositions of 20:80, 40:60, and 50:50 were synthesized, characterized, and used in the fabrication of microspheres by water-in-oil-in-water double emulsion solvent evaporation technique.
  • Insulin encapsulation efficiency (EE) and in vitro release kinetics were influenced by the molar ratios of CPP:SA copolymer.
  • Increasing CPP content and addition of zinc oxide increased EE, reduced burst release, and prolonged insulin in vitro release over a month.
  • Dimer aggregates were observed for insulin encapsulated in CPP:SA 50:50 microspheres and addition of zinc oxide prevented dimer formation.
  • Subcutaneous administration of CPP:SA 50:50 microspheres in diabetic rats controlled insulin release over a month, and the released insulin was bioactive as determined by lowering blood glucose levels.
  • The results indicate that CPP:SA microspheres controlled insulin release in vitro and in vivo over a month and the released insulin was conformationally and chemically stable, and bioactive.
  • [MeSH-minor] Absorption. Animals. Blood Glucose / metabolism. Chemistry, Pharmaceutical. Diabetes Mellitus, Experimental / drug therapy. Drug Carriers / chemistry. Drug Compounding. Drug Delivery Systems. Drug Stability. Insulin, Long-Acting. Kinetics. Male. Microscopy, Electron, Scanning. Molecular Structure. Molecular Weight. Particle Size. Polymers / chemical synthesis. Polymers / chemistry. Rats. Rats, Sprague-Dawley. Technology, Pharmaceutical / methods

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • Hazardous Substances Data Bank. ZINC COMPOUNDS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc. and the American Pharmacists Association
  • (PMID = 19472196.001).
  • [ISSN] 1520-6017
  • [Journal-full-title] Journal of pharmaceutical sciences
  • [ISO-abbreviation] J Pharm Sci
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Drug Carriers; 0 / Hypoglycemic Agents; 0 / Insulin; 0 / Insulin, Long-Acting; 0 / Polyanhydrides; 0 / Polymers; 0 / Zinc Compounds
  •  go-up   go-down


65. Narotam PK, Puri V, Roberts JM, Taylon C, Vora Y, Nathoo N: Management of hypertensive emergencies in acute brain disease: evaluation of the treatment effects of intravenous nicardipine on cerebral oxygenation. J Neurosurg; 2008 Dec;109(6):1065-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of hypertensive emergencies in acute brain disease: evaluation of the treatment effects of intravenous nicardipine on cerebral oxygenation.
  • This study explores the effect of nicardipine on regional brain tissue O(2) (PbtO(2)) during treatment of acute hypertensive emergencies.
  • All patients had a parenchymal PbtO(2) and intracranial pressure bolt inserted following resuscitation.
  • Intravenous nicardipine (5-15 mg/hour) was titrated to systolic BP < 160 mm Hg, diastolic BP < 90 mm Hg, mean arterial BP (MABP) 90-110 mm Hg, and PbtO(2) > 20 mm Hg.
  • Physiological parameters-intracranial pressure, PbtO(2), central venous pressure, systolic BP, diastolic BP, MABP, fraction of inspired O(2), and cerebral perfusion pressure (CPP)-were compared before infusion, at 4 hours, and at 8 hours using a t-test.
  • RESULTS: Sixty episodes of hypertension were reported in 30 patients (traumatic brain injury in 13 patients; aneurysmal subarachnoid hemorrhage in 11; intracerebral and intraventricular hemorrhage in 3 and 1, respectively; arteriovenous malformation in 1; and hypoxic brain injury in 1).
  • Nicardipine was effective in 87% of the patients (with intravenous beta blockers in 4 patients), with a 19.7% reduction in mean 4-hour MABP (115.3 +/- 13.1 mm Hg preinfusion vs 92.9 +/- 11.40 mm Hg after 4 hours of therapy, p < 0.001).
  • No deleterious effect on mean PbtO(2) was recorded (26.74 +/- 15.42 mm Hg preinfusion vs 27.68 +/- 12.51 mm Hg after 4 hours of therapy, p = 0.883) despite significant reduction in CPP.
  • Less dependence on normobaric hyperoxia was achieved at 8 hours (0.72 +/- 0.289 mm Hg preinfusion vs 0.626 +/- 0.286 mm Hg after 8 hours of therapy, p < 0.01).
  • Subgroup analysis revealed that 12 patients had low pretreatment PbtO(2) (10.30 +/- 6.49 mm Hg), with higher CPP (p < 0.001) requiring hyperoxia (p = 0.02).
  • In this group, intravenous nicardipine resulted in an 83% improvement in 4- and 8-hour PbtO(2) levels (18.1 +/- 11.33 and 19.59 +/- 23.68 mm Hg, respectively; p < 0.01) despite significant reductions in both mean MABP (120.6 +/- 16.65 vs 95.8 +/- 8.3 mm Hg, p < 0.001) and CPP (105.00 +/- 20.7 vs 81.2 +/- 15.4 mm Hg, p < 0.001).
  • CONCLUSIONS: Intravenous nicardipine is effective for the treatment of hypertensive neurological emergencies and has no adverse effect on PbtO(2).
  • [MeSH-major] Antihypertensive Agents / therapeutic use. Brain Injuries / physiopathology. Cerebral Hemorrhage / physiopathology. Hypertension / drug therapy. Intracranial Arteriovenous Malformations / physiopathology. Nicardipine / therapeutic use. Subarachnoid Hemorrhage / physiopathology
  • [MeSH-minor] Acute Disease. Adult. Aged. Blood Pressure / drug effects. Blood Pressure / physiology. Brain / metabolism. Female. Humans. Hypoxia, Brain / physiopathology. Infusions, Intravenous. Male. Middle Aged. Oxygen / metabolism. Prospective Studies


66. Baviera M, Invernizzi RW, Carli M: Haloperidol and clozapine have dissociable effects in a model of attentional performance deficits induced by blockade of NMDA receptors in the mPFC. Psychopharmacology (Berl); 2008 Feb;196(2):269-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The aim of this study was to compare the effects of conventional and atypical antipsychotics in a model of attentional performance deficit of schizophrenia induced by blockade of N-methyl-D: -aspartate (NMDA) receptors in the medial prefrontal cortex.
  • MATERIALS AND METHODS: Attentional performance was assessed using the five-choice serial reaction time task.
  • The task provides indices of attentional functioning (% correct responses), executive control (measured by anticipatory and perseverative responding), decision time (measured by correct response latency), and omissions.
  • Haloperidol and clozapine were given intraperitoneally (IP) to animals that had received vehicle or a competitive NMDA receptor antagonist, 3-(R)-2-carboxypiperazin-4-propyl-1-phosphonic acid (CPP), directly into the medial prefrontal cortex.
  • RESULTS: Fifty nanograms/side of CPP reduced accuracy (% correct responses) and increased anticipatory and perseverative responding.
  • Haloperidol (0.03 mg/kg IP) reduced the CPP-induced anticipatory and perseverative overresponding but not the impairment in accuracy.
  • CPP increased decision time and omissions, but these effects were not affected by either haloperidol or clozapine.
  • [MeSH-major] Attention / drug effects. Clozapine / pharmacology. Haloperidol / pharmacology. Prefrontal Cortex / drug effects. Schizophrenia / physiopathology
  • [MeSH-minor] Analysis of Variance. Animals. Antipsychotic Agents / administration & dosage. Antipsychotic Agents / pharmacology. Behavior, Animal / drug effects. Dopamine Antagonists / administration & dosage. Dopamine Antagonists / pharmacology. Dose-Response Relationship, Drug. Injections, Intraperitoneal. Male. Microinjections. Piperazines / administration & dosage. Piperazines / toxicity. Rats. Reaction Time / drug effects. Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors. Serial Learning / drug effects. Serotonin Antagonists / administration & dosage. Serotonin Antagonists / pharmacology

  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • Hazardous Substances Data Bank. HALOPERIDOL .
  • Hazardous Substances Data Bank. CLOZAPINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuron. 2006 Feb 16;49(4):603-15 [16476668.001]
  • [Cites] Neuropharmacology. 1999 Aug;38(8):1185-94 [10462131.001]
  • [Cites] Behav Neurosci. 2001 Aug;115(4):812-25 [11508720.001]
  • [Cites] J Neurosci. 1997 Dec 1;17(23):9285-97 [9364074.001]
  • [Cites] Psychopharmacology (Berl). 2006 Jul;187(1):73-85 [16767417.001]
  • [Cites] Synapse. 2005 Apr;56(1):12-20 [15700289.001]
  • [Cites] Schizophr Bull. 1999;25(2):201-22 [10416727.001]
  • [Cites] Neuropsychopharmacology. 2001 Oct;25(4):476-88 [11557161.001]
  • [Cites] Behav Brain Res. 1999 Apr;100(1-2):99-112 [10212057.001]
  • [Cites] Eur J Pharmacol. 2005 Sep 5;519(1-2):114-7 [16099452.001]
  • [Cites] Behav Neurosci. 2001 Aug;115(4):799-811 [11508719.001]
  • [Cites] Psychopharmacology (Berl). 1998 May;137(1):33-42 [9631954.001]
  • [Cites] Psychopharmacology (Berl). 2002 Oct;163(3-4):362-80 [12373437.001]
  • [Cites] Behav Brain Res. 1983 Sep;9(3):361-80 [6639741.001]
  • [Cites] Psychopharmacology (Berl). 1999 Oct;146(4):348-61 [10550486.001]
  • [Cites] J Pharmacol Exp Ther. 1997 Nov;283(2):666-74 [9353384.001]
  • [Cites] Psychopharmacology (Berl). 1992;106(2):228-34 [1532259.001]
  • [Cites] Psychopharmacology (Berl). 2003 May;167(3):304-14 [12677356.001]
  • [Cites] Neuropsychopharmacology. 2006 Sep;31(9):1854-63 [16319908.001]
  • [Cites] Neuron. 2004 May 27;42(4):653-63 [15157425.001]
  • [Cites] Neuropsychopharmacology. 2002 Jun;26(6):716-28 [12007742.001]
  • [Cites] Am J Psychiatry. 1996 Mar;153(3):321-30 [8610818.001]
  • [Cites] J Pharmacol Exp Ther. 1998 Dec;287(3):839-46 [9864262.001]
  • [Cites] Neuroscience. 1993 Feb;52(3):595-604 [8450961.001]
  • [Cites] Behav Brain Res. 1997 Dec;89(1-2):135-49 [9475622.001]
  • [Cites] Brain Res. 1995 Jan 23;670(1):165-8 [7719718.001]
  • [Cites] J Pharmacol Exp Ther. 1997 Oct;283(1):226-34 [9336328.001]
  • [Cites] J Pharmacol Exp Ther. 1993 Sep;266(3):1374-84 [8103793.001]
  • [Cites] Neuropsychopharmacology. 2006 Sep;31(9):1900-9 [16421514.001]
  • [Cites] Psychopharmacology (Berl). 1987;91(4):458-66 [3108926.001]
  • [Cites] J Neurosci. 2000 Feb 1;20(3):1208-15 [10648725.001]
  • [Cites] Neuropsychopharmacology. 1998 Feb;18(2):63-101 [9430133.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1159-72 [14642974.001]
  • [Cites] Psychopharmacology (Berl). 1999 Jul;145(2):193-204 [10463321.001]
  • [Cites] Am J Psychiatry. 2004 Jun;161(6):985-95 [15169686.001]
  • [Cites] J Neurosci. 1999 Jun 1;19(11):4585-94 [10341256.001]
  • [Cites] Psychopharmacology (Berl). 1998 Jan;135(2):194-200 [9497025.001]
  • [Cites] Neuropsychopharmacology. 2006 Apr;31(4):757-67 [16192987.001]
  • [Cites] Cereb Cortex. 1996 May-Jun;6(3):470-81 [8670672.001]
  • [Cites] J Clin Psychiatry. 1994 Sep;55 Suppl B:8-14 [7961581.001]
  • [Cites] J Comp Neurol. 2002 Jan 21;442(4):392-404 [11793342.001]
  • [Cites] Behav Brain Res. 2003 Jan 6;138(1):59-69 [12493630.001]
  • [Cites] J Neural Transm Gen Sect. 1995;101(1-3):127-48 [8695043.001]
  • [Cites] J Neurochem. 2001 Mar;76(5):1521-31 [11238736.001]
  • [Cites] Psychopharmacology (Berl). 1993;111(3):339-44 [7870972.001]
  • [Cites] Psychopharmacology (Berl). 2003 Nov;170(3):309-19 [12904968.001]
  • [Cites] Psychopharmacology (Berl). 2004 Nov;176(3-4):376-85 [15232674.001]
  • [Cites] J Pharmacol Exp Ther. 1994 Nov;271(2):787-94 [7965797.001]
  • [Cites] Neuropsychopharmacology. 2007 Feb;32(2):273-83 [16641946.001]
  • [Cites] Eur Neuropsychopharmacol. 1996 Nov;6(4):305-10 [8985714.001]
  • [Cites] J Neurosci. 1996 Jan;16(1):373-9 [8613804.001]
  • [Cites] Am J Psychiatry. 1991 Oct;148(10):1301-8 [1654746.001]
  • [Cites] Neuropsychopharmacology. 2004 Sep;29(9):1637-47 [15127084.001]
  • [Cites] Neuropsychopharmacology. 1996 Feb;14 (2):87-96 [8822531.001]
  • [Cites] Schizophr Bull. 1999;25(2):233-55 [10416729.001]
  • [Cites] Brain Res. 2002 Aug 30;947(2):157-65 [12176156.001]
  • [Cites] Br J Psychiatry. 1993 Oct;163:451-5 [7902766.001]
  • [Cites] Biol Psychiatry. 2001 Nov 15;50(10 ):750-7 [11720693.001]
  • [Cites] Neuroscience. 1998 Mar;83(2):489-99 [9460757.001]
  • [Cites] Neuropsychopharmacology. 1995 Feb;12(1):57-64 [7766287.001]
  • [Cites] Psychopharmacology (Berl). 2005 Apr;179(1):99-107 [15678364.001]
  • [Cites] Neuropsychopharmacology. 1994 Nov;11(3):167-77 [7865098.001]
  • [Cites] Neurosci Lett. 1993 Apr 2;152(1-2):61-4 [8100055.001]
  • [Cites] Cereb Cortex. 2003 Apr;13(4):400-8 [12631569.001]
  • [Cites] Eur J Pharmacol. 1996 Aug 1;309(1):1-11 [8864686.001]
  • [Cites] Am J Psychiatry. 2001 Feb;158(2):176-84 [11156796.001]
  • [Cites] Psychopharmacology (Berl). 2003 Sep;169(3-4):404-11 [12590356.001]
  • [Cites] Biol Psychiatry. 2002 Jun 15;51(12):972-8 [12062881.001]
  • [Cites] J Neurophysiol. 2001 Feb;85(2):659-70 [11160501.001]
  • [Cites] Schizophr Bull. 2000;26(1):119-36 [10755673.001]
  • [Cites] J Neurosci. 2004 Jan 28;24(4):773-80 [14749421.001]
  • [Cites] Arch Gen Psychiatry. 2000 Mar;57(3):249-58 [10711911.001]
  • [Cites] Brain. 1993 Oct;116 ( Pt 5):1159-75 [8221053.001]
  • (PMID = 17940750.001).
  • [ISSN] 0033-3158
  • [Journal-full-title] Psychopharmacology
  • [ISO-abbreviation] Psychopharmacology (Berl.)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antipsychotic Agents; 0 / Dopamine Antagonists; 0 / Piperazines; 0 / Receptors, N-Methyl-D-Aspartate; 0 / Serotonin Antagonists; 98Y1I8ZD4M / 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid; J60AR2IKIC / Clozapine; J6292F8L3D / Haloperidol
  •  go-up   go-down


67. Chiu WT, Lin TJ, Lin JW, Huang SJ, Chang CK, Chen HY: Multicenter evaluation of propofol for head-injured patients in Taiwan. Surg Neurol; 2006;66 Suppl 2:S37-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The present study was a multicenter, retrospective study which aimed to evaluate the efficacy of propofol, a new choice of pharmacotherapy in head-injured patients.
  • Data on patients' demographics, laboratory data, GCS score, ICP, CPP, concurrent medications, and therapeutic outcomes were collected.
  • Mean CPP for the first 5 days in the ICU was 71.10 +/- 15.32 mm Hg in the propofol group and 43.20 +/- 29.92 mm Hg in the nonpropofol group (P<.001).
  • [MeSH-major] Brain Injuries / drug therapy. Brain Injuries / mortality. Hypnotics and Sedatives / therapeutic use. Propofol / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Glasgow Coma Scale. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Taiwan / epidemiology. Treatment Outcome

  • Hazardous Substances Data Bank. PROPOFOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17071254.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hypnotics and Sedatives; YI7VU623SF / Propofol
  •  go-up   go-down


68. Toussaint M, Delair B, Foulon C, Lempereur N, Vaccher C, Maurice T, Melnyk P: Tic hydantoin sigma-1 agonist: pharmacological characterization on cocaine-induced stimulant and appetitive effects. Eur Neuropsychopharmacol; 2009 Jul;19(7):504-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tic hydantoin sigma-1 agonist: pharmacological characterization on cocaine-induced stimulant and appetitive effects.
  • The most active enantiomer 4, facilitated CPP acquisition but failed to substitute for cocaine.
  • When CPP was acquired with cocaine and then extinguished, 4 provoked reactivation of CPP.
  • Preliminary ADME properties are in favour of an optimal therapeutic development.
  • Such Tic-hydantoin compound may serve as a new effective agonist therapy in cocaine addiction.
  • [MeSH-major] Appetitive Behavior / drug effects. Cocaine / pharmacology. Dopamine Uptake Inhibitors / pharmacology. Hydantoins / pharmacology. Hyperkinesis / chemically induced. Receptors, sigma / agonists
  • [MeSH-minor] Analysis of Variance. Animals. Behavior, Animal / drug effects. Cellulose, Oxidized / pharmacology. Chromatography, High Pressure Liquid / methods. Conditioning, Operant / drug effects. Enzyme Inhibitors / pharmacology. Ethylenediamines / pharmacology. Extinction, Psychological / drug effects. Locomotion / drug effects. Male. Mice. Protein Binding / drug effects. Time Factors

  • Hazardous Substances Data Bank. COCAINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19249191.001).
  • [ISSN] 1873-7862
  • [Journal-full-title] European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
  • [ISO-abbreviation] Eur Neuropsychopharmacol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cellulose, Oxidized; 0 / Dopamine Uptake Inhibitors; 0 / Enzyme Inhibitors; 0 / Ethylenediamines; 0 / Hydantoins; 0 / INTERCEED; 0 / Receptors, sigma; 138356-20-4 / BD 1047; I5Y540LHVR / Cocaine
  •  go-up   go-down


69. Strojan P, Popović M, Surlan K, Jereb B: Choroid plexus tumors: a review of 28-year experience. Neoplasma; 2004;51(4):306-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Choroid plexus tumors: a review of 28-year experience.
  • The aims of the study were to review the patients with choroid plexus tumor (CPT) treated in Slovenia between 1972-1999, to calculate the incidence of CPTs, and to evaluate treatment results in respect to tumor histology and mode of therapy.
  • Twelve patients (7 females, 5 males), 0.8-43 years old (median 6.1 years; <15 years: 10/12,83%) with CPT, representing 0.36% of all intracranial tumors registered during the period under study, were identified.
  • There were eight papillomas (CPPs) and four carcinomas (CPCs) with no difference in age distribution between the groups.
  • Of seven patients with gross tumor resection in CPP group, one patient died of postoperative meningitis and one had local recurrence 1.6 years after surgery; the latter is disease-free 17.9 years after re-operation.
  • In the CPC-group, only the patient who received adjuvant BEP chemotherapy and craniospinal irradiation following incomplete surgery is alive with no signs of disease after 6.5 years.
  • Ten-year disease-specific survival for all CPTs and for CPP subgroup was 73% and 100%, respectively.
  • In Slovenia, CPTs represent 0.36% of intracranial tumors.
  • In CPPs, the treatment of choice is surgery alone.
  • For CPCs, adjuvant multiagent chemotherapy and craniospinal radiotherapy following surgery should be considered.
  • [MeSH-major] Choroid Plexus Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Brain Neoplasms / diagnosis. Brain Neoplasms / epidemiology. Brain Neoplasms / therapy. Carcinoma / diagnosis. Carcinoma / epidemiology. Carcinoma / therapy. Child. Child, Preschool. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Papilloma, Choroid Plexus / diagnosis. Papilloma, Choroid Plexus / epidemiology. Papilloma, Choroid Plexus / therapy. Recurrence. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15254663.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  •  go-up   go-down


70. Cavus E, Meybohm P, Doerges V, Hugo HH, Steinfath M, Nordstroem J, Scholz J, Bein B: Cerebral effects of three resuscitation protocols in uncontrolled haemorrhagic shock: a randomised controlled experimental study. Resuscitation; 2009 May;80(5):567-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: To compare haemodynamic and cerebral variables during aggressive fluid resuscitation vs. administration of a hypertonic starch solution (HS) combined with either noradrenaline [norepinephrine] or arginine vasopressin in an animal model of uncontrolled haemorrhagic shock.
  • Thirty minutes after drug administration, bleeding was controlled manually.
  • RESULTS: Mean arterial blood pressure (MAP), cerebral perfusion pressure (CPP), and brain tissue oxygen pressure (P(bt)O(2)) decreased significantly with haemorrhage in all groups (p<0.05).
  • AVP/HS resulted in a faster and higher increase of MAP and CPP compared to both NA/HS and FR (p<0.001 vs. FR; p<0.01 vs. NA/HS).
  • Compared to FR, P(bt)O(2) increased faster with AVP/HS and NA/HS (p<0.05) after therapy, and ICP was lower at the end of the study period (p<0.05).
  • CONCLUSIONS: Following uncontrolled haemorrhagic shock in this animal model, combination of HS with arginine vasopressin increased CPP and cerebral oxygenation faster than aggressive fluid resuscitation, without re-increasing ICP.
  • [MeSH-major] Clinical Protocols. Resuscitation / methods. Shock, Hemorrhagic / therapy
  • [MeSH-minor] Animals. Arginine Vasopressin / administration & dosage. Brain / blood supply. Brain / drug effects. Brain / physiopathology. Cerebrovascular Circulation / drug effects. Combined Modality Therapy / methods. Disease Models, Animal. Female. Fluid Therapy / methods. Hydroxyethyl Starch Derivatives / administration & dosage. Hypertonic Solutions / administration & dosage. Male. Norepinephrine / administration & dosage. Oxygen Consumption / drug effects. Plasma Substitutes / administration & dosage. Prospective Studies. Random Allocation. Swine. Treatment Outcome. Vasoconstrictor Agents / administration & dosage

  • Hazardous Substances Data Bank. Norepinephrine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19217706.001).
  • [ISSN] 0300-9572
  • [Journal-full-title] Resuscitation
  • [ISO-abbreviation] Resuscitation
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Hydroxyethyl Starch Derivatives; 0 / Hypertonic Solutions; 0 / Plasma Substitutes; 0 / Vasoconstrictor Agents; 113-79-1 / Arginine Vasopressin; X4W3ENH1CV / Norepinephrine
  •  go-up   go-down


71. Isaac H, Patel L, Meyer S, Hall CM, Cusick C, Price DA, Clayton PE: Efficacy of a monthly compared to 3-monthly depot GnRH analogue (goserelin) in the treatment of children with central precocious puberty. Horm Res; 2007;68(4):157-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of a monthly compared to 3-monthly depot GnRH analogue (goserelin) in the treatment of children with central precocious puberty.
  • AIMS: To compare the efficacy of goserelin 10.8 mg (Zoladex LA-ZLA) administered 9-12 weekly with 3.6 mg (Zoladex-Z) given monthly in suppressing pubertal development, and effect on body mass index (BMI).
  • METHODS: Children with central precocious puberty (CPP) treated with Z (n = 34) or ZLA (n = 28) were studied retrospectively.
  • Pubertal scores and BMI SDS during 24 months' treatment were compared.
  • RESULTS: To attain adequate pubertal suppression, more patients on ZLA than Z required increase in injection frequency (p = 0.02) and this was so for 7/8 patients with a structural aetiology for CPP on ZLA and 2/8 on Z.
  • Children with CPP had an elevated BMI at the onset of therapy and ZLA had a transient positive influence on BMI.
  • [MeSH-major] Gonadotropin-Releasing Hormone / analogs & derivatives. Goserelin / administration & dosage. Puberty, Precocious / drug therapy
  • [MeSH-minor] Body Height / drug effects. Body Mass Index. Child. Delayed-Action Preparations. Drug Administration Schedule. Female. Growth and Development / drug effects. Humans. Male. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Precocious puberty.
  • Genetic Alliance. consumer health - Central precocious puberty.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GOSERELIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 S. Karger AG, Basel.
  • (PMID = 17356292.001).
  • [ISSN] 1423-0046
  • [Journal-full-title] Hormone research
  • [ISO-abbreviation] Horm. Res.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Delayed-Action Preparations; 0F65R8P09N / Goserelin; 33515-09-2 / Gonadotropin-Releasing Hormone
  •  go-up   go-down


72. Meybohm P, Cavus E, Bein B, Steinfath M, Weber B, Hamann C, Scholz J, Dörges V: Small volume resuscitation: a randomized controlled trial with either norepinephrine or vasopressin during severe hemorrhage. J Trauma; 2007 Mar;62(3):640-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The present study was designed to evaluate the effects of hypertonic-hyperoncotic hydroxyethyl starch solution (HHS) combined with either norepinephrine (NE) or arginine vasopressin (AVP) on cerebral perfusion pressure (CPP) and brain metabolism after hemorrhagic shock.
  • After 30 minutes of therapy, bleeding was controlled by manual compression and all surviving animals were observed for 1 hour.
  • RESULTS: After hemodynamic decompensation, AVP resulted in a significantly higher increase of CPP (mean +/- SD; 47 +/- 19 versus 28 +/- 9 mm Hg; p < 0.01) and cerebral venous partial pressure of oxygen (66 +/- 8 versus 49 +/- 9 mm Hg; p < 0.05) compared with NE after 10 minutes of therapy.
  • Brain metabolism was found comparable in both groups at any time.
  • CONCLUSIONS: AVP was comparable to NE with respect to hemodynamics and blood gases, as well as brain metabolism in surviving animals throughout the study period.
  • [MeSH-major] Hydroxyethyl Starch Derivatives / therapeutic use. Norepinephrine / therapeutic use. Plasma Substitutes / therapeutic use. Resuscitation / methods. Shock, Hemorrhagic / therapy. Vasoconstrictor Agents / therapeutic use. Vasopressins / therapeutic use
  • [MeSH-minor] Animals. Blood Pressure / drug effects. Brain / metabolism. Cardiac Output / drug effects. Cerebrovascular Circulation / drug effects. Microdialysis. Oxygen / blood. Sus scrofa

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VASOPRESSIN .
  • Hazardous Substances Data Bank. Norepinephrine .
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414341.001).
  • [ISSN] 0022-5282
  • [Journal-full-title] The Journal of trauma
  • [ISO-abbreviation] J Trauma
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hydroxyethyl Starch Derivatives; 0 / Plasma Substitutes; 0 / Vasoconstrictor Agents; 11000-17-2 / Vasopressins; S88TT14065 / Oxygen; X4W3ENH1CV / Norepinephrine
  •  go-up   go-down


73. Koos B, Paulsson J, Jarvius M, Sanchez BC, Wrede B, Mertsch S, Jeibmann A, Kruse A, Peters O, Wolff JE, Galla HJ, Söderberg O, Paulus W, Ostman A, Hasselblatt M: Platelet-derived growth factor receptor expression and activation in choroid plexus tumors. Am J Pathol; 2009 Oct;175(4):1631-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Platelet-derived growth factor receptor expression and activation in choroid plexus tumors.
  • Choroid plexus tumors are intraventricular neoplasms predominantly affecting young children.
  • In contrast to choroid plexus papillomas, choroid plexus carcinomas progress frequently, necessitating the development of adjuvant treatment concepts.
  • The finding of PDGF receptor expression in choroid plexus tumors prompted us to elucidate PDGF receptor activation state using a novel method, in situ proximity ligation assay, on formalin-fixed, paraffin-embedded, archival samples of 19 choroid plexus tumors.
  • As assessed by in situ proximity ligation assay, the proportion of phosphorylated PDGF receptor alpha was low in choroid plexus papillomas and choroid plexus carcinomas, whereas phosphorylated PDGF receptor beta was found to be significantly higher in choroid plexus carcinomas.
  • In the immortalized choroid plexus epithelial cell line Z310 expressing PDGF receptor beta, PDGF-BB exhibited a time- and dose-dependent proliferative response, which was significantly attenuated by imatinib (gleevec).
  • In conclusion, our findings suggest that PDGF receptor beta is functionally involved in the biology of choroid plexus tumors and may represent a molecular target for therapy.
  • In addition, this study demonstrates the feasibility and usefulness of in situ proximity ligation assay for monitoring receptor tyrosine kinase activation in formalin-fixed, paraffin-embedded, archival tissues.
  • [MeSH-major] Choroid Plexus Neoplasms / metabolism. Receptor, Platelet-Derived Growth Factor alpha / metabolism. Receptor, Platelet-Derived Growth Factor beta / metabolism
  • [MeSH-minor] Animals. Cell Line. Cell Line, Transformed. Cell Proliferation / drug effects. Epithelial Cells / drug effects. Epithelial Cells / metabolism. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry. Infant. Male. Papilloma / metabolism. Papilloma / pathology. Phosphorylation / drug effects. Platelet-Derived Growth Factor / pharmacology. Rats

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2001 Oct;29(2):143-52 [11544480.001]
  • [Cites] Comput Methods Programs Biomed. 2009 Apr;94(1):58-65 [18950895.001]
  • [Cites] Brain Res. 2002 Dec 27;958(2):371-80 [12470873.001]
  • [Cites] Cytokine Growth Factor Rev. 2004 Aug;15(4):197-204 [15207811.001]
  • [Cites] Mol Cancer. 2003 Jan 3;2:1 [12537587.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2655-60 [15231574.001]
  • [Cites] EMBO J. 1992 Feb;11(2):543-50 [1311251.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 May;64(5):391-7 [15892296.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):66-74 [16330944.001]
  • [Cites] J Neurooncol. 2006 Jan;76(2):105-9 [16205964.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Nov;65(11):1069-73 [17086103.001]
  • [Cites] Adv Cancer Res. 2007;97:247-74 [17419949.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Mol Cell Proteomics. 2007 Sep;6(9):1500-9 [17565975.001]
  • [Cites] Mod Pathol. 2008 Mar;21(3):265-70 [18157090.001]
  • [Cites] Genes Dev. 2008 May 15;22(10):1276-312 [18483217.001]
  • [Cites] Nat Rev Drug Discov. 2002 Jul;1(7):493-502 [12120256.001]
  • (PMID = 19717644.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Platelet-Derived Growth Factor; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  • [Other-IDs] NLM/ PMC2751559
  •  go-up   go-down


74. Dekundy A, Kaminski RM, Zielinska E, Turski WA: NMDA antagonists exert distinct effects in experimental organophosphate or carbamate poisoning in mice. Toxicol Appl Pharmacol; 2007 Mar;219(2-3):114-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anticonvulsant and neuroprotective properties of N-methyl-D-aspartate (NMDA) antagonists encourage the investigation of their effects in AChE inhibitor-induced poisonings.
  • In the present study, the effects of dizocilpine (MK-801, 1 mg/kg) or 3-((RS)-2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid (CPP, 10 mg/kg), alone or combined with muscarinic antagonist atropine (1.8 mg/kg), on convulsant and lethal properties of an OP pesticide dichlorvos or a carbamate drug physostigmine, were studied in mice.
  • MK-801 or CPP blocked or attenuated, respectively, dichlorvos-induced convulsions.
  • Concurrent pretreatment with atropine and either MK-801 or CPP blocked or alleviated seizures produced by dichlorvos, but not by physostigmine.
  • Both MK-801 and CPP co-administered with atropine enhanced its antilethal effects in both dichlorvos and physostigmine poisoning.
  • In both saline- and AChE inhibitor-treated mice, no interaction of the investigated antidotes with brain cholinesterase was found.
  • [MeSH-minor] Animals. Atropine / therapeutic use. Dizocilpine Maleate / therapeutic use. Dose-Response Relationship, Drug. Drug Therapy, Combination. Lethal Dose 50. Male. Mice. Piperazines / therapeutic use

  • MedlinePlus Health Information. consumer health - Seizures.
  • Hazardous Substances Data Bank. ATROPINE .
  • Hazardous Substances Data Bank. DICHLORVOS .
  • Hazardous Substances Data Bank. DIZOCILPINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17157343.001).
  • [ISSN] 0041-008X
  • [Journal-full-title] Toxicology and applied pharmacology
  • [ISO-abbreviation] Toxicol. Appl. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbamates; 0 / Cholinesterase Inhibitors; 0 / Piperazines; 100828-16-8 / 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid; 6384-92-5 / N-Methylaspartate; 6LR8C1B66Q / Dizocilpine Maleate; 7C0697DR9I / Atropine; 7U370BPS14 / Dichlorvos
  •  go-up   go-down


75. Heger S, Müller M, Ranke M, Schwarz HP, Waldhauser F, Partsch CJ, Sippell WG: Long-term GnRH agonist treatment for female central precocious puberty does not impair reproductive function. Mol Cell Endocrinol; 2006 Jul 25;254-255:217-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term GnRH agonist treatment for female central precocious puberty does not impair reproductive function.
  • Depot gonadotropin releasing hormone (GnRH) agonist (GnRHa) therapy is the treatment of choice for patients with central precocious puberty (CPP).
  • The present study was performed on 46 women, former CPP patients, 12.5+/-3.7 years after the discontinuation of treatment with depot GnRHa.
  • In a structured interview, we assessed general health status, clinical signs possibly associated with hyperandrogenism, menstrual cycle, gynaecological diseases and reproductive function.
  • It appears that long-term treatment with depot GnRHa is safe and does not impair reproductive function.
  • The risk of former CPP patients to develop hirsutism and/or polycystic ovary syndrome does not seem to be increased compared to the normal population but this issue needs to be addressed in further long-term follow-up studies.
  • [MeSH-major] Gonadotropin-Releasing Hormone / agonists. Gonadotropin-Releasing Hormone / therapeutic use. Puberty, Precocious / drug therapy. Reproduction / drug effects
  • [MeSH-minor] Adult. Androgens / adverse effects. Body Height / drug effects. Body Mass Index. Body Weight / drug effects. Delayed-Action Preparations / administration & dosage. Drug Administration Routes. Female. Fertility / drug effects. Follow-Up Studies. Genital Diseases, Female / etiology. Health Status. Humans. Hyperandrogenism / diagnosis. Interviews as Topic. Long-Term Care. Menstrual Cycle / drug effects. Triptorelin Pamoate / therapeutic use

  • Genetic Alliance. consumer health - Precocious puberty.
  • Genetic Alliance. consumer health - Central precocious puberty.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16757104.001).
  • [ISSN] 0303-7207
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Androgens; 0 / Delayed-Action Preparations; 33515-09-2 / Gonadotropin-Releasing Hormone; 57773-63-4 / Triptorelin Pamoate
  •  go-up   go-down


76. Petrone C, Hall G, Langman M, Filiaggi MJ: Compaction strategies for modifying the drug delivery capabilities of gelled calcium polyphosphate matrices. Acta Biomater; 2008 Mar;4(2):403-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Compaction strategies for modifying the drug delivery capabilities of gelled calcium polyphosphate matrices.
  • Calcium polyphosphates (CPPs) have shown potential as drug delivery matrices, particularly in treating bone-related chronic diseases such as osteomyelitis, where maintenance of sufficient bactericidal concentrations at the infected bone site is essential.
  • The objective of this study was to incorporate an additional compaction step as part of a gelling protocol to optimize CPP matrix properties while enhancing their drug delivery capabilities.
  • Vancomycin-loaded CPP powders were produced using a previously established gelling and drying protocol, G1, and then subsequently compacted at prescribed levels (30, 113 or 452MPa) before subjecting to an additional gelling and drying protocol (G2).
  • The compaction regelling protocol did, however, eliminate the burst release phenomena observed with the G1 disks and further extended the release of vancomycin into a clinically acceptable therapeutic range of 3weeks.
  • The ability to modulate this release profile to a limited extent by altering compaction stress, particle size distribution and regelling time was also demonstrated.
  • Overall, the compaction regelling protocol described here, when used in conjunction with an initial gelling step to achieve matrix drug loading, enhances the flexibility and long-term drug delivery capability of this CPP matrix.
  • [MeSH-major] Biocompatible Materials. Calcium Phosphates. Drug Delivery Systems
  • [MeSH-minor] Anti-Bacterial Agents / administration & dosage. Compressive Strength. Gels. Humans. Materials Testing. Microscopy, Electron, Scanning. Osteomyelitis / drug therapy. Vancomycin / administration & dosage

  • Hazardous Substances Data Bank. Vancomycin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17997374.001).
  • [ISSN] 1742-7061
  • [Journal-full-title] Acta biomaterialia
  • [ISO-abbreviation] Acta Biomater
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Biocompatible Materials; 0 / Calcium Phosphates; 0 / Gels; 6Q205EH1VU / Vancomycin
  •  go-up   go-down


77. Di Gennaro JL, Mack CD, Malakouti A, Zimmerman JJ, Armstead W, Vavilala MS: Use and effect of vasopressors after pediatric traumatic brain injury. Dev Neurosci; 2010;32(5-6):420-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use and effect of vasopressors after pediatric traumatic brain injury.
  • BACKGROUND: Vasopressors are commonly used to increase mean arterial blood pressure (MAP) and cerebral perfusion pressure (CPP) after traumatic brain injury (TBI), but there are few data comparing vasopressor effectiveness after pediatric TBI.
  • OBJECTIVE: To determine which vasopressor is most effective at increasing MAP and CPP in children with moderate-to-severe TBI.
  • We evaluated differences in MAP and CPP at 3 h after initiation of therapy between phenylephrine, dopamine and norepinephrine among patients who did not require a second vasopressor during this time.
  • Multivariate linear regression was used to adjust for age, gender, injury severity score and baseline MAP or CPP and to cluster by subject.
  • The most common initial medication was phenylephrine for 47 (57%).
  • Thirteen (16%) of the patients received a second vasopressor during the first 3 h of treatment and were thus not included in the regression analyses; these patients received more fluid resuscitation and exhibited higher in-hospital mortality (77 vs. 32%; p = 0.004) compared to patients receiving a single vasopressor.
  • The norepinephrine group exhibited a 5 mm Hg higher MAP (95% CI: -4 to 13; p = 0.31) and a 12 mm Hg higher CPP (95% CI: -2 to 26; p = 0.10) than the phenylephrine group, and a 5 mm Hg higher MAP (95% CI: -4 to 15; p = 0.27) and a 10 mm Hg higher CPP (95% CI: -5 to 25; p = 0.18) than the dopamine group.
  • However, in post hoc analysis, after adjusting for time to start of vasopressor, hypertonic saline and pentobarbital, the effect on MAP was lost, but the CPP was 8 mm Hg higher (95% CI: -10 to 25; p = 0.39) than in the phenylephrine group, and 5 mm Hg higher (95% CI: -14 to 24; p = 0.59) than in the dopamine group.
  • While there was no statistically significant difference in MAP or CPP between vasopressor groups, norepinephrine was associated with a clinically relevant higher CPP and lower intracranial pressure at 3 h after start of vasopressor therapy compared to the other vasopressors examined.
  • [MeSH-major] Brain / drug effects. Brain Injuries / drug therapy. Vasoconstrictor Agents / therapeutic use
  • [MeSH-minor] Adolescent. Blood Pressure / drug effects. Child. Child, Preschool. Cohort Studies. Dopamine / therapeutic use. Female. Humans. Infant. Infant, Newborn. Male. Norepinephrine / therapeutic use. Phenylephrine / therapeutic use. Retrospective Studies

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Norepinephrine .
  • Hazardous Substances Data Bank. DOPAMINE .
  • Hazardous Substances Data Bank. PHENYLEPHRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • [Cites] Intensive Care Med. 2001 Jan;27(1):101-6 [11280619.001]
  • [Cites] Crit Care Med. 2009 Nov;37(11):2968-72 [19770747.001]
  • [Cites] Crit Care Med. 2002 Apr;30(4):739-45 [11940738.001]
  • [Cites] Crit Care Med. 2002 Jul;30(7):1630-5 [12130990.001]
  • [Cites] Acta Neurochir Suppl. 2002;81:225-7 [12168310.001]
  • [Cites] J Neurosurg. 2002 Aug;97(2):326-36 [12186460.001]
  • [Cites] J Neurotrauma. 2002 Nov;19(11):1421-32 [12490007.001]
  • [Cites] Pediatr Crit Care Med. 2003 Jul;4(3 Suppl):S45-8 [12847348.001]
  • [Cites] J Trauma. 2003 Dec;55(6):1039-44 [14676648.001]
  • [Cites] Crit Care Med. 2004 Apr;32(4):1049-54 [15071400.001]
  • [Cites] Intensive Care Med. 2004 May;30(5):791-7 [15048550.001]
  • [Cites] Neuropediatrics. 1984 May;15(2):68-75 [6738819.001]
  • [Cites] J Trauma. 1987 Sep;27(9):1007-13 [3656462.001]
  • [Cites] Arch Dis Child. 1992 Dec;67(12):1430-5 [1489220.001]
  • [Cites] J Trauma. 1993 Feb;34(2):216-22 [8459458.001]
  • [Cites] Acta Neurochir Suppl (Wien). 1993;59:121-5 [8310858.001]
  • [Cites] J Pediatr Surg. 1998 Feb;33(2):333-8 [9498412.001]
  • [Cites] Acta Neurochir Suppl. 1998;71:19-21 [9779132.001]
  • [Cites] J Appl Physiol (1985). 2005 Oct;99(4):1545-51 [15976364.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2006 Feb;77(2):234-40 [16103043.001]
  • [Cites] J Physiol. 2006 Oct 15;576(Pt 2):569-83 [16873404.001]
  • [Cites] J Head Trauma Rehabil. 2006 Nov-Dec;21(6):544-8 [17122685.001]
  • [Cites] Shock. 2009 Aug;32(2):190-3 [19174739.001]
  • [Cites] Crit Care Med. 2008 Sep;36(9):2641-50 [18679110.001]
  • [Cites] J Neurotrauma. 2009 May;26(5):657-63 [19292656.001]
  • [Cites] J Trauma. 2000 Oct;49(4):654-8; discussion 658-9 [11038082.001]
  • [Cites] Shock. 2007 Apr;27(4):416-21 [17414425.001]
  • [Cites] J Neurotrauma. 2007;24 Suppl 1:S7-13 [17511549.001]
  • [Cites] J Neurosurg. 2007 Jun;106(6 Suppl):463-6 [17566403.001]
  • [Cites] Br J Anaesth. 2007 Jul;99(1):4-9 [17573392.001]
  • [Cites] Childs Nerv Syst. 2008 Feb;24(2):245-51 [17712566.001]
  • [Cites] J Neurotrauma. 2001 Nov;18(11):1247-54 [11721743.001]
  • (PMID = 21124016.001).
  • [ISSN] 1421-9859
  • [Journal-full-title] Developmental neuroscience
  • [ISO-abbreviation] Dev. Neurosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Vasoconstrictor Agents; 1WS297W6MV / Phenylephrine; VTD58H1Z2X / Dopamine; X4W3ENH1CV / Norepinephrine
  • [Other-IDs] NLM/ PMC3073759
  •  go-up   go-down


78. Pollack AE, Haisley EC: NMDA glutamate receptor stimulation is required for the expression of D2 dopamine mediated responses in apomorphine primed 6-hydroxydopamine lesioned rats. Brain Res; 2001 Apr 6;897(1-2):213-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pretreatment with NMDA glutamate antagonists MK-801 or CPP dose-dependently attenuates these quinpirole-mediated responses.
  • [MeSH-minor] Animals. Behavior, Animal / drug effects. Brain Chemistry / drug effects. Denervation. Dizocilpine Maleate / pharmacology. Excitatory Amino Acid Antagonists / pharmacology. Male. Oxidopamine. Parkinson Disease / drug therapy. Parkinson Disease / metabolism. Piperazines / pharmacology. Proto-Oncogene Proteins c-fos / metabolism. Rats. Rats, Sprague-Dawley. Sympatholytics

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. APOMORPHINE .
  • Hazardous Substances Data Bank. DIZOCILPINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11282380.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Dopamine Agonists; 0 / Excitatory Amino Acid Antagonists; 0 / Piperazines; 0 / Proto-Oncogene Proteins c-fos; 0 / Receptors, Dopamine D2; 0 / Receptors, N-Methyl-D-Aspartate; 0 / Sympatholytics; 100828-16-8 / 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid; 6LR8C1B66Q / Dizocilpine Maleate; 8HW4YBZ748 / Oxidopamine; N21FAR7B4S / Apomorphine
  •  go-up   go-down


79. Vottero A, Pedori S, Verna M, Pagano B, Cappa M, Loche S, Bernasconi S, Ghizzoni L: Final height in girls with central idiopathic precocious puberty treated with gonadotropin-releasing hormone analog and oxandrolone. J Clin Endocrinol Metab; 2006 Apr;91(4):1284-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: GnRH analogs (GnRHa) are considered the treatment of choice for central precocious puberty (CPP).
  • OBJECTIVE: The objective of this study was to assess whether the addition of oxandrolone (Ox) may affect the height outcome of patients with CPP and growth deceleration during GnRHa treatment.
  • PATIENTS: Twenty patients with CPP and marked growth deceleration during GnRHa treatment were studied.
  • INTERVENTIONS: Treatment consisted of GnRHa (Leuprorelina, 3.75 mg im every 28 d) alone (10 patients) or in combination with Ox (0.06 mg/kg.d by mouth) (10 patients).
  • CONCLUSIONS: Combined GnRHa and Ox therapy is a viable treatment option for children with CPP and marked growth deceleration during treatment with GnRHa alone.
  • [MeSH-major] Anabolic Agents / therapeutic use. Body Height / drug effects. Oxandrolone / therapeutic use. Puberty, Precocious / drug therapy. Puberty, Precocious / pathology
  • [MeSH-minor] Bone Development / physiology. Child. Female. Follicle Stimulating Hormone / blood. Growth / drug effects. Humans. Insulin-Like Growth Factor I / metabolism. Leuprolide / therapeutic use. Luteinizing Hormone / blood

  • Genetic Alliance. consumer health - Precocious puberty.
  • Genetic Alliance. consumer health - Central precocious puberty.
  • MedlinePlus Health Information. consumer health - Anabolic Steroids.
  • Hazardous Substances Data Bank. OXANDROLONE .
  • Hazardous Substances Data Bank. LEUPROLIDE .
  • Hazardous Substances Data Bank. MENOTROPINS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16449342.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anabolic Agents; 67763-96-6 / Insulin-Like Growth Factor I; 7H6TM3CT4L / Oxandrolone; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone; EFY6W0M8TG / Leuprolide
  •  go-up   go-down


80. Sadler R, Herzig V, Schmidt WJ: Repeated treatment with the NMDA antagonist MK-801 disrupts reconsolidation of memory for amphetamine-conditioned place preference. Behav Pharmacol; 2007 Nov;18(7):699-703
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repeated treatment with the NMDA antagonist MK-801 disrupts reconsolidation of memory for amphetamine-conditioned place preference.
  • Long-lasting drug-associated memories can contribute to relapse; therefore these memories must be inactivated to enable sustainable success in addiction therapy.
  • As drug associations are usually acquired over several conditioning events, we assume that an effective treatment should be repeatedly applied to achieve persistent effects.
  • In this study, we examine whether 10 repeated memory reactivation tests followed by systemic N-methyl-D-aspartate receptor antagonist MK-801 (0.1 mg/kg) administrations can disrupt memory reconsolidation in rats, leading to a reduction of well-established amphetamine-conditioned place preference (CPP).
  • We found that immediate (but not 60-min delayed) administration of MK-801 after the tests reduced amphetamine-CPP expression after at least four treatments.
  • These effects were specific to CPP expression as no MK-801-induced change in locomotion was observed during all tests.
  • We discuss these results as being caused by MK-801 disrupting memory reconsolidation and we propose the applied repeated-treatment regimen as a new therapeutic research strategy to persistently disrupt drug-associated memories.
  • [MeSH-major] Amphetamine / pharmacology. Central Nervous System Stimulants / pharmacology. Conditioning, Operant / drug effects. Dizocilpine Maleate / pharmacology. Memory / drug effects. Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors
  • [MeSH-minor] Animals. Behavior, Animal / drug effects. Male. Motor Activity / drug effects. Rats. Rats, Sprague-Dawley

  • MedlinePlus Health Information. consumer health - Memory.
  • Hazardous Substances Data Bank. AMPHETAMINE .
  • Hazardous Substances Data Bank. DIZOCILPINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17912055.001).
  • [ISSN] 0955-8810
  • [Journal-full-title] Behavioural pharmacology
  • [ISO-abbreviation] Behav Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Central Nervous System Stimulants; 0 / Receptors, N-Methyl-D-Aspartate; 6LR8C1B66Q / Dizocilpine Maleate; CK833KGX7E / Amphetamine
  •  go-up   go-down


81. Ortega-Martínez M, Cabezudo-Artero JM, Fernández-Portales I, Pimentel JJ, Gómez de Tejada R: Diffuse leptomeningeal seeding from benign choroid plexus papilloma. Acta Neurochir (Wien); 2007 Dec;149(12):1229-36; discussion 1236-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse leptomeningeal seeding from benign choroid plexus papilloma.
  • Choroid plexus papillomas (CPP) are rare intracranial tumours with a favourable long-term outcome after surgical excision.
  • Although they are histologically benign, local recurrences may occasionally occur, but leptomeningeal dissemination is exceptional.
  • We report an unusual example of a fourth ventricle choroid plexus papilloma with diffuse leptomeningeal seeding.
  • Treatment with systemic and intrathecal chemotherapy was ineffective in this patient.
  • We review the literature concerning leptomeningeal dissemination of benign choroid plexus papillomas.
  • [MeSH-major] Cerebral Ventricle Neoplasms / surgery. Fourth Ventricle / surgery. Meningeal Neoplasms / secondary. Neoplasm Seeding. Papilloma, Choroid Plexus / surgery
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Biopsy. Disease Progression. Fatal Outcome. Female. Humans. Ki-67 Antigen / analysis. Laminectomy. Magnetic Resonance Imaging. Meninges / pathology. Reoperation. S100 Proteins / analysis

  • Genetic Alliance. consumer health - Choroid Plexus Papilloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17924056.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / S100 Proteins
  •  go-up   go-down


82. Fishbain DA, Lewis JE, Gao J, Cole B, Rosomoff RS: Alleged breaches of "standards of medical care" in a patient overdose death possibly related to chronic opioid analgesic therapy, application of the controlled substances model guidelines: case report. Pain Med; 2009 Apr;10(3):565-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alleged breaches of "standards of medical care" in a patient overdose death possibly related to chronic opioid analgesic therapy, application of the controlled substances model guidelines: case report.
  • 1) to present details of a chronic pain patient (CPP) who was placed on chronic opioid analgesic therapy (COAT), and subsequently overdosed on multiple drugs, some of which were not prescribed by his COAT physician;.
  • METHODS: This is a case report of a CPP treated by a pain physician.
  • CONCLUSIONS: Some CPPs may withhold information critical to their COAT treatment.
  • [MeSH-major] Analgesics, Opioid / poisoning. Malpractice / legislation & jurisprudence. Pain / drug therapy. Practice Guidelines as Topic / standards
  • [MeSH-minor] Adult. Anti-Anxiety Agents / poisoning. Antidepressive Agents, Tricyclic / poisoning. Diazepam / poisoning. Doxepin / poisoning. Drug Overdose. Female. Heroin Dependence / complications. Heroin Dependence / drug therapy. Humans. Hydrocodone / poisoning. Methadone / therapeutic use. Nordazepam / poisoning. Pain Measurement. Shoulder / injuries. Shoulder / pathology. Temazepam / poisoning

  • MedlinePlus Health Information. consumer health - Pain.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROCODONE .
  • Hazardous Substances Data Bank. DOXEPIN .
  • Hazardous Substances Data Bank. DIAZEPAM .
  • Hazardous Substances Data Bank. METHADONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pain Med. 2009 Apr;10(3):562-3; discussion 564 [19416441.001]
  • [CommentIn] Pain Med. 2010 Jun;11(6):981; author reply 982-3 [20624246.001]
  • (PMID = 18992043.001).
  • [ISSN] 1526-4637
  • [Journal-full-title] Pain medicine (Malden, Mass.)
  • [ISO-abbreviation] Pain Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Anti-Anxiety Agents; 0 / Antidepressive Agents, Tricyclic; 1668-19-5 / Doxepin; 67220MCM01 / Nordazepam; 6YKS4Y3WQ7 / Hydrocodone; CHB1QD2QSS / Temazepam; Q3JTX2Q7TU / Diazepam; UC6VBE7V1Z / Methadone
  •  go-up   go-down


83. Adan Y, Goldman Y, Haimovitz R, Mammon K, Eilon T, Tal S, Tene A, Karmel Y, Shinitzky M: Phenotypic differentiation of human breast cancer cells by 1,3 cyclic propanediol phosphate. Cancer Lett; 2003 May 8;194(1):67-79
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have recently shown that 1,3 cyclic propanediol phosphate (1,3 cPP), an analog of 1,3 cyclic glycerophosphate (1,3 cGP), can promote morphological, neuronal-like differentiation in pheochromocytoma-12 cells in vitro.
  • In view of this observation, we tested the potential of 1,3 cPP to elevate the state of cellular differentiation of the human breast cancer cell lines MCF-7 (ER(+)) and HCC1954 (ER(-)), as characterized by the expression of steroid receptors, casein kinase, lipid droplet histology and signal-transduction gene profiles.
  • In the range of 5-100 microM 1,3 cPP the in vitro expression of ER-alpha, PR and casein kinase increased by approximately 2-fold while the mRNA transcription increased by 2-6-fold.
  • Moreover, following 9-12 days of incubation with 1,3 cPP, HCC1954 cells exhibited a significant increase in the production of lipid droplets as observed by Oil Red O staining.
  • After 4 biweekly i.p. injections of 0.5 mg 1,3 cPP per mouse, tumors in the 1,3 cPP treated virtually did not grow at all while the tumors in the control group grew rapidly.
  • Based on these findings, we propose that this novel differentiating compound has the potential to transform the malignant tumor phenotype into a near-normal phenotype, as well as to sensitize the tumor cells to anti-estrogen therapy via upgrading the status of steroid hormone receptors.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Propylene Glycols / pharmacology
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Azo Compounds / pharmacology. Biomarkers, Tumor. Blotting, Western. Casein Kinases. Cell Differentiation / drug effects. Cell Division. Coloring Agents / pharmacology. Dose-Response Relationship, Drug. Estrogen Receptor alpha. Exons. Female. Humans. Lipid Metabolism. Male. Mice. Mice, Nude. Neoplasm Transplantation. Oligonucleotide Array Sequence Analysis. Phenotype. Protein Kinases / metabolism. RNA, Messenger / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction. Time Factors. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12706860.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / 1,3-cyclic propanediol phosphate; 0 / Antineoplastic Agents; 0 / Azo Compounds; 0 / Biomarkers, Tumor; 0 / Coloring Agents; 0 / Estrogen Receptor alpha; 0 / Propylene Glycols; 0 / RNA, Messenger; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 1320-06-5 / oil red O; EC 2.7.- / Protein Kinases; EC 2.7.11.1 / Casein Kinases
  •  go-up   go-down


84. Meybohm P, Cavus E, Dörges V, Weber B, Stadlbauer KH, Wenzel V, Scholz J, Steffen M, Bein B: Release of protein S100B in haemorrhagic shock: effects of small volume resuscitation combined with arginine vasopressin. Resuscitation; 2008 Mar;76(3):449-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The present study was designed to evaluate the effect of conventional fluid resuscitation and small volume resuscitation alone and combined with arginine vasopressin (AVP) on cerebral perfusion pressure (CPP) and protein S100B during experimental haemorrhagic shock.
  • RESULTS: Compared to baseline, CPP decreased and S100B levels increased significantly at haemodynamic decompensation (S100B: fluid, 0.52+/-0.23 microg L(-1) vs. 0.85+/-0.37 microg L(-1), p<0.05; HHS+NS, 0.47+/-0.18 microg L(-1) vs. 0.90+/-0.33 microg L(-1), p<0.05; HHS+AVP, 0.53+/-0.18 microg L(-1) vs. 0.90+/-0.39 microg L(-1), p<0.01).
  • During the initial 10 min of therapy, CPP of HHS+NS was significantly higher compared to the fluid group, increased more rapidly in the HHS+AVP group, but was not significantly different thereafter.
  • CONCLUSION: HHS+AVP resulted in higher CPP compared to fluid and HHS+NS in the initial phase of therapy, but did not differ thereafter.
  • [MeSH-minor] Animals. Blood Pressure / drug effects. Cerebrovascular Circulation / drug effects. Colloids. Disease Models, Animal. Female. Intracranial Pressure / drug effects. Isotonic Solutions. Liver / injuries. Male. Prospective Studies. Rehydration Solutions / administration & dosage. S100 Calcium Binding Protein beta Subunit. Saline Solution, Hypertonic. Swine

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17976887.001).
  • [ISSN] 0300-9572
  • [Journal-full-title] Resuscitation
  • [ISO-abbreviation] Resuscitation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Colloids; 0 / Hemostatics; 0 / Isotonic Solutions; 0 / Nerve Growth Factors; 0 / Rehydration Solutions; 0 / S100 Calcium Binding Protein beta Subunit; 0 / S100 Proteins; 0 / Saline Solution, Hypertonic; 0 / crystalloid solutions; 113-79-1 / Arginine Vasopressin
  •  go-up   go-down


85. Bordman R, Jackson B: Below the belt: approach to chronic pelvic pain. Can Fam Physician; 2006 Dec;52(12):1556-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To present a practical approach to the symptom complex called chronic pelvic pain (CPP).
  • Chronic pelvic pain is defined as nonmenstrual pain lasting 6 months or more that is severe enough to cause functional disability or require medical or surgical treatment.
  • MAIN MESSAGE: While the source of pain in CPP can be gynecologic, urologic, gastrointestinal, musculoskeletal, or psychoneurologic, 4 conditions account for most CPP: endometriosis, adhesions, interstitial cystitis, and irritable bowel syndrome.
  • Nonnarcotic analgesics are first-line therapy for pain relief; hormonal therapies are beneficial if the pain has a cyclical component.
  • CONCLUSION: Although caring for patients with CPP can be challenging and frustrating, family physicians are in an ideal position to manage and coordinate their care.
  • [MeSH-major] Pelvic Pain / diagnosis. Pelvic Pain / therapy
  • [MeSH-minor] Abdominal Pain / etiology. Adult. Chronic Disease. Cystitis, Interstitial / complications. Cystitis, Interstitial / diagnosis. Cystitis, Interstitial / drug therapy. Endometriosis / complications. Endometriosis / diagnosis. Endometriosis / drug therapy. Female. Humans. Irritable Bowel Syndrome / complications. Irritable Bowel Syndrome / diagnosis. Irritable Bowel Syndrome / therapy. Physical Examination

  • MedlinePlus Health Information. consumer health - Pelvic Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br Med Bull. 2004;72:15-29 [15767561.001]
  • [Cites] Clin Obstet Gynecol. 1998 Jun;41(2):422-35 [9646974.001]
  • [Cites] Am Fam Physician. 1999 Oct 15;60(6):1753-62, 1767-8 [10537390.001]
  • [Cites] Baillieres Best Pract Res Clin Obstet Gynaecol. 2000 Jun;14(3):467-94 [10962637.001]
  • [Cites] Cochrane Database Syst Rev. 2000;(4):CD000387 [11034686.001]
  • [Cites] J Am Board Fam Pract. 2001 Mar-Apr;14(2):95-106 [11314930.001]
  • [Cites] Int J Gynaecol Obstet. 2001 Sep;74 Suppl 1:S15-20 [11549395.001]
  • [Cites] Obstet Gynecol Surv. 2001 Dec;56(12):757-64 [11753178.001]
  • [Cites] J Obstet Gynaecol Can. 2002 Jan;24(1):37-61; quiz 74-6 [12196887.001]
  • [Cites] Fertil Steril. 2002 Nov;78(5):961-72 [12413979.001]
  • [Cites] Obstet Gynecol. 2003 Mar;101(3):594-611 [12636968.001]
  • [Cites] Obstet Gynecol Clin North Am. 2003 Mar;30(1):133-50 [12699262.001]
  • [Cites] J Urol. 2003 Sep;170(3):807-9 [12913704.001]
  • [Cites] Obstet Gynecol Surv. 2003 Sep;58(9):615-23 [12972837.001]
  • [Cites] J Fam Pract. 2003 Dec;52(12):942-50 [14653980.001]
  • [Cites] Obstet Gynecol. 2004 Mar;103(3):589-605 [14990428.001]
  • [Cites] J Reprod Med. 2004 Mar;49(3 Suppl):230-4 [15088861.001]
  • [Cites] Obstet Gynecol. 1991 May;77(5):740-4 [1826544.001]
  • [Cites] Br J Obstet Gynaecol. 1992 Jan;99(1):59-62 [1547175.001]
  • [Cites] Urology. 1997 May;49(5A Suppl):58-63 [9146003.001]
  • [Cites] J Gen Intern Med. 1997 Jul;12(7):439-45 [9229283.001]
  • [Cites] Clin Obstet Gynecol. 1997 Sep;40(3):554-63 [9328736.001]
  • [Cites] Obstet Gynecol. 2003 Aug;102(2):397-408 [12907119.001]
  • (PMID = 17279236.001).
  • [ISSN] 1715-5258
  • [Journal-full-title] Canadian family physician Médecin de famille canadien
  • [ISO-abbreviation] Can Fam Physician
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC1783755
  •  go-up   go-down


86. Järver P, Mäger I, Langel Ü: In vivo biodistribution and efficacy of peptide mediated delivery. Trends Pharmacol Sci; 2010 Nov;31(11):528-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since the late 1990s, cell-penetrating peptides (CPPs) have been utilized as transport vectors for a broad spectrum of 'biological cargoes', ranging from inert gold particles to multifaceted macromolecules such as proteins and plasmids.
  • However, even though CPPs are versatile transport vectors, this does not guarantee they can be developed into useful pharmaceutical molecules.
  • Nevertheless, recent progress in the field has shown CPPs to be effective for in vivo delivery with retained biological activity of a wide variety of bioactive cargoes into virtually any mammalian tissue.
  • This review will focus on recent developments and applications for CPP delivery and distribution in vivo.
  • [MeSH-minor] Animals. Cell Membrane / metabolism. Cell Membrane Permeability. Drug Carriers. Humans. Inflammation / drug therapy. Neoplasms / drug therapy. Protein Transport. Proteins / metabolism. Proteins / pharmacology. RNA Interference. RNA, Small Interfering / metabolism. Tissue Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20828841.001).
  • [ISSN] 1873-3735
  • [Journal-full-title] Trends in pharmacological sciences
  • [ISO-abbreviation] Trends Pharmacol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antineoplastic Agents; 0 / Cell-Penetrating Peptides; 0 / Drug Carriers; 0 / Oligonucleotides; 0 / Proteins; 0 / RNA, Small Interfering
  •  go-up   go-down


87. Mori T, Sasaki J, Aoyama Y, Sera T: Regulation of cancer-related growth factor expression by artificial zinc-finger proteins. Nucleic Acids Symp Ser (Oxf); 2006;(50):291-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One attractive approach to anticancer therapy is repression of expression of vascular endothelial growth factor (VEGF) gene, which is a potent target for prevention of tumor growth.
  • We demonstrated ATFs fused to CPPs, designated CPP-ATFs or designed regulatory proteins (DRPs), could penetrate into mammalian cells and transiently repress expression of a reporter gene, which was under control of the VEGF promoter/5'-UTR.
  • We discuss gene-regulatory properties of CPP-ATFs in detail.
  • [MeSH-minor] Gene Expression / drug effects. Genes, Reporter. Humans. Neoplasms / blood supply. Zinc Fingers

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17150932.001).
  • [ISSN] 1746-8272
  • [Journal-full-title] Nucleic acids symposium series (2004)
  • [ISO-abbreviation] Nucleic Acids Symp Ser (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Carrier Proteins; 0 / PTD4-ATF protein; 0 / Recombinant Fusion Proteins; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


88. Fricks-Gleason AN, Marshall JF: Post-retrieval beta-adrenergic receptor blockade: effects on extinction and reconsolidation of cocaine-cue memories. Learn Mem; 2008 Sep;15(9):643-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Contexts and discrete cues associated with drug-taking are often responsible for relapse among addicts.
  • Animal models have shown that interference with the reconsolidation of drug-cue memories can reduce seeking of drugs or drug-paired stimuli.
  • One such model is conditioned place preference (CPP) in which an animal is trained to associate a particular environment with the rewarding effects of a drug.
  • Previous work from this laboratory has shown that intra-nucleus accumbens core infusions of a MEK inhibitor can interfere with reconsolidation of these drug-cue memories.
  • A question that remains is whether post-retrieval drug effects on subsequent memories represent an interference with reconsolidation processes or rather a facilitation of extinction.
  • In this experiment, we explore the effect of post-retrieval injections of propranolol, a beta-adrenergic receptor antagonist, on reconsolidation and extinction of cocaine CPP.
  • After acquisition of cocaine CPP, animals were given post-retrieval propranolol injections once or each day during a protocol of unreinforced preference tests, until the animals showed no preference for the previously cocaine-paired environment.
  • Following a cocaine priming injection, the animals that received daily post-test propranolol injections did not reinstate their preference for the drug-paired side.
  • These data suggest that daily post-retrieval systemic injections of propranolol decrease the conditioned preference by interfering with reconsolidation of the memory for the association between the drug-paired side and the reinforcing effects of the drug, rather than facilitating new extinction learning.

  • MedlinePlus Health Information. consumer health - Memory.
  • Hazardous Substances Data Bank. COCAINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci. 2006 May 31;26(22):5881-7 [16738229.001]
  • [Cites] Behav Brain Res. 2006 Jun 30;170(2):333-6 [16600394.001]
  • [Cites] Neuroreport. 2006 Sep 18;17(13):1443-7 [16932155.001]
  • [Cites] Neuroreport. 2007 May 28;18(8):777-80 [17471065.001]
  • [Cites] Behav Brain Res. 2007 Aug 22;182(1):129-34 [17604134.001]
  • [Cites] Behav Pharmacol. 2007 Nov;18(7):699-703 [17912055.001]
  • [Cites] Learn Mem. 2008 Feb;15(2):88-92 [18235109.001]
  • [Cites] Learn Mem. 2000 Mar-Apr;7(2):73-84 [10753974.001]
  • [Cites] Behav Brain Res. 2000 Oct;115(1):39-47 [10996406.001]
  • [Cites] Nat Neurosci. 2001 Aug;4(8):813-8 [11477427.001]
  • [Cites] Neuron. 2002 Nov 14;36(4):567-84 [12441048.001]
  • [Cites] Science. 2004 May 7;304(5672):839-43 [15073322.001]
  • [Cites] Q J Exp Psychol B. 2004 Apr;57(2):97-132 [15204112.001]
  • [Cites] J Neurosci. 2004 Oct 20;24(42):9269-75 [15496662.001]
  • [Cites] Neuroscience. 2004;129(2):267-72 [15501585.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 1983;7(4-6):591-7 [6686696.001]
  • [Cites] NIDA Res Monogr. 1988;81:74-80 [3136393.001]
  • [Cites] Neuron. 2005 Sep 15;47(6):795-801 [16157275.001]
  • [Cites] Neuron. 2005 Sep 15;47(6):873-84 [16157281.001]
  • [Cites] Neuropsychopharmacology. 2006 Jan;31(1):160-70 [15886718.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3428-33 [16492789.001]
  • [Cites] J Neurosci. 2006 Mar 15;26(11):3010-20 [16540579.001]
  • [Cites] Behav Brain Res. 2006 Sep 15;172(1):173-8 [16769132.001]
  • (PMID = 18772251.001).
  • [ISSN] 1549-5485
  • [Journal-full-title] Learning & memory (Cold Spring Harbor, N.Y.)
  • [ISO-abbreviation] Learn. Mem.
  • [Language] ENG
  • [Grant] United States / NIDA NIH HHS / DA / R01 DA021807; United States / NIDA NIH HHS / DA / DA 021807
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenergic beta-Antagonists; 0 / Dopamine Uptake Inhibitors; I5Y540LHVR / Cocaine
  • [Other-IDs] NLM/ PMC2632789
  •  go-up   go-down


89. Leri F, Franklin KB: Diazepam in the ventral striatum dissociates dopamine-dependent and dopamine-independent place conditioning. Neuroreport; 2000 Aug 3;11(11):2553-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have previously shown that diazepam blocks both the formation and the expression of amphetamine-induced conditioned place preference (CPP), but has no effect on the CPP induced by morphine.
  • The second and third experiments demonstrated that intra-cranial injections of diazepam in the nucleus accumbens blocked the expression of amphetamine CPP but not of morphine CPP.
  • It is concluded that diazepam interferes with mesolimbic dopamine-dependent motivational effects of drugs.
  • [MeSH-major] Conditioning (Psychology) / drug effects. Diazepam / pharmacology. Dopamine / metabolism. Neural Pathways / drug effects. Neurons / drug effects. Nucleus Accumbens / drug effects. Ventral Tegmental Area / drug effects
  • [MeSH-minor] 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer / pharmacology. Amphetamine / pharmacology. Animals. Drug Interactions / physiology. Male. Morphine / pharmacology. Motor Activity / drug effects. Motor Activity / physiology. Rats. Rats, Long-Evans. Receptors, Opioid, kappa / agonists. Receptors, Opioid, kappa / metabolism. Substance-Related Disorders / drug therapy. Substance-Related Disorders / metabolism. Substance-Related Disorders / physiopathology

  • Hazardous Substances Data Bank. AMPHETAMINE .
  • Hazardous Substances Data Bank. DIAZEPAM .
  • Hazardous Substances Data Bank. DOPAMINE .
  • Hazardous Substances Data Bank. MORPHINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10943721.001).
  • [ISSN] 0959-4965
  • [Journal-full-title] Neuroreport
  • [ISO-abbreviation] Neuroreport
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Receptors, Opioid, kappa; 67198-13-4 / 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; 76I7G6D29C / Morphine; CK833KGX7E / Amphetamine; Q3JTX2Q7TU / Diazepam; VTD58H1Z2X / Dopamine
  •  go-up   go-down


90. Tan M, Lan KH, Yao J, Lu CH, Sun M, Neal CL, Lu J, Yu D: Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide. Cancer Res; 2006 Apr 1;66(7):3764-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ErbB2 is an excellent target for cancer therapies.
  • Unfortunately, the outcome of current therapies for ErbB2-positive breast cancers remains unsatisfying due to resistance and side effects.
  • New therapies for ErbB2-overexpressing breast cancers continue to be in great need.
  • Peptide therapy using cell-penetrating peptides (CPP) as peptide carriers is promising because the internalization is highly efficient, and the cargoes delivered can be bioactive.
  • However, the major obstacle in using these powerful CPPs for therapy is their lack of specificity.
  • Here, we sought to develop a peptide carrier that could introduce therapeutics specifically to ErbB2-overexpressing breast cancer cells.
  • By modifying the HIV TAT-derived CPP and conjugating anti-HER-2/neu peptide mimetic (AHNP), we developed the peptide carrier (P3-AHNP) that specifically targeted ErbB2-overexpressing breast cancer cells in vitro and in vivo.
  • P3-AHNP-STAT3BP inhibited cell growth in vitro, with ErbB2-overexpressing 435.eB breast cancer cells being more sensitive to the treatment than the ErbB2 low-expressing MDA-MB-435 cells.
  • Compared with ErbB2 low-expressing MDA-MB-435 xenografts, i.p. injected P3-AHNP-STAT3BP preferentially accumulated in 435.eB xenografts, which led to more reduction of proliferation and increased apoptosis and targeted inhibition of tumor growth.
  • This novel peptide delivery system provided a sound basis for the future development of safe and effective new-generation therapeutics to cancer-specific molecular targets.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / metabolism. Gene Products, tat / pharmacology. Peptide Fragments / pharmacology. Receptor, ErbB-2 / metabolism. STAT3 Transcription Factor / antagonists & inhibitors
  • [MeSH-minor] Amino Acid Sequence. Animals. Antibodies, Monoclonal / pharmacokinetics. Antibodies, Monoclonal / pharmacology. Drug Delivery Systems. Female. Humans. Immunoconjugates / pharmacokinetics. Immunoconjugates / pharmacology. Mice. Mice, SCID. Molecular Sequence Data. NIH 3T3 Cells. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16585203.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1R01 CA 109570; United States / NCI NIH HHS / CA / 1R01 CA 119127-01; United States / NCI NIH HHS / CA / P01 CA 099031; United States / NCI NIH HHS / CA / P30 CA 16672
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Gene Products, tat; 0 / Immunoconjugates; 0 / Peptide Fragments; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / anti-HER2-neu peptide mimic, 1.5 kDa; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


91. Wang YQ, Zhou W, Liu YY, Liu YH, Peng T, Wang ZR: [The role of circadian gene period1 in morphine reward in mice]. Space Med Med Eng (Beijing); 2004 Oct;17(5):383-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the role of circadian gene Period1 on drug dependence.
  • Conditional place preference (CPP) paradigm used to investigate the effect of intracerebroventricular (ICV) injection of pcDNA 3.1-per1RZ on drug reward in BALB/C mice.
  • CPP test displayed the block of drug reward in pcDNA 3.1-per1RZ ICV injection group.
  • Period1 expression in brain was attenuated of pcDNA 3.1-per1RZ ICV injection group demonstrated by western blot.
  • CONCLUSION: Interfere the Period1 expression in brain could attenuate the psychological dependence of drug in mammals.
  • [MeSH-major] Circadian Rhythm / genetics. Morphine / pharmacology. Morphine Dependence / drug therapy. Nuclear Proteins / pharmacology. Substance-Related Disorders / drug therapy
  • [MeSH-minor] Animals. Behavior, Animal / drug effects. Behavior, Animal / physiology. Cell Cycle Proteins. Disease Models, Animal. Genetic Therapy. Mice. Mice, Inbred BALB C. Period Circadian Proteins. RNA, Messenger / metabolism

  • MedlinePlus Health Information. consumer health - Drug Abuse.
  • MedlinePlus Health Information. consumer health - Opioid Abuse and Addiction.
  • Hazardous Substances Data Bank. MORPHINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15926241.001).
  • [ISSN] 1002-0837
  • [Journal-full-title] Hang tian yi xue yu yi xue gong cheng = Space medicine & medical engineering
  • [ISO-abbreviation] Space Med Med Eng (Beijing)
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Nuclear Proteins; 0 / Per1 protein, mouse; 0 / Period Circadian Proteins; 0 / RNA, Messenger; 76I7G6D29C / Morphine
  • [Other-IDs] NASA/ 00031288
  •  go-up   go-down


92. Read SP, Cashman SM, Kumar-Singh R: POD nanoparticles expressing GDNF provide structural and functional rescue of light-induced retinal degeneration in an adult mouse. Mol Ther; 2010 Nov;18(11):1917-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Peptide for ocular delivery (POD) is a novel cationic cell-penetrating peptide (CPP) which, when conjugated with polyethylene glycol (PEG-POD), can deliver plasmid DNA to the retinal pigment epithelium (RPE) of adult murine retina.
  • The thickness of the outer nuclear layer (ONL) of the superior retina of PEG-POD~GDNF-injected eyes was significantly greater (23.6-39.3%) than control-injected retina 14 days post-light treatment.
  • PEG-POD~GDNF-injected eyes showed a 27-39% greater functional response relative to controls, as measured by electroretinogram (ERG) 7 days post-light treatment.
  • This is one of only two studies demonstrating histological and functional rescue of a mouse model of retinal degeneration following nonviral administration of a transgene into adult retina.
  • Although rescue is short lived for clinical application, this study represents an important step in the development of nonviral gene therapy for retinal diseases.
  • [MeSH-major] Genetic Therapy. Glial Cell Line-Derived Neurotrophic Factor / genetics. Nanoparticles. Radiation Injuries, Experimental / therapy. Retina / radiation effects. Retinal Degeneration / therapy
  • [MeSH-minor] Animals. Apoptosis. Caspases / metabolism. Drug Delivery Systems. Electroretinography. Light / adverse effects. Mice. Mice, Inbred BALB C. Peptide Fragments / therapeutic use. Polyethylene Glycols. Rats

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Pharmacol Sci. 2000 Mar;21(3):99-103 [10689363.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3896-901 [16505355.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2001 May;42(6):1356-62 [11328751.001]
  • [Cites] Mol Ther. 2001 Dec;4(6):622-9 [11735347.001]
  • [Cites] Br J Ophthalmol. 2006 Aug;90(8):1060-6 [16707518.001]
  • [Cites] Surv Ophthalmol. 2006 Sep-Oct;51(5):461-81 [16950247.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2007 Jun;48(6):2753-9 [17525209.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2007 Nov;48(11):5199-206 [17962474.001]
  • [Cites] Mol Ther. 2008 Jan;16(1):107-14 [17923842.001]
  • [Cites] Exp Eye Res. 2008 Sep;87(3):168-75 [18653181.001]
  • [Cites] J Neurosci. 2008 Sep 24;28(39):9880-9 [18815272.001]
  • [Cites] Curr Gene Ther. 2008 Oct;8(5):353-66 [18855632.001]
  • [Cites] PLoS One. 2009;4(4):e5290 [19390689.001]
  • [Cites] Curr Eye Res. 2009 Sep;34(9):791-9 [19839873.001]
  • [Cites] J Gene Med. 2010 Jan;12(1):86-96 [19937991.001]
  • [Cites] Vision Res. 2010 Mar 31;50(7):686-97 [19733192.001]
  • [Cites] FASEB J. 2010 Apr;24(4):1178-91 [19952284.001]
  • [Cites] Nat Genet. 2002 Oct;32(2):254-60 [12219089.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2002 Oct;43(10):3349-54 [12356844.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2002 Nov;43(11):3480-8 [12407159.001]
  • [Cites] Arch Ophthalmol. 2002 Nov;120(11):1435-42 [12427055.001]
  • [Cites] Mol Ther. 2002 Dec;6(6):813-23 [12498777.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2003 Feb;44(2):486-92 [12556372.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2003 Feb;44(2):848-55 [12556421.001]
  • [Cites] Mol Ther. 2003 Jul;8(1):130-42 [12842436.001]
  • [Cites] Neuroscience. 2003;122(1):229-35 [14596863.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2004 Jan;45(1):267-74 [14691183.001]
  • [Cites] Mol Vis. 2004 Feb 10;10:93-102 [14961006.001]
  • [Cites] Photochem Photobiol. 1989 Sep;50(3):429-38 [2675140.001]
  • [Cites] Arch Ophthalmol. 1992 Jan;110(1):99-104 [1731731.001]
  • [Cites] Ophthalmology. 1992 Jun;99(6):933-43 [1630784.001]
  • [Cites] J Neurosci. 1992 Sep;12(9):3554-67 [1527595.001]
  • [Cites] Neuron. 1993 Oct;11(4):595-605 [8398150.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1995 Apr;36(5):851-63 [7706033.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jan 23;93(2):589-95 [8570600.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1996 Apr;37(5):775-82 [8603862.001]
  • [Cites] Hum Gene Ther. 1996 Jan 20;7(2):215-22 [8788172.001]
  • [Cites] Exp Eye Res. 1997 Jun;64(6):963-70 [9301477.001]
  • [Cites] J Neurosci. 1999 Jun 15;19(12):4778-85 [10366612.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 1999 Oct;237(10):855-60 [10502061.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2724-34 [10509671.001]
  • [Cites] J Biol Chem. 2004 Nov 12;279(46):48434-42 [15345713.001]
  • [Cites] Prog Retin Eye Res. 2005 Mar;24(2):275-306 [15610977.001]
  • [Cites] Gene Ther. 2005 May;12(10):843-51 [15789063.001]
  • [Cites] Mol Cell Biol. 2006 Apr;26(7):2746-57 [16537917.001]
  • [Cites] Hum Gene Ther. 2000 Sep 1;11(13):1875-90 [10986560.001]
  • (PMID = 20700110.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Grant] United States / NEI NIH HHS / EY / EY013887; United States / NEI NIH HHS / EY / EY014991; United States / NEI NIH HHS / EY / R01 EY013837; United States / NEI NIH HHS / EY / R01 EY021805; United States / NEI NIH HHS / EY / R01 EY014991
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gdnf protein, rat; 0 / Glial Cell Line-Derived Neurotrophic Factor; 0 / Peptide Fragments; 30IQX730WE / Polyethylene Glycols; EC 3.4.22.- / Caspases
  • [Other-IDs] NLM/ PMC2990513
  •  go-up   go-down


93. You ZD, Li JH, Song CY, Lu CL, He C: Oxytocin mediates the inhibitory action of acute lithium on the morphine dependence in rats. Neurosci Res; 2001 Oct;41(2):143-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acute lithium could enhance the morphine-induced analgesia in rats with or without chronic morphine treatment; this effect could be inhibited by intraventricular injection of oxytocin antagonist d (CH(2))(5)-Tyr (Me)-[Orn(8)]-Vasotocin (OVT).
  • The lithium significantly inhibited the conditioned place preference (CPP) induced by morphine, which inhibitory action of lithium could also reverse by ICV injection of OVT.
  • [MeSH-major] Analgesics, Opioid / pharmacology. Antimanic Agents / pharmacology. Hypothalamo-Hypophyseal System / drug effects. Hypothalamus, Anterior / drug effects. Lithium Chloride / pharmacology. Morphine / pharmacology. Morphine Dependence / drug therapy. Oxytocin / analogs & derivatives. Oxytocin / secretion
  • [MeSH-minor] Animals. Behavior, Animal / drug effects. Behavior, Animal / physiology. Conditioning (Psychology) / drug effects. Conditioning (Psychology) / physiology. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Interactions / physiology. Male. Naloxone / pharmacology. Narcotic Antagonists / pharmacology. Neurosecretion / drug effects. Neurosecretion / physiology. Pain Measurement / drug effects. Pain Threshold / drug effects. Pain Threshold / physiology. Rats. Rats, Sprague-Dawley. Substance Withdrawal Syndrome / drug therapy. Substance Withdrawal Syndrome / metabolism. Substance Withdrawal Syndrome / physiopathology

  • Hazardous Substances Data Bank. NALOXONE .
  • Hazardous Substances Data Bank. Oxytocin .
  • Hazardous Substances Data Bank. MORPHINE .
  • Hazardous Substances Data Bank. LITHIUM CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11591442.001).
  • [ISSN] 0168-0102
  • [Journal-full-title] Neuroscience research
  • [ISO-abbreviation] Neurosci. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Antimanic Agents; 0 / Narcotic Antagonists; 36B82AMQ7N / Naloxone; 50-56-6 / Oxytocin; 76I7G6D29C / Morphine; 77327-45-8 / oxytocin,1-(beta-mercapto-(beta, beta-cyclopentamethylene)propionic acid)-Tyr(OMe)(2)-Orn(8)-; G4962QA067 / Lithium Chloride
  •  go-up   go-down


94. Dalpiaz O, Kerschbaumer A, Mitterberger M, Pinggera G, Bartsch G, Strasser H: Chronic pelvic pain in women: still a challenge. BJU Int; 2008 Nov;102(9):1061-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chronic pelvic pain (CPP), a common condition particularly in reproductive-aged women, causes disability and distress, and significantly compromises quality of life and affects healthcare costs.
  • The pathogenesis of CPP is still poorly understood and consequently poorly managed.
  • Furthermore, the lack of a consensus on the definition of CPP greatly hinders epidemiological studies.
  • Other conditions, e.g. depression, anxiety and drug addiction, can also coexist.
  • The key to treating CPP is to treat it as the complex disease it is.
  • Treatment options range from conservative medical therapy to surgical intervention, and are primarily directed towards symptom relief.
  • Unsatisfactory results of treatment render this condition a frustrating problem for both patients and physicians.
  • [MeSH-major] Pelvic Pain / therapy. Quality of Life
  • [MeSH-minor] Adolescent. Adult. Chronic Disease. Female. Humans. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Pelvic Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18540938.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 34
  •  go-up   go-down


95. Ciccocioppo R, Economidou D, Fedeli A, Massi M: The nociceptin/orphanin FQ/NOP receptor system as a target for treatment of alcohol abuse: a review of recent work in alcohol-preferring rats. Physiol Behav; 2003 Jun;79(1):121-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The nociceptin/orphanin FQ/NOP receptor system as a target